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Synopsis 
Chapter 1 
Synopsis 
Apoptosis can be distinguished from necrosis, the classical form of cell death, by 
several morphological and biochemical criteria. Apoptotic cells, but not necrotic cells, show 
early condensation of chromatin as well as endonuclease activation resulting in cleavage of the 
nuclear DNA into oligonucleosomal fragments. Both physiological and low level cytotoxic 
stimuli have been shown to induce apoptosis, which in some cell models can be suppressed by 
inhibitors of protein and RNA synthesis. The concept of the cell being actively involved in its 
own death, combined with the demonstration that factors which alter the rate of cell death, 
such as the proto-oncogene bcl-2, can directly affect the number of cells within a population, 
has resulted in the identification of cell death alongside proliferation and differentiation as a 
means for controlling celi population growth. 
The purpose of this study was to determine if bcl-2 and the Epstein-Barr virus gene 
BHRF1, which share 25% primary amino acid sequence homology, could suppress apoptosis 
in response to a variety of anti-cancer treatments. After demonstrating apoptotic cell death on 
treatment with chemotherapeutic agents in an IL-3 dependent cell line (FDCP-1) and three 
different EBV genome-positive Burkitt's lymphoma cell lines, the survival of EBV-BL cell 
lines expressing either exogenous bcl-2 or BHRF1 was examined. Suppression of apoptosis in 
response to treatment with chemotherapeutic drugs or y radiation was clearly shown in EBV- 
BL cells expressing bcl-2 or BHRF1 when compared to control transfectants. 
This study has further confirmed that BHRF1 is functionally homologous to bcl-2, 
suggesting that BHRF1 may act to prevent apoptosis during EBV infection. Suppression of 
chemotherapeutic drug induced cell death by either bcl-2 or BHRF1 also represents a novel 
form of drug resistance and may form an alternative mechanism by which multidrug resistance 
may arise during chemotherapy. The identification and investigation of other genes which 
produce suppression of apoptosis is also important in order to determine the extent of 
involvement of apoptotic suppression in the transformation to the malignant state and in the 
acquisition of multidrug resistance. A protocol to screen for 'apoptosis-suppressed cells' in the 
FDCP-1 E - 3  dependent cell line was developed to identify new genes involved in the 
pathway(s) of apoptosis. 
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Chapter 2 
Aims and Objectives 
The observation that the proto-oncogene bcl-2 was able to act as a molecular 
suppressor of apoptosis both in vitro (Vaux et al., 1988; Nunez et al., 1990) and in vivo 
(McDonnell et al., 1989) was paramount in demonstrating that cell death was fundamentally 
important in the growth control of cell populations. 
The translocation of a gene on chromosome 18q21 to the immunoglobulin heavy chain 
gene locus on chromosome 14q32 is strongly associated with follicular lymphoma. The gene 
on chromosome 18 was named B-cell leukaemia/lymphoma gene 2, representing the proposed 
proto-oncogene bcl-2 (Tsujimoto et al., 1984). bcl-2 has since been shown to be oncogenic in 
nude mice injected with 3T3 cells which express an exogenous form of the gene (Reed et al., 
1988), but bcl-2 is not able to produce a transformed cell phenotype in the absence of other 
genetic changes, Work with bcl-2-Ig transgenic mice demonstrated that they had expanded 
pre-B and B-cell populations which arose as a direct consequence of the ability of bcl-2 to 
prevent the death of these cells (McDonnell et al., 1989). Initially the mice exhibited no 
clinical effects, however, after 12 months many of the mice developed lymphoma and in 50% 
of the mice this was associated with a deregulated c-myc gene (McDonnell and Korsmeyer 
1991). This demonstrated that bcl-2, by providing a survival signal for cells which would 
otherwise have died to maintain a B-cell population of normal size, had increased the chances 
of oncogenic mutation(s) occurring to produce clonal malignant outgrowth. 
One the first genes to be identified with homology to bcl-2 was the Epstein Barr virus 
gene BHRF1 (Cleary et al., 1986). This gene is expressed early in the EBV lytic cycle 
(Pearson et al., 1986) and in some tightly latent cell lines after serum starvation, followed by 
reculture in high serum concentrations (Kocache and Pearson, 1990). EBV is associated with 
several human cancers, including endemic Burkitt's lymphoma found in areas defined by the 
African malaria belt. BHRF1 shares 25% primary amino acid sequence homology with bcl-2, 
mainly at the C-terminus (Cleary et al., 1986). 
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One of the aims of this study is to analyse further the extent of functional homology 
between bcl-2 and BHRF1. Eukaryotic expression constructs are available for these genes in 
the form of a BHRF1 construct produced by Dr. David Huen (Dept. Cancer Studies, 
University of Birmingham) and the Tsujimoto bcl-2 construct, (used by kind permission of 
Yoshihide Tsujimoto), as described in Tsujimoto (1989). Functional homology will be 
determined in transfected cells by the ability of BHRF1 to suppress cell death in a comparable 
manner to bcl-2. 
Bcl-2 has also been shown to induce stress resistance in response to several stimuli 
including heat shock and methotrexate (Tsujimoto 1989). Chemotherapeutic drugs such as 
methotrexate are known to induce apoptosis (e.g. Wyllie et al., 1980; Li and Kaminskas, 
1984; Lennon et al., 1990). A primary aim of the project is to investigate whether bcl-2 or 
BHRF1 are able to suppress chemotherapeutic drug induced cell death. Initially, induction of 
apoptosis in three human Burkitt's lymphoma cell lines and a murine IL-3 dependent cell line 
by chemotherapeutic drugs will be confirmed. This will be demonstrated by morphological 
criteria using both light and electron microscopy techniques and by biochemical analysis to 
demonstrate fragmentation of the DNA, a classical marker of apoptosis (Wyllie, 1980). Once 
this has been established, cells transfected with either a bel-2 or a BHRF1 expressing construct 
will be used to investigate whether or not expression of these genes can produce a novel form 
of multidrug resistance by suppressing apoptosis. One documented form of multidrug 
resistance is produced by the over expression of a human gene mdr1, which codes for a 
glycoprotein able to actively pump naturally occurring chemotherapeutic drugs from the 
cytoplasm of cancer cells (Ling, 1990). The drugs used in the present study include 
methotrexate, primarily because it does not interact with the MDR1 glycoprotein and 
therefore is not actively removed from the cell by this mechanism (Mickisch et al., 1991). A 
demonstration of multidrug resistance in the transfected cells, including resistance to 
methotrexate, would suggest a mechanism for multidrug resistance involving bcl-2 or BHRF 1 
which is independent of MDR1 expression. 
The discovery of BHRF1, albeit a viral gene, which has homology to bcl-2, along with 
the evidence that bcl-2 is not able to suppress apoptosis in all cell types (Nunez et al., 1990), 
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implies that other cellular genes may well function to promote cell survival, and has been 
recently demonstrated by the discovery of three cellular bcl-2 homologues (reviewed in 
Williams and Smith, 1993). Work with the IL-3 dependent cell line FDCP-1 has shown that 
some of these cells appear viable after 7 days, as judged by vital dye exclusion, in the absence 
of IL-3 and do not appear to enter apoptosis (N. J. McCarthy, B.Sc. thesis 1990). However, 
these cells do not appear to grow under these conditions, suggesting that they may be unable 
either to proliferate or to die, behaviour which is comparable to FDCP- 1 cells expressing bcl-2 
(Vaux et al., 1988). A screening protocol is to be developed to assess the phenotype of these 
'survivor' cells to examine the possibility that some may be live cells blocked from entering 
apoptosis on IL-3 withdrawal. The attainment of cells with this phenotype will enable 
genotyping of the mutant cells to see whether they over expresses bcl-2 or a new, previously 
uncharacterised gene involved in the apoptotic pathway(s), possibly a bcl-2 homologue. A 
longer term possibility would be the production of mutants using insertional mutagenesis to 
identify such genes. 
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Chapter 3 
Introduction 
Section 3.1 Apoptosis and Necrosis 
3.1.1 What is apoptosis? 
Apoptosis was the word coined in a paper by Wyllie, Kerr and Currie in 1972 for a 
newly described mode of cell death. This does not mean, of course, that cells had evolved a 
new way of dying, but that the above authors had identified a mode of cell death which was 
morphologically and biochemically distinct from the classical form of death known as 
coagulative necrosis. The fundamental difference between apoptosis and necrosis is that 
apoptosis represents a controllable form of cell death, which has wide ranging implications in 
many biological fields. However, it was the morphological characteristics which first alerted 
Wyllie and colleagues to apoptosis and hence it is useful to start an introduction on this subject 
from a morphological point of view. 
3.1.1.1 Cell death by coagulative necrosis 
Necrosis is the classically accepted form of cell death and occurs in response to any 
severe physiological or environmental deviation i.e. change in temperature, lack of oxygen 
(ischemia) and injury by agents such as chemical toxins etc., (Trump et al., 1973; Wyllie et al., 
1972; Wyllie et ai., 1980). Such environmental deviations lead to a loss of homeostatic control 
by the cell and this is thought to occur in two ways: 
• Damage to the plasmalemma, such as that produced by complement 
attack or osmotic fluctuations, which enables an influx of ions, especially 
calcium, into the cell (Wyllie et al., 1980) 
Damage to respiratory apparatus, such as mitochondria, leads to a lack 
of ATP which causes a failure of ion pumps in the membrane. This again 
allows a large scale influx of ions into the cell, including calcium ions, 
which cause further damage to the mitochondria as well as stimulating 
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which cause further damage to the mitochondria as well as stimulating 
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Ca2+ dependent proteases and phospholipases (Laiho and Trump 1975; 
Trump et al., 1973). 
Morphologically, cells dying by necrosis show a distinct pattern of cellular breakdown, 
see figure 3.1 A, which consists of two stages, one reversible, the other irreversible (Trump et 
al., 1973). The reversible stage, in which cells may be able to adapt to environmental changes, 
is characterised by the dilation of the endoplasmic reticulum along with a slight clumping of 
the nuclear chromatin. Other changes in the cell also include cytoplasmic swelling, whilst the 
mitochondria appear to be condensed due to the inner membrane shrinking from the outer. 
The irreversible stage is reached when the cell is unable to adapt to the environmental change. 
This stage can be identified by the mitochondria undergoing 'high amplitude swelling' which is 
characterised by the appearance of dense lipid rich aggregates within the inner membrane, 
which stili continues to shrink from the outer. The cell continues to swell and the chromatin 
takes on the appearance of flocculent masses which eventually disappear leaving a nuclear 
ghost (Wyllie et al., 1980). Finally all membranes rupture and the cell undergoes autolysis and 
denaturation. Areas of tissue affected by the initial toxic insult often involve large numbers of 
necrotic cells and this can result in exudative inflammation in viable tissue nearby, damaging 
these also. Cellular debris resulting from necrosis is phagocytosed by monocytes. 
3.1.1.2 Cell death by apoptosis 
Celi death by apoptosis is found to occur in many different biological situations. Single 
apoptotic cells are often found in healthy growing tissues such as small gut crypts. Apoptosis 
also occurs at many stages of embryonic development, for example, during the formation of 
digits from a solid limb paddle where interdigital cells between the digits are seen to die 
(Hmchliffe and Ede 1973). It has also been observed in metamorphosis (reabsorption of the 
tadpole tail), in endocrine induced atrophy of tissues, in celi mediated immunity and in 
neoplasms (Wyllie et al., 1980). In many of the cases mentioned above, apoptosis occurs as a 
control or regulatory process in the tissue, often under normal physiological circumstances. 
Perhaps one of the best examples of this is the deletion of autoreactive cells in the thymus 
(Smith et al., 1989; Jenkinson et al., 1989). Immature thymocytes fall into three categories, 
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those expressing a useful T cell receptor (TCR), able to recognise MHC and antigen, those 
expressing a useless TCR, unable to recognise self MHC or antigen and those expressing a 
TCR which recognises self only. The latter two categories are of no use or are dangerous to 
the body and are therefore signalled to enter apoptosis and die. The former category are useful 
and able to bind to antigen presented by dendritic cells which results in a signal to proliferate 
and therefore survive. This in itself is an interesting concept, since most of the control in a 
tissue was previously thought to occur during the proliferation and differentiation stages of 
cell development, (see section 3.2.1). 
Morphologically, an apoptotic cell is different from a necrotic cell (Wyllie et al., 1980; 
Kerr 1971; Wyllie et al., 1972), see figure 3.1B. One of the most prominent and earliest stages 
of apoptosis involves the nucleus. Chromatin is seen to condense and form aggregates near the 
nuclear membrane which becomes convoluted, whilst the nucleolus becomes enlarged and 
appears abnormally granular. In parallel to this, detectable changes in the cytoplasm occur 
with it becoming condensed and protuberances appearing at the membrane surface. There are 
two main theories so far which account for the reduction in the volume of the cell cytoplasm. 
Wyllie's original suggestion was that cells lost intra-cellular fluid selectively by osmosis to 
combat the efflux of ions such as K+ from the cell (Wyllie 1987). 
A second theory and one which is not necessarily independent from the former, is that 
of microtubule disruption. Early morphological studies suggested that a redistribution of 
microtubules occurred in apoptosis (Wyllie et al., 1980). More recently, Martin and Cotter 
(1 990) followed microtubule patterns in differentiating HL60 cells undergoing apoptosis. 
Staining of the microtubule network using immunofluorescence revealed a disrupted network 
when compared to viable cells. Such disruption could be effected by the increase in 
intracellular calcium observed in apoptosis since microtubules are known to be sensitive to 
changes in calcium homeostasis (Schliwa, 1976). Conversely, treatment of undifferentiated 
HL60 cells with microtubule disruptants, such as colchicine and vinblastin, resulted in a loss of 
viability together with the morphological characteristics, such as chromatin condensation, 
associated with apoptosis. 
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At the point of cytoplasmic condensation the cell will still appear viable in the presence 
of vital dyes, therefore indicating no structural failure in the cell membrane. In structured 
epithelial tissues, cells at this stage will have rounded up and severed all junctions with 
surrounding viable cells. Progression of the cytoplasmic condensation results in crowding of 
the organelles, but unlike necrotic cells, the organelles of apoptotic cells are morphologically 
normal except for the dilation of the endoplasmic reticulum. 
Later stages of apoptosis result in fragmentation of the condensed chromatin which 
forms crescent shaped caps. Migration of the chromatin occurs into the highly convoluted 
areas of the cell which can bud off, producing apoptotic bodies, some of which contain dark 
condensed chromatin and others just intact cellular organelles. The apoptotic bodies are 
normally phagocytosed by the surrounding viable cells or by cells of the mononuclear 
phagocytic system (see the following subsection). Phagosomes containing apoptotic bodies 
finally fuse with primay and secondary lysosomes produced by the ingesting cells for 
degradation. 
3.1.2 The recognition and phagocytosis of apoptotic cells 
Recognition of apoptotic cells as 'senescent self by macrophages is thought to be 
mediated partly by the vitronectin receptor, a member of the integrin family of receptors found 
on macrophage cell surfaces (Savill et al., 1990). This receptor is able to recognise a specific 
amino acid sequence (Arg-Gly-Asp), known as an RGD sequence, which was thought to be 
expressed on the extracellular matrix of apoptotic cells. However, it would seem that 
apoptotic cells do not express RGD containing molecules on their cell surface, and instead this 
sequence may be important in facilitating the recognition of apoptotic cells by a more indirect 
mechanism. Work by Savill and colleagues (1992) has demonstrated that recognition of 
apoptotic neutrophils may indeed be via the vitronectin receptor, as well as the CD36 ligand, 
which are able to bind thrombospondin, a soluble RGD containing protein which may act as a 
molecular bridge and bind to an anionic site on the apoptotic cell. Interestingly, GM-CSF 
increases the secretion of thrombospondin by macrophages and hence increases the capacity of 
macrophages to bind apoptotic cells. 
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Changes in cell surface charge also appear to be important in apoptotic cell 
recognition. Changes in pH have been shown to reduce dramatically the binding of apoptotic 
neutrophils by macrophages (Savill et al., 1989) and reductions in cell surface charge have 
been documented in apoptotic thymocytes. This may be due in part to the desialylation of 
surface carbohydrate (Morris et al., 1984) as well as the expression of phosphatidylserine on 
the plasma membrane (Fadok et al., 1990). 
Therefore, recognition of apoptotic cells could be mediated by one or more of the 
following mechanisms; 
Loss of sialic acid moieties expressed on carbohydrate molecules, 
Recognition through the vitronectin receptor using thrombospondin as a 
linker protein and 
• 
Efficient recognition of apoptotic cells is thought to aid the rapid disposal of cell debris 
which is one of the reasons why apoptosis occurring in healthy tissue is often hard to identify. 
In vitro, apoptotic cells may undergo secondary necrosis which leads to cell swelling and 
membrane breakdown (Wyllie et al., 1980). 
Recognition of cell surface phosphatidylserine. 
3.1.3 The significance of chromatin degradation in apoptosis 
One of the most striking morphological features of apoptosis is the very early 
condensation of the chromatin. In thymocytes this is concomitant with the activation of the 
calcium and magnesium dependent endonuclease (Wyllie 1980), and much of the in vitro work 
on the identification of the endonuclease has been carried out on these cells, since they readily 
undergo apoptosis in the presence of glucocorticoids (Wyllie et al., 1980). 
At the point of chromatin condensation, analysis of the DNA by agarose gel 
electrophoresis reveals the presence of a DNA ladder. The appearance of the DNA is 
comparable to that of DNA digested with microccocal nuclease. 
The endonuclease is only able to cut linker DNA between nucleosomes, (see diagram 
3.2). DNA within the nucleus is structured, i.e., it undergoes some form of packaging. Some 
of the proteins involved in the packaging are histones, H1, H2a, H2b, H3 and H4. These 
Page 9 

Introduction 
proteins interact with one another and the DNA to produce structures known as nucleosomes. 
Nucleosomes are made up of histone cores around which the DNA is wound. DNA within 
these complexes is protected from the endonuclease, but linker DNA between nucleosomes 
remains susceptible to cleavage and is digested in the presence of the activated endonuclease. 
Not all linker DNA is cleaved at the same rate due to differing accessibility between active and 
condensed chromatin and therefore oligonucleosomal fragments are produced resulting in the 
formation of the characteristic DNA ladder. Recent work by Arends et al., ( I  990) has shown 
that oligonucleosomal fragments of 180-540bp in length are associated primarily with High 
Mobility Group (HMG) proteins 14 and 17 and are free from the nuclear membrane. Larger 
fragments however are fixed to the nuclear membrane and are associated with histone H1. 
This may be explained by the smaller fragments representing active genes more accessible to 
the endonuclease since actively transcribed genes are believed to associate with HMG 
proteins. Larger fragments may represent still tightly bound inactive genes to which the 
endonuclease would have delayed access, hence larger fragments and the presence of histone 
H1 (Weintraub 1985). Only when a protease is present in conjunction with an activated 
endonuclease can all the DNA be digested resulting in a smear of DNA being produced on an 
electrophoresis gel. This result is generally associated with necrotic cell death, where 
degradation of all cellular organelles is seen. Fragmentation of the DNA is thought to be 
directly responsible for the condensation of the nucleus, since incubation with micrococcal 
endonuclease results in the same effect (Arends et al., 1990). 
Efforts to purify the endonuclease at first proved unsuccessful (Baxter et al., 1989), 
despite claims that the endonuclease is always present in the nuclei of immature 
thymocytes (Cohen and Duke 1984; Wyllie et al., 1987; Wyllie 1980). However, some 
candidate endonucleases have now been described, including three dependent enzymes 
present in thymocyte nuclei (Gaido and Cidlowski 1990; Arends et al., 1990; Peitsch et al., 
1993). Ail three endonucleases appear to be different molecules, with one having been shown 
to be DNase I, an endonuclease which is found in several tissues other than thymocytes 
(Peitsch et al., 1993). The presence of three different dependent endonucleases implies 
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that the dependent pathway may exhibit some redundancy, but this has not yet been 
shown and requires fùrther investigation. 
Other candidates for the role of the apoptotic endonuclease have been documented in 
cells other than thymocytes (Barry and Eastman 1993; R. Fernandes personal communication). 
Both groups have isolated enzymes which are activated by a change in pH levels within the 
cell, but do not appear to be affected by an increase in the intracellular levels of Barry 
and Eastman have suggested that the endonuclease found in apoptotic CHO cells after 
treatment with chemotherapeutic drugs is DNase II, activated by a rise in pH within the 
cytoplasm during apoptosis, the same result has also been shown for HL60 cells (Barry et al., 
1993). dependent endonucleases have also been found in tissues other than thymocytes, 
such as the endonuclease implicated in rat prostate cells undergoing apoptosis after androgen 
withdrawal (Kyprianou et al., 1988). This suggests that there may be both dependent and 
independent endonucleases present in cells and either can be used depending on the signal 
received and whether a rise in internal calcium levels occurs. This also implies that there are 
several different signalling pathways within cells which can effect the same cellular responses, 
such as endonuclease activation (D. J. McConkey, personal communication). 
Section 3.2 The significance of apoptosis 
3.2.1 Apoptosis and cell population growth control 
In general, control of cell population size was previously thought to be mediated at the 
cell proliferation and cell differentiation level. With the discovery of apoptosis identifying a 
pathway of active, controllable cell death, it has now become feasible that control of cell 
populations can be exerted at the level of cell death, as depicted in figure 3.3.  Many cellular 
models have reflected this, (see below), along with demonstrating that inhibition of cell death 
can lead directly to an accumulation of cells within a given population. 
Many physiological apoptotic stimuli have been identified, including withdrawal of IL- 
3 from factor dependent cells (Williams et al., 1990), or stimulation of the T-cell receptor in 
immature thymocytes (Smith et al., 1989; McConkey et al., 1989d). The response of such 
cells to these stimuli is in turn dependent on the intracellular state of the cell, (see figure 3.4). 
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For example, changes in gene expression can alter the response of a cell to a given stimulus. 
Deregulated c-myc, for example, causes apoptosis in response to serum withdrawal in 
fibroblast cells, a signal which in fibroblasts with regulated c-myc results in quiescence and the 
down regulation of c-myc expression (Evan et al., 1992). 
Perhaps one of the best examples for demonstrating cellular growth control carried out 
at the level of cell death is found in the nematode Caenorhabditis elegans, in which the 
cellular development pathways within this animal have been precisely mapped. 
3.2.2 Invertebrate models of programmed cell death 
In recent years invertebrate models have given an invaluable insight into the genetic 
controls of cell death. Work in the tobacco hornworm Manduca sexta has shown that a host 
of mRNAs are produced in the final ecdysis before emergence of the adult moth, a process 
triggered by a fall in the levels of ecdysteroid hormone (Schwartz and Truman 1982, 1983). 
Regression of intersegmental muscles causes the prominent gene expression to change from 
myofibrillar proteins to a large number of smaller mRNAs, one of which is homologous to 
TRPM-2 (testosterone repressed prostate message 2), a gene also expressed during apoptosis 
within the rat prostate (Wadewitz and Lockshin, 1988; Buttyan et al., 1989; see section 
3.4.5). In addition Schwartz and co-workers (1990) demonstrated that this form of cell death 
requires the activation of several genes including polyubiquitin which could be involved in 
tagging proteins for degradation. 
A definitive plan of gene expression during cell development and death has been 
mapped in the nematode Caenorhabditis elegans (Ellis and Horvitz 1986; Hedgecock et al., 
1983; Sulston et al., 1983). The cell lineage development pattern within this animal has been 
extensively investigated and hence it has been established that exactly 131 cells normally die 
during the animal's development. Some of the genes involved in the programmed cell deaths 
have been identified and are shown in figure 3.5. Of particular interest are two genes, 
programmed cell death gene 3 (ced 3) and ced 4, which have been shown to be directly 
responsible for the death of specific cells during development. Loss of function mutants of ced 
3 or 4 result in an animal where cells which normally die during development do not, but 
instead take up the same differentiated form as their sister cells (Ellis and Horvitz 1986). 
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Construction of mosaic animals demonstrated that ced 3 and 4 gene products acted within the 
cells which died and not as a killer signal produced by neighbouring or surrounding cells 
(Yuan and Horvitz 1990). 
The genetic control of ced 3 and ced 4 was determined by the discovery of ced 9 which 
acts to suppress the expression of ced 3 and ced 4, thereby blocking cell death. Ced 9 gain of 
function mutants illustrated that in the presence of ced 9 expression no cell death was seen, 
but in the absence of ced 9 expression i.e., loss of function mutants, cell death was seen, not 
only in the 131 cells which normally died, but also in other cells within the nematode 
(Hengartner et al., 1992). This illustrated that ced 9 was a general genetic suppressor of cell 
death within these animals, acting on genes in addition to ced 3 and ced 4.  Loss of ced 9 
expression also caused a maternal effect with offspring from ced 9 mutants being semi sterile 
and any resulting eggs produced from the offspring failing to develop. 
Recent work with ced 9 loss of function mutants has demonstrated that functional 
suppression of cell death can be restored in ced 9 mutants by the transgenic expression of bcl- 
2,  (Vaux et al., 1992), the B cell leukaemidlymphoma gene which in several mammalian cell 
systems is able to suppress apoptotic cell death (see section 3.5). This neatly identified ced 9 
as a functional homologue of bcl-2 and also demonstrated that the suppression of cell death is 
an evolutional conserved mechanism for controlling cell population size, implying that genes 
with similar functions to those identified in C. elegans should exist in mammalian cells. 
Other genes within the programmed cell death pathway which have been identified are 
involved in the phagocytosis of dead cells (see figure 3.5). Mutants which lack one or more of 
these genes do not phagocytose the dead cells, instead the cells are left within the cellular 
tissues with no apparent deleterious effects (Ellis et al., 199 1). 
This model has identified specific genes which when activated can either promote or 
suppress cell death. 
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3.2.3 Vertebrate models of apoptosis 
3.2.3.1 Haemopoiesis 
Haemopoiesis is the word used to describe the production and control of all blood cells 
in the body. The tissue responsible for this is mainly the bone marrow, with additional roles 
played by the spleen and liver. Production of haemopoietic cells starts early during 
embryogenesis with stem cells first appearing in the yolk sac of an embryo and then migrating 
to the liver. Populations of stem cells are transient and those stem cells which seed in the liver 
and later in the spleen and bone marrow are the only stem cells the organism has. These stem 
cells must therefore be capable of self renewal and the production of many different blood cell 
lineages in order to give rise to a mature blood cell population. Haemopoietic stem cells give 
rise to eight distinct lineages: erythroid, neutrophil-granulocytic, monocytic, eosinophilic, mast 
cell, megakaryocytic, T-lymphoid and B-lymphoid, as neatly illustrated by the spleen colony 
forming assay (Metcalf 1988). 
The non-lymphoid cell lineages are formed mainly in the bone marrow, with the spleen 
playing a minor but expandable role in the case of some diseases. For B and T-lymphocytes 
however, stem cells may give rise to them in the bone marrow, but then T-cell precursors 
migrate and enter the thymus where they undergo proliferation and differentiation. B-cell 
precursors stay longer in the bone marrow but eventually migrate to the spleen and lymph 
nodes where further proliferation and maturation occurs (see Liu et al., 1989 and section 
3.5.2). Haemopoietic cells show a hierarchy of cell populations which is exhibited in the 
development in all eight cell lineages: 
Page 14 
Introduction 
The first and most important cell population is the stem cell. These cells are able to self 
renew as weil as produce a further differentiated celi population known as progenitor cells. 
The mechanism by which stem cells are able to reproduce themselves as well as produce 
progenitor cells is unknown. Evidence suggests that stem cells undergo asymmetrical divisions 
which give rise to one stem cell and one progenitor cell (Metcalf 1988). Committed progenitor 
cells produced by the stem cells are further differentiated, being unable to self renew 
indefinitely or to produce stem cells. Most progenitor cells are unipotential i.e. only able to 
produce colonies of one celi lineage, although some multipotential progenitor cells have been 
identified (Metcalf 1988). Progenitor cells give rise to morphologically identifiable cells which 
then terminally differentiate to produce the mature cell population. 
The control of haemopoiesis 
Most of the work carried out on this subject has been with cells of the 
granulocyte/macrophage lineage. The processes described above are thought to be controlled 
by Colony Stimulating Factors or CSFs (Metcalf 1989) and stromal cells, both of which make 
up the haemopoietic microenvironment (Metcalf 1988; Roberts et al., 1987). In vitro 
haemopoietic stem cells require the presence of stromal cells in order to survive and proliferate 
(Roberts et al., 1987). How the stromal cells are able to support a proliferating stem cell 
population is not clear, but it is thought that it involves the production and presentation of 
CSFs by the stromal cells (Spooncer et al., 1986; Roberts et al., 1987). 
There are four main CSFs involved in the granulocyte/macrophage developmental 
pathway, these are multipotential CSF or multi-CSF also known as interleukin-3 or IL-3, 
granulocyte-macrophage CSF or GM-CSF, granulocyte CSF or G-CSF and macrophage CSF 
or M-CSF. All CSFs are glycoproteins with Mr between 18,000 and 90,000; a third to a half 
of which is made up of carbohydrate. They act by triggering membrane receptors on 
appropriate cells and each CSF has its own specialised receptor which is not cross reactive, 
that is, an IL-3 receptor cannot be triggered by the binding of a GM-CSF ligand. IL-3 is 
known to promote the growth of both stem and more mature progenitor cells and could 
therefore be fundamentally important in the control of haemopoiesis. 
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The involvement of CSF in haemopoiesis can be split into two roles, that leading to 
cell survival and that leading to proliferation. On removal of CSFs from the growth medium 
most haemopoietic cells will die, as was first noted by Paran and Sachs in 1968. Similarly, a 
delay in the addition of GM-CSF to granulocyte/macrophage progenitor cells results in a 
decline in ability to form colonies in soft agar. This occurs due to the cells being unable to 
survive in the absence of GM-CSF (Metcalf and Merchev, 1982), which has now been shown 
to be due to the induction of apoptosis in the absence of the required cytokine (e.g., Williams 
et al., 1990). Low concentrations of IL-3 have been shown simply to keep cells alive and 
addition of more IL-3 to these cells results in a rise in intracellular pH and stimulation of 
cellular proliferation. Mature haemopoietic cells also respond to the absence of a specific 
cytokine, for example, erythrocyte progenitors will undergo apoptosis in the absence of 
erythropoietin (Koury and Bondurant, 1990a,b). Hence the presence of cytokines is required 
not only as a proliferative signal, but also as a suppressor of apoptosis. Therefore, control of 
haemopoietic cell population numbers in vivo is thought to be primarily at the levei of cell 
death. 
Cells which respond to CSF can be said to be 'programmed' in their response (Whetton 
et al., 1988), that is, the actual response of a cell is determined by two points of genetic 
programming: 
that leading to the display and synthesis of specific receptors and 
that determining whether cells proliferate, enter defined differentiation 
pathways or exhibit enhanced functional activity on receptor stimulation. 
Very recent work by Fairbairn and colleagues (1993) has demonstrated that 
differentiation of FDCP-mix cells can occur in the absence of cytokine, as long as a survival 
signal is present. A gene which has been demonstrated to suppress apoptosis in the FDCP-1 
cell lines is bcl-2 (Vaux et al., 1988) and this acts as a genetic survival signal in the absence of 
the cytokine. If this gene is expressed in FDCP-mix cells not only do the cells survive in the 
absence of the cytokine, they also begin to differentiate and produce more mature lineage 
cells. Differentiation of a single cell also occurred without concomitant proliferation. This 
suggests that differentiation in some cells is genetically predetermined and the presence of 
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different cytokines is not required for differentiation to occur per se. Cytokines may simply be 
required to provide a proliferative signal in order to increase the cell population number. 
However, cells can be influenced by the type of CSF present. If a bipotential 
progenitor cell of the granulocyte/macrophage lineage is incubated with both M-CSF and GM- 
CSF then an enhanced proliferation and competitive production of cells is seen. This results in 
both macrophage colonies and granulocyte colonies, the amounts of which depend on the 
concentrations of M-CSF and GM-CSF present (Metcalf 1989). So, in summary, colony 
stimulating factors influence haemopoietic cells in four ways: 
as a proliferative stimulus, 
in the enhancement of survival, i.e., in the suppression of apoptosis, 
• as an influence in cellular differentiation and 
• as an influence in cellular maturation. 
3.2.3.2 Induction of apoptosis in the immune system 
The study of apoptosis in immature thymocytes has led to morphological and 
biochemical events within this pathway being widely accepted as definitive landmarks through 
which a cell has to pass to be classified as apoptotic (Wyllie et al., 1980; Wyllie 1980). 
However, with the increasing number of cell models studied, it has become apparent that not 
all apoptotic cells progress in exactly the same manner. 
Immature thymocytes and mature T lymphocytes. 
Immature thymocytes die by apoptosis on addition of glucocorticoid hormone and 
have provided the paradigm for apoptosis, defining several characteristics of the process 
(Wyllie et al., 1972; Wyllie 1980; McConkey et al., 1989a). Addition of a glucocorticoid 
results in cell lysis after 10 hours with DNA fragmentation detectable as early as 1 hour after 
glucocorticoid addition (Wyllie et al., 1980; McConkey et al., 1989a). By the use of gel 
electrophoresis, DNA can be seen to be cleaved into multiples of approximately 180-200 base 
pairs i.e., oligonucleosomal sized fragments comparable to chromosomal DNA which has been 
cleaved by micrococcal endonuclease (Wyllie 1980; Arends et al., 1990). In virtually all cases 
of apoptotic cell death activation of the endonuclease occurs and in thymocytes, it is accepted 
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that the endonuclease is calcium and magnesium dependent (Cohen and Duke 1984) and 
probably requires extracellular calcium to remain activated. It is also established that the 
endonuclease results in fragmentation of the DNA into oligonucleosomes by cutting linker 
regions of DNA not protected by the presence of histones. 
Glucocorticoid stimulated cell death can be prevented by both inhibitors of RNA 
synthesis, e.g. actinomycin D and by inhibitors of protein synthesis, e.g. cycloheximide (Wyllie 
et al., 1984; Cohen and Duke 1984). 
Binding of the glucocorticoid to its receptor within the thymocyte results in an 
immediate increase in intracellular calcium (McConkey et al., 1989a). Later stages of 
apoptosis can be blocked by introducing the binding dye quin-2-AM or by placing the 
cells in depleted medium, implying that a calcium signal is required to stimulate cell death 
(McConkey et al., 1989a). Thymocyte apoptosis can also be induced by incubating the cells in 
the presence of a calcium ionophore such as ionomycin (e.g., Wyllie et al., 1984; McConkey 
1989b) which presumably mimics the calcium rise associated with glucocorticoid binding. 
Much of the pathway through which glucocorticoids stimulate an increase in cytosolic 
calcium concentration is unknown. However, it is well established that glucocorticoids have 
specific receptors within the cell which become active on binding the glucocorticoid and are 
then able to bind DNA. This in turn promotes the transcription of glucocorticoid dependent 
genes (Luisi et al., 1991; Evans 1988; Yamamoto 1985). It is most unlikely that the 
expression of the glucocorticoid dependent genes is required for the immediate increase, 
but induced gene product(s) may help to sustain it. McConkey et al., (1989a) have suggested 
that such a gene product could be a pore protein involved in the transport of calcium across 
the nuclear membrane. Blocking of calcium dependent proteins such as calmodulin will also 
block apoptosis, therefore suggesting that calcium may initiate a signalling cascade involving 
calmodulin. Other calcium dependent proteins such as proteases and phospholipases, so 
crucial to necrotic cell death, are not activated in thymocyte apoptosis. Inhibition of these 
enzymes fails to abrogate apoptotic cell death (McConkey et al., 1989~). 
CEM cells, originally derived from an acute lymphoblastic T cell leukaemia, also 
undergo apoptosis on exposure to glucocorticoid (Alnemri and Litwack 1989). However, this 
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study demonstrated that the death of these cells is independent of an intracellular calcium 
increase. Novobiocin, a topoisomerase II inhibitor, also causes apoptosis in these cells which 
again is independent of a calcium increase (Alnemri and Litwack 1990). Furthermore, CEM 
nuclei incubated in the presence of calcium do not undergo DNA fragmentation, suggesting 
that there is no detectable calcium and magnesium dependent endonuclease in these cells. This 
is supported by the work of Barry and Eastman (1993) who show that DNase II can become 
activated in some apoptotic cells due to a drop in pH levels within the cell, rather than an 
increase in concentrations. 
Cell death which is independent of protein synthesis has been shown both in S49 
mouse lymphoma cells in response to a glucocorticoid (Vedickis and Bradshaw 1983) and in 
human leukaemic HL60 cells on treatment with calcium ionophore (Martin et al., 1990). Both 
groups concluded that some cell lines may not require new gene expression in order to 
activate the endonuclease or produce changes in cellular morphology. This suggests that some 
cells are continuously primed to enter apoptosis but the required proteins within the cytoplasm 
are kept in an inactive form until the appropriate apoptotic stimulus is received. 
Glucocorticoids and calcium ionophores are not the only means of inducing T-cell 
apoptosis. Immature thymocytes expressing the CD3/T-cell receptor (TCR) 
complex can be signalled to die by apoptosis either by anti-CD3 antibody or by a superantigen 
complex such as Staphylococcus enterotoxin B (SEB) which bind to and signal through the 
TCR (Smith e? al., 1989; McConkey et al., 1989d; Jenkinson et al., 1989). Apoptotic death of 
immature double positive thymocytes within thymic cultures is also seen in response to the 
above stimuli and this has important implications for the production of a tolerant immune 
system (Kappler et al., 1987; Kingston et al., 1985). Apoptosis produced by stimulation of the 
TCR can be mimicked by calcium ionophores (McConkey et al., 1989d). Comparable results 
have been obtained by Ucker et al., (1989) in transformed T-cell hybridomas. 
Therefore apoptosis in immature thymocytes can be signalled both by antigen binding 
to the CD3/TCR complex and by binding of glucocorticoid to its intracellular receptor, both 
resulting in an increase in Cytosolic calcium. Apoptosis can be inhibited by blocking the 
calcium influx or by inhibiting RNA or protein synthesis. These systems have provided some 
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of the first information about biochemical signalling pathways leading to apoptosis, but we are 
still some way from a clearly defined molecular mechanism (see section 3.3) .  
Interleukin 2 (IL-2) dependent T-cell clones die by apoptosis on withdrawal of the 
cytokine (Cohen and Duke 1986). This can be prevented by the presence of phorbol esters 
(Rodriguez-Tarduchy and Lopez-Rivas 1989), suggesting that PKC activation can block 
apoptosis in this system. It is not known how removal of a growth factor results in apoptosis, 
but it has been suggested that such cells are again continuously primed to enter apoptosis, but 
that the process is actively suppressed by the presence of the appropriate factors (Raff 1992). 
Cytotoxic and natural killer cell induced death within the immune system is a very 
interesting but complex model system. This in part stems from the fact that such cells are 
known to secrete a wide range of cytotoxic molecules on contact with target cells. Some of 
these are able to produce necrosis, e.g., Perforin (Duke et al., 1989; Young and Liu 1988), 
whereas others, such as tumour necrosis factor, can induce both necrosis and apoptosis 
(Laster et al., 1988). It is interesting to note however that some of these models diverge 
noticeably from the classical concept of apoptosis. For example, there is evidence for protein 
synthesis required for cell death that is independent of DNA fragmentation (Hirota et al., 
1989, reviewed in Golstein et al., 1991). Such models are valuable because they indicate that 
apoptosis may be modified in certain circumstances to provide cell death more appropriate for 
the situation e.g., rapid target cell destruction to combat viral infection. 
Other ligands expressed on the surface of cells have been found to induce apoptosis on 
stimulation (Trauth et al., 1989; Yonehara et al., 1989). Trauth and co-workers, by raising 
monoclonal antibodies to malignant B cells, produced an antibody, anti APO- 1. This antibody, 
on binding the APO-1 antigen caused apoptosis. Engagement of the Fas antigen, which is 
expressed on many cells including myeloid cells, T lymphoblastoid cells and diploid fibroblasts 
(Yonehara et al., 1989), also leads to cell lysis. Expression of the fas cDNA in normally non- 
expressing cells can also result in lysis in the presence of anti fas antibodies (Itoh et al., 1991). 
These two cell ligands have now been shown to be one and the same (Oehm et al., 1992) and 
to belong to an emerging protein receptor superfamily which includes the tumour necrosis 
factor receptor, nerve growth factor receptor and CD40. 
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As a final note to this section, one should also consider radiation-induced cell death. In 
both lymphocytes and thymocytes this is a valuable model because it provides yet another 
signal with which cells die, but the rate at which they die can depend on their respective 
activation states. Both thymocytes and lymphocytes die quickly if they are in the resting state 
(Yamada and Ohyama 1988; Sellins and Cohen 1987). If the cells are active then they may 
take much longer to die, with activated lymphocytes this may be a matter of days (Filippovich 
et al., 1988; Lowenthal and Landers 1985). Why this occurs is not clear, but proliferating cells 
are likely to have different molecules present in the cytoplasm which can suppress apoptosis 
and this is further implied by the fact that phorbol esters protect lymphocytes from radiation 
damage (Tomei et al., 1988). However, other reasons have been suggested, Filippovich et al., 
(1988) believing that the rate of apoptosis is dependent on the amount of DNA breaks already 
present in the cell before radiation exposure. 
B-cell models 
Work with developing B-cell populations has shown that these cells may also go 
through positive selection much like thymocytes. A proportion of developing centrocytes in 
follicles of secondary lymphoid organs undergo apoptosis when placed in vitro (Liu et al., 
1989). However, this can be prevented if the cells are stimulated through their surface 
immunoglobulin. These cells are thought to represent a population of B cells which have just 
undergone somatic mutation, and as a result are selected in vivo on the basis of their affinity 
for antigen expressed on follicular dendritic cells (MacLennan and Gray 1986). This selection 
through surface immunoglobulin may prevent cells with high affinity for antigen from 
undergoing apoptosis as is seen in vitro, and allow these cells to differentiate into memory B 
cells. In direct contrast, mature surface IgM positive murine B lymphomas die by apoptosis on 
stimulation of their surface Ig receptors (Hasbold and Klaus 1990). There is evidence that the 
differing sensitivity of immature and mature thymocytes to apoptotic stimuli, i.e., susceptibility 
to undergo apoptosis depending on the developmental point of the cell and the stimulus 
received, may well occur in B cell development, hence allowing for the differing outcomes in 
response to Ig stimulation. 
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Further work in this area has shown that a subset of germinal centre B cells, which 
specifically express the antigen cluster CD 77, undergo apoptosis both in vivo and in vitro 
(Mageney et al., 1991). In vitro, these cells can be rescued from dying by both interleukin 4 
and anti CD40 antibodies. Germinal centre B cells and early myeloid cells can also be rescued 
by the presence of antibodies to the CD23 receptor and interleukin la (Liu et al., 1991a; 
Mossalayi et al., 1990). In germinal centre B cells this latter signal resulted in differentiation 
towards the plasmacytoid pathway and may provide an explanation for the role of a subset of 
follicular dendritic cells known to express CD23. Interestingly these B cells could also be 
rescued by monoclonal anti CD40 antibodies, but this did not result in differentiation. Liu et 
al., (1991a) have suggested that this may represent a bifurcation in the development of 
germinal centre B cells. 
Section 3.3 Mechanisms of the apoptotic pathway(s) 
3.3.1 Introduction 
Extracellular signals can trigger apoptosis through several cytoplasmic pathways, some 
of which are represented in figure 3.6. Most of the intracellular signals which induce apoptosis 
can stimulate other responses (e.g., proliferation or differentiation) in different cell types or in 
cells under different environmental conditions. 
In thymocytes and some other cell systems, induction of apoptosis is associated with 
an increase in intracellular calcium concentration. This increase can be produced by the 
production of inositol triphosphate from the hydrolysis of phosphatidylinositol, which causes 
the release of calcium stored within the endoplasmic reticulum (Berridge 1984). A sustained 
increase in calcium concentration is thought to be maintained by the entry of extracellular 
calcium through channels in the cytoplasmic membrane. 
Cyclic AMP can also act as a second messenger in apoptosis (Bourne et al., 1975; 
Vedickis and Bradshaw 1983; McConkey et al., 1990c; Lanotte et al., 1991). Cyclic AMP and 
calcium activated calmodulin pathways are known to interact, e.g. via protein kinase A, which 
is stimulated by CAMP and is thought to act in the endonuclease activation pathway, and can 
phosphorylate some channels and pumps (McConkey et al., 1990c). Protein Kinases C 
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and -A also interact during cellular signalling (Yoshimasa et al., 1987) and in apoptosis, 
stimulation of PKC is able to block DNA fragmentation and cell death stimulated by calcium 
and cAMP pathways (McConkey et al., 1990c). Therefore, in thymocytes signals within the 
cell may interact directly i.e., cross talk, via the two protein kinase systems (see figure 3.6). 
3.3.2 Cytosolic signalling pathways involved in apoptosis 
Thymocyte apoptosis induced by glucocorticoids or ionophores can be blocked 
by phorbol esters (McConkey et al., 1989b). These compounds act by directly stimulating 
PKC, probably by mimicking diacylglycerol, the physiological activator of PKC (Berridge 
1984). This implies that a signal involving PKC activation can block the apoptotic signal. 
Consistent with this, interleukin 1 (IL-1), which can activate PKC, (Rosoff et. al., 1988), is 
able to block apoptosis in thymocytes stimulated via the T-cell receptor complex. IL-1 also 
blocked cell death in thymocytes exposed to glucocorticoids, calcium ionophores and 
antibodies to the antigen receptor complex (McConkey et al., 1990b). Using the above and 
other T-cell signalling models, McConkey et al., (1990a) have proposed a mechanism for cell 
signalling in apoptosis. This is based on the idea of unbalanced cell signalling and follows from 
the observation that signalling of mature T-cells to proliferate involves the use of two 
pathways; that given by occupation of the TCR, resulting in a / CAMP signal, and that 
given by an accessory molecule such as IL-1 which involves PKC activation. If however these 
cells receive a stimulus from the TCR only, then the cells enter a state of non responsiveness, 
known as clonal anergy, (Jenkins et al., 1987; Jenkins et al., 1988; Quill and Schwartz, 1987) 
which may be important in the down regulation of the immune response. If an analogous 
interplay between signals occurs in immature thymocytes then a cell which receives stimulation 
by both glucocorticoid and IL-1, i.e., both /cAMP and PKC pathways, will receive a 
balanced signal which will not result in cell death. This is also consistent with studies on IL-2 
dependent cells where the presence of IL.-2 protects the cells from the effects of glucocorticoid 
(Nieto and Lopez-Rivas, 1989). If only the glucocorticoid or TCR signal is received then an 
increase in cytosolic calcium, or CAMP activation occurs without the balancing PKC signal 
and this results in apoptosis (McConkey et al., 1990a). This is a plausible mechanism when 
considered in T cells, but it should be remembered that immature thymocytes in particular are 
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a population of cells undergoing a complex process of selection and therefore represent a 
special case. 
Section 3.4 Genes and cell signalling in apoptosis 
3.4.1 Introduction 
A paper published by Wyllie and colleagues in 1987 illustrated how various 
deregulated oncogenes could affect the rate of apoptosis within a tumour by determining the 
apoptotic and mitotic rates in various induced fibroblast tumours in immune compromised 
animals. In fibroblasts transfected with an SV40 promoter containing plasmid, only small 
nodules of fibrosarcomas were produced which corresponded to the cells having a low mitotic 
rate but a high apoptotic rate. Fibroblasts which over expressed exogenous myc produced 
tumours which had both high apoptotic and mitotic rates and produced indolent tumours (see 
section 3.4.3). Cells over-expressing ras, however, produced highly metastatic cancers with a 
high rate of mitosis and a low rate of apoptosis. These results neatly demonstrated that cancers 
which showed a low incidence of apoptosis coupled with a high mitotic rate in vivo, had a 
distinct advantage for unrestrained celi population growth. This system also illustrated that 
even with a relatively high incidence of apoptosis tumours still form, as is seen for the myc 
transformed fibroblasts. A reduction in the rate of apoptosis is therefore not the only factor 
involved in malignancy, but may well represent an early step towards the cancerous state. 
3.4.2 Viral gene suppression of apoptosis 
The ability of viral genes to mediate cellular transformation has long provided an active 
area for cancer research. More recently, specific viral genes required for cellular 
transformation have been identified and genes such as DNA tumour virus oncoproteins, 
adenovirus E 1 b and human papilloma virus E6 have been found to bind the tumour suppressor 
gene p53 (Braithwaite and Jenkins 1989; Gannon and Lane 1987; Sarnow et al., 1982). Hence 
such genes are able suppress normal p53 activity and arrest which probably causes the 
observed increase in proliferation (Momand et al., 1992; Lane and Benchimol 1990; Werness 
et al., 1990). In addition, recent research has shown that some virai genes may affect cellular 
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growth either by directly suppressing apoptosis or by upregulating bcl-2 and indirectly 
suppressing apoptosis (see section 3.6) ,  
3.4.3 c-myc and apoptosis 
Classically, expression of c-myc during the cell cycle is associated with cell 
proliferation and, in cases where c-myc is deregulated, cell transformation. c-myc expression is 
known to occur throughout the cell cycle, and is up-regulated in cells entering from a 
state and down-regulated in cells entering or terminally differentiating (Cole 1986). 
Two recent papers have shown that under certain conditions, continuous expression of 
c-myc is associated with apoptosis. Rat-1 fibroblasts, in the presence of low serum, normally 
enter a quiescent state which corresponds to a decline in the level of c-myc expression (Dean 
et al., 1986; Waters et al., 1991). However, when transfected with a constitutively expressed 
c-myc gene these cells fail to enter on removal of serum and instead enter apoptosis (Evan 
et al., 1992). Examination of Rat-1 myc clones expressing different levels of the proto- 
oncogene, revealed that the higher the level of enforced c-myc expression, the faster the 
resulting entry into apoptosis and the greater the sensitivity to a drop in the concentration of 
serum. Deregulated c-myc was also shown to induce apoptosis in cells which were growth 
arrested in other phases of the cell cycle. Similar results have been obtained in an IL-3- 
dependent myeloid cell line continuously expressing c-myc (Askew et al., 1991). The parental 
cell line, on removal of IL-3, down regulates the expression of both c-myc and ornithine 
decarboxylase (ODC) and accumulates in from which cell death follows several hours later. 
Cells which continuously express c-myc fail to down regulate both myc and ODC gene 
expression in response to cytokine withdrawal and do not progress to block in but instead 
rapidly enter apoptosis. Similarly in this system, cells were able to enter apoptosis from 
wherever growth arrest occurred in the cell cycle. 
Induction of apoptosis by c-myc requires the same regions within the protein, i.e., the 
helix-loop-helix domains and the leucine zipper, as are required for Co-transformation and 
inhibition of differentiation (Freytag et al., 1990; Stone et al., 1987). Hence, the ability of c- 
myc to bind DNA and other proteins may suggest a role in the initiation of apoptosis in some 
cases (Evan et al., 1992). Consistent with this hypothesis is the upregulation of c-myc 
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expression seen in rat ventral prostate cells undergoing apoptosis in response to the removal of 
androgen (Buttyan er al., 1989) and the requirement of Myc in activation-induced apoptotic 
cell death in T-cell hybridomas (Shi et al., 1992). It also supports the suggestion that 
apoptosis is in some ways related to cell proliferation since some of the same genes have been 
implicated in the regulation of both processes (see Ucker 1991 for review). 
3.4.4 p53 and its role in apoptosis 
Another gene able to promote apoptosis within myeloid cells is the tumour suppressor 
gene p53 (Yonish-Rouach et al., 1991). p53 expression normally results in inhibition of 
proliferation, however, wt p53 expression in M1 cells results in apoptosis. IL-6, however, is 
able to block the apoptotic response by inducing differentiation possibly involving the ability of 
IL-6 to down-regulate c-myc (Kimchi et al., 1988; Resnitzky and Kimchi 1991). 
Acute myeloid leukaemia cells both from patients and in vitro celi lines have been 
found to express mutant p53 and this appears to confer a growth advantage (Slingland et al., 
1991). How p53 exerts its effect as a tumour suppressor gene is unclear, but it has been 
proposed that it may be involved in the cellular response to DNA damage (e.g., Lane 1992). 
Accumulation of p53 protein within the cell nucleus is often seen after DNA damage 
producing arrest in (Maltzman and Czyzyk 1984; Kastan et al., 1991), which is thought to 
facilitate repair of the damaged DNA. However, if the damage to the genome is too great, 
apoptosis results. Therefore p53 is proposed to act as a molecular sensor of DNA damage, 
allowing efficient repair to occur or possibly facilitating the correct genomic environment for 
cell death to occur (Yonish-Rouach et al., 1993). Cells which express mutant p53 or have 
incapacitated p53 due to the presence of viral oncogenes will fail to enter under the same 
conditions and continue to proliferate. The resulting failure to deal appropriately with DNA 
damage leads to genetic instability with an increased risk of progression towards malignancy. 
Recent work with p53 null mice has neatly illustrated how p53 can act as a molecular 
detector of DNA damage. Thymocytes from these mice remained sensitive to apoptotic 
stimuli, such as glucocorticoids and calcium ionophore, but were insensitive to stimuli such as 
y radiation and double strand breaks induced by the drug etoposide (Clarke et al., 1993; Lowe 
et al., 1993). This has neatly illustrated that an absence of wild type p53 in cells which 
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normally express it can lead to a block in one particular apoptotic pathway, i.e., that pathway 
which is induced directly by damaged to the DNA. Whether or not p53 is involved in 
apoptotic signalling pathways produced by different signals has yet to be established. 
3.4.5 Death genes 
Inhibitors of protein synthesis are able to delay apoptosis in many cell systems. This 
implies that the cell must be active in its own death, i.e., it must synthesise new gene products 
or continue synthesising particular gene products before apoptosis can occur. Some, but not 
all of these gene products may be specific to cell death by apoptosis. The genes which may 
need to be transcribed and their relevant functions are now an intense area of research. 
Apoptosis in the rat ventral prostate was one of the first models in which genes 
expressed during the cell death period were analysed (Buttyan et al., 1988; Sanford et al., 
1984). Analysis of known genes revealed expression of c-fos, c-myc, a-tubulin and HSP70 
over a 3 day period in vivo. This is a similar progression to that seen in cells stimulated to 
undergo proliferation (Curran et al., 1985). Another gene identified in rat tissues which was 
associated with apoptosis was the testosterone repressed prostate message 2 (TRPM-2) gene 
(Leger et al., 1986; Monpetit et al., 1988; Buttyan et al., 1989). TRPM-2 has been shown to 
be the rat homologue of sulphated glycoprotein 2 or clusterin (Cheng et al., 1988; Collard and 
Griswold, 1987), a lectin like molecule secreted by healthy sertoli cells. 
Thymocytes have also been widely used to isolate 'death genes'. mRNA has been 
examined from thymocytes undergoing apoptosis after y-irradiation or treatment with 
glucocorticoids and cAMP analogues (Harrigan et al., 1989; Owens et al., 1991). RP8 and 
RP2 were isolated after treatment with y-irradiation and glucocorticoid, and have been shown 
to have DNA binding motifs and integral membrane properties respectively (Owens et al., 
1991). Eleven mRNA clones have also been isolated from glucocorticoid and CAMP analogue 
treated thymocytes, three of which required the presence of both stimulants in order to be 
expressed (Harrigan et al., 1989). Subsequent analysis has revealed that one of the clones 
encodes a glucocorticoid-induced receptor with homology to the family of G-protein coupled 
tachykinin receptors (Harrigan et al., 1991). So far the role of these isolated genes within the 
cell death pathway has not been elucidated. 
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Section 3.5 The importance of bcl-2 in apoptosis 
3.5.1 bcl-2, a molecular suppressor of apoptosis 
Impairment of apoptosis resulting in predisposition to oncogenesis has been clearly 
shown in cell systems both in vitro and in vivo for the proto-oncogene bcl-2 (Reed et al., 
1988; Korsmeyer et al., 1990; Strasser et al., 1991). 
Bcl-2's oncogenicity was first implied by its association with follicular lymphoma, 
which in 90% of human cases involves the t(14;18) translocation. This results in the 
segment of the immunoglobulin heavy chain gene on 14q32 becoming juxtaposed to a 
transcriptionally active gene on 18q21 (Cleary and Sklar, 1985), termed the B cell 
leukaemia/lymphoma gene 2 or bcl-2 (Tsujimoto et al., 1984). Sequencing revealed that the 
full Bcl-2 polypeptide is encoded by two exons, the 5' exon being separated by a 50kb 
fragment from the second exon which has a long 3' untranslated region, Most of the bcl-2 
reading frame is contained within the 5' exon with the major-breakpoint cluster region (MCR) 
occurring in the middle of the 3' untranslated region (Cleary and Sklar 1985; Tsujimoto et al., 
1985; Bahkshi et al., 1985; Cleary et al., 1986). Why this translocation occurs within such a 
high percentage of follicular lymphomas is not clear. One possibility is that a region around the 
bcl-2 MCR has sequences which are similar to heptamer and nonomer sequences involved in 
germline VDJ rearrangements of the IgH gene (Taussig et al., 1989) and this leads to 
inappropriate rearrangements (Tsujimoto et al., 1988). Another possibility is illegitimate 
pairing between and ends of chromosome 14 with staggered double strand breaks on 
chromosome 18 (Bahkshi et al., 1987; Cotter et al., 1990). 
Human bcl-2 gene transcripts generate two primary proteins, Bcl-2a and BcI-2ß of 
26kDa and 22kDa respectively, which are generated by alternate splice and polyadenylation 
site selection (Cleary et al., 1985, Tsujimoto and Croce 1988). Bcl-2a and Bcl-2ß have the 
first 196 amino acids in common but differ in their C-termini. Early fractionation studies 
suggested that the Bcl-2 protein was associated with the plasma membrane fraction of the cell 
and since its DNA sequence revealed no transmembrane or signal peptide domain, Bcl-2 was 
assigned a location within the inner cytoplasmic membrane (Tsujimoto and Croce 1988). 
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Several attempts have been made to identify the exact location of Bcl-2 and with the use of 
monoclonal antibodies raised against human Bcl-2, the protein has been localised to the inner 
mitochondrial membrane (Hockenbery et al., 1990) and other areas within the cytoplasm (Liu 
et al., 1991; Chen-Levy et al., 1989, 1990; Hamilton et al., 1991). 
Of fundamental importance in bcl-2s meteoric rise to fame was the demonstration that 
it prolonged the survival of IL-3-dependent cells in the absence of the cytokine (Vaux et al., 
1988). Such cells were subsequently shown to enter apoptosis on withdrawal of the growth 
factor, indicating clearly that bcl-2 could suppress apoptosis and prolong cell survival in 
environments in which they would normally die (Williams et al., 1990; Rodriguez-Tarduchy et 
al., 1990; Crompton 1991). Suppression of apoptosis by bcl-2 however, is not a universal 
effect since IL6-dependent cells over expressing bcl-2 are not prevented from entering 
apoptosis on cytokine removal. Suppression by bcl-2 is therefore associated with particular 
cell lineages and may be mediated by interactions with in specific cytokine signalling pathways 
(Nunez et al., 1990). 
3.5.2 The role of bcl-2 in B cell selection 
Within the immune system Bcl-2 is expressed in thymus, spleen and tonsillar tissue, 
with staining patterns for both T and B cells within these areas conforming to a similar pattern, 
(Hockenbery et al., 1991). T-cells within the thymus show no staining in the cortex, a region 
associated with tolerance induction of immature T-cells, but stain positively at the 
corticomedullary junction and medullar, areas which correspond to mature T-cells 
(MacDonald et al., 1988; Miller et al., 1989). A similar pattern can be seen in tonsillar tissue 
containing germinal centres. B cells within the germinal centre dark and light zones show no 
Bcl-2 expression, but cells at the follicular mantle zone surrounding the germinal centre do 
express the gene. Both germinal centres and thymic cortex contain large numbers of cells 
which are often seen to be undergoing the process of apoptosis (McPhee et al., 1979; 
Swartzendruber and Congdon, 1963). Non-expression of Bcl-2 within these areas is thought 
to correlate with this susceptibility to induction of cell death. BcI-2 expression is also seen in 
plasma cells and myeloid cells within normal bone marrow (Hamilton et al., 1991) as well as in 
memory B cells (Nunez et al., 1991). Mature B and T cells stimulated with mitogens also 
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produce an increased amount of bcl-2 mRNA (Reed et al., 1987) and in plasma cells, peak 
antibody secretion correlates with down regulation of bcl-2 expression (Mushinski et al., 
1988). 
The ability of B cells to recognise unlimited numbers of foreign antigens is facilitated 
not only by rearrangement of the light and heavy Ig chain genes, but also by somatic mutation 
within the variable regions of the Ig chain (Taussig et al., 1988). This somatic mutation can 
result in amino acid changes in the complementarity determining regions or hypervariable 
regions of the Ig receptor which can cause a change in the Ig binding affinity. This 'affinity 
maturation' occurs after the initial exposure of T-cell dependent B-cells to antigen and on re- 
challenge, antibodies of higher than average affinity are produced. This process of affinity 
maturation gives rise to more efficient Ig receptors for recognising a specific type of antigen as 
well as to receptors of unchanged or lower affinity. It is in the selection of cells displaying 
higher affinity Ig that bcl-2 expression is a critical determining factor. 
Affinity maturation occurs in the germinal centres, such as those found in tonsillar 
tissue (MacLennan and Gray, 1986). Germinal centres can be divided anatomically into two 
areas (Nieuwenhuis and Opstelten 1984), the dark zone which contains proliferating 
centroblasts and the light zone which contains centrocytes which are generally not 
proliferating (Searle et al., 1982). Within this region follicular dendritic cells (FDC), are 
numerous and according to the type of surface protein which they present can be subdivided 
into two zones within the light zone. The basai zone contains FDC which express I-CAM 1 
(CD54) and CD73 (Johnson et al., 1989), and the apical zone contains FDC which express 
CD23 (Bettler et al., 1989; Johnson et al., 1986). Evidence that selection occurs in these areas 
has been based on the culture of purified germinal centre B cells which do not express bcl-2 
(see Liu et al., 1989 and section 3.2.3). These cells spontaneously enter apoptosis in vitro, but 
this can be prevented if the cells are stimulated through their surface immunoglobulin i.e., their 
receptors are cross linked by the use of anti Ig antibodies on the surface of sheep red blood 
cells. These B cells can also be rescued by anti-CD40 antibody and by soluble CD23 with 
interleukin-1a (Mangeney er al., 1991, Liu et al., 1991a). In all three cases rescue from 
apoptosis was associated with induction of bcl-2 expression. 
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Expression of bcl-2 appears to be critical in deciding the fate of B-cells within the 
germinal centre (Liu et al., 1991b). Centroblasts and centrocytes within the germinal centre do 
not express bcl-2 whereas cells at the follicular mantle zone surrounding the germinal centre 
do (Hockenbery et al., 1991). Cells which fail to interact with antigen in the germinal centre 
therefore enter apoptosis, but those which contact antigen presented by the follicular dendritic 
cells are rescued by a specific signal and resume expression of bcl-2 (Liu et al., 1991b). 
3.5.3 The oncogenicity of bcl-2 
When first discovered bcl-2 was regarded as only a potential proto-oncogene since 
there was no direct evidence of its transforming ability. The oncogenicity of bcl-2 was 
demonstrated by Reed and colleagues in 1988 using constructs producing Bcl-2a and Bcl-2ß 
which proved to be tumourigenic in 3T3 fibroblasts injected into nude mice. However, unlike 
ras and myc, bcl-2 did not have the ability to transform 3T3 cells in vitro, suggesting 
secondary somatic changes were required to produce the resulting tumours. 
The use of bcl-2 transgenic mice has taken this concept further and has illustrated that 
artificially induced expression of bcl-2 can provide the first step towards the development of 
lymphoma. 
A bcl-2-immunoglobulin minigene construct, mimicking the t( 14; 18) translocation 
found in follicular lymphoma, was used to produce bcl-2 transgenic mice (McDonnell et al., 
1989). These bcf-2-Ig transgenic mice displayed tissue specific expression of bcl-2, i.e., bcl-2 
expression was mainly restricted to lymphoid tissue including spleen and thymus from about 8 
to 13 weeks of age. Examination of the spleens revealed extensive hyperplasia in white pulp 
zones. Expanded follicular centre areas were evident with an abundance of small follicular 
centre cells and occasional immunoblasts, macrophages and plasma cells. The mice in general 
demonstrated an expanded B cell compartment bearing B220, Ia, IgM/IgD and K markers, 
corresponding to mature B cells when compared to litter mates. The B cells also expressed 
high levels of AA4.1 showing that the expanded B cell compartment still expressed some 
immature markers. Bcl-2 did not suppress maturation since plasma cells, immunoblasts and 
high levels of serum IgD and IgA were present. None of the mice at this stage showed any 
signs of developing neoplasia and there was no evidence of monoclonal outgrowth. Bcl-2 
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deregulation within B cells therefore resulted in a higher steady state number of B cells and 
these B cells had a much increased ability to survive in culture in the phase compared with 
normal B cells from littermates. This is in some ways analogous to the ability of bcl-2 to 
prolong myeloid cell survival in IL-3 deprived conditions (Vaux et al., 1988). The high level 
of surviving B cells was predicted to increase the chance of a B cell undergoing further 
genetic change leading to the production of a malignant monoclonal B cell tumour 
(McDonnell et al., 1989). 
Further evidence for bcl-2s ability to aid tumour production was demonstrated in 
another bcl-2 transgenic mouse model. Mice expressing an gene construct (i.e., 
bcl-2 under the control of the Ig heavy chain enhancer) were crossed with expressing 
mice (Adams et al., 1985) to produce mice (Strasser et al., 1990). These mice 
rapidly developed a disseminated malignant lymphoma, much faster than the 
littermates. The tumour formed within these mice was unusual since it represented a very 
primitive haemato-lymphoid stem or progenitor cell. In addition these transgenics again 
demonstrated excess pre B and B cells, but these cells were not malignant and did not grow 
well in culture. However, after a number of weeks, spleen and bone marrow cultures did 
produce a clonai outgrowth of B cells indicating that further genetic alterations were required 
in these cells to result in malignant clones. 
The bcl-2-Ig transgenic mice of McDonnell e? al., (1989) went on to develop 
malignant lymphoma at about 12 months of age (McDonnell and Korsmeyer 1991). This 
resulted from clonal malignant outgrowth of cells from the original lymphoid hyperplasia. This 
again indicated that secondary changes occurred to produce the lymphoma and in half of the 
mice these changes included a deregulated myc gene. 
In summary, bcl-2 is strongly implicated in the development of follicular lymphoma 
since deregulated bcl-2 expression in transgenic mice produces high numbers of surviving pre 
B and B cells, an analogous situation to that found in human follicular lymphoma (McDonnell 
and Korsmeyer 1991). Bcl-2 does this by suppressing signais which would normally result in 
germinal centre B cell death by apoptosis during clonal selection (Liu et al., 199 1 b). This large 
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surviving pool increases the chance of cells acquiring random genetic mutations which 
eventually lead to malignant clonal outgrowth. 
It is interesting to note that a number of papers recently published (Hamilton et al., 
1991; Pezzella et al., 1990) find bcl-2 expression in lymphomas not associated with the 
t(14;lS) translocation. It may well be that the result of the deregulation of bcl-2 by the IgH 
enhancer is not the only genetic mishap within lymphoid cells which can result in bcl-2 
deregulation. 
An interesting offshoot of the effect of artificial induction of bcl-2 expression on B cell 
development has been found in transgenic mice. Strasser et al., (1991a) report 
several perturbations in mature B cell responses. Transgenic mice show prolonged responses 
to antigen which corresponded to a accumulation of small B cells, immunoglobulin secreting 
cells and serum immunoglobulin in vivo and most of the transgenic mice developed 
autoimmune disease. Mice were shown to be developing and dying of acute renal failure which 
on examination was due to lymphoid infiltration of the glomeruli. Serum examination revealed 
the mice contained antibodies against nuclear antigens including histones and double stranded 
DNA. This is often found in patients suffering from autoimmune systemic lupus 
erythematosus. This was a common finding in the mice and was therefore not 
dependent on the point of integration of the transgene. The condition appeared to be due to 
the failure of the bcl-2 transgenic mice to terminate the immune response in the normal 
manner, implying that such termination may involve apoptosis under physiological conditions. 
Strasser et al., (1991a) propose that the absence of detectable autoimmunity in bcl-2 
transgenics from McDonnell et al., (1989) may be due to the differences between the mouse 
stains used to produce the transgenic mice. It remains to be seen whether an accumulation of 
plasma cells and serum immunoglobulin caused by the deregulation of bcl-2 has any role to 
play in human autoimmune diseases. 
3.5.4 The effect of bcl-2 expression in developing T cells 
Strasser et al., (1991b) reported the production of bcl-2 transgenics which expressed 
bcl-2 within the thymocytes and T cells. Sentman et al., (1991) also constructed transgenic 
mice which expressed bcl-2 within the thymus by using the lck gene promoter which has been 
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used successfully to express transgenes within cortical thymocytes (Chaffin et al., 1990). Bcl-2 
expression enhances immature thymocyte survival both on culture in vitro and in the presence 
of several stimuli which normally result in apoptosis in these cells such as anti-CD3 antibodies 
(Smith et al., 1989), calcium ionophores (McConkey et al., 1989a), glucocorticoids (Wyllie 
1980) and ionising radiation (Sellins and Cohen 1987). 
It has been suggested that apoptosis induced by engagement of the CD3/TCR complex 
by self antigens bound to self MHC molecules maybe involved in the clonal deletion of 
autoreactive thymocytes, an important element of tolerance induction (Smith et al., 1989). The 
negative selection of such autoreactive cells is thought to be concomitant with a down- 
regulation in bcl-2 expression. Therefore, constant expression of bcl-2 in the transgenic mice 
might be expected to inhibit this selection process. However, thymic selection did not appear 
to be disrupted in the bcl-2 transgenic mice when the mice were crossed to mice expressing a 
superantigen which normally causes deletion of a specific set of T cell subsets. Some 
autoreactive thymocytes were detected in one of the mouse models (Strasser et al., 1991b), 
but this was not reproduced in the bcl-2 transgenic mice of Sentman et al., (1991). Therefore, 
the role of bcl-2 expression in the selection of T cells still needs to be clearly defined. Recent 
evidence has shown that a cellular homologue of bcl-2, is expressed within thymocytes 
and is able to inhibit bcl-2's ability to suppress cell death (Boise et al., 1993). If the levels of 
mRNA found in thymocytes prove to be representative of the levels of protein 
expressed, then this may explain why the effects of bcl-2 expression on T-cell repertoire 
selection are difficult to detect (Williams and Smith 1993). 
Section 3.6 Epstein Barr virus and BHRF1 
3.6.1 Introduction 
Epstein Barr virus is a typical gammaherpesvirus which infects around 95% of all 
human populations. The virus is normally acquired asymptomatically in early childhood, but 
infection in adolescence in 50% of cases leads to infectious mononucleosis. Once acquired the 
virus persists in the host throughout life due to the persistent (latent) infection of B- 
lymphocytes (Gratama et al., 1988; Yao et al., 1985). Once the virus is induced into lytic 
Page 34 
Introduction 
cycle, virus particles are shed mainly from epithelial tissue and from the oropharynx area 
(reviewed by Rodgers et al., 1992). 
Epstein Barr virus, or EBV, is associated with several types of human cancers. In 
Africa in areas which are within the malaria belt, a childhood cancer, Burkitt's lymphoma, (BL) 
is an endemic disease which is associated with EBV infection (Epstein, 1985). Burkitt's 
lymphoma has been shown to be either EBV negative or positive and in areas where Burkitt's 
lymphoma is non-endemic, EBV-negative-BL predominates. In southern China EBV infection 
is strongly associated with nasopharangeal carcinoma (de The 1982). 
Two strains of EBV have been identified, types A and B, of which B is less efficient 
than A in the transformation of B-cells (Rowe et al., 1989; Rickinson et al., 1987). 
3.6.2 Epstein Barr virus infection in B-lymphocytes 
EBV binds to B-lymphocytes via a viral glycoprotein receptor, gp350/220 which 
interacts with CR2, a cell surface receptor for the C3d complement fragment. EBV is able to 
transform B-lymphocytes of both humans and primates producing continuous latently infected 
lymphoblastoid cell lines or LCLs which exhibit continuous proliferation in vitro (Rodgers et 
al., 1992). Once EBV is established within a host cell it can undergo one of two life cycles, the 
lytic or latent cycle. In the latent cycle i.e., non production of virus, cells either express 1 or 
progress to expressing 8 latent genes. These are the only genes expressed out of the 100 or so 
genes which are encoded within the EBV genome. Induction of the lytic cycle, i.e., viral 
production, results in nearly all of the 1 00 viral genes being expressed. 
Primary infection by EBV occurs in the oropharynx where the virus establishes 
persistent infection of epithelial cells by cycles of infection, virus replication, cell death and 
virus release followed by infection of new cells (Leibowitz et al., 1988). Initial infection of B- 
cells occurs in the oropharynx area by contact of sub-epithelial B-cells, which are largely non- 
permissive for viral infection, with virus shed from the infected epithelial cells. The ability of 
EBV to immortalise B-cells has been studied mainly in vitro using lymphoblastoid cell lines 
which represent the infected form of normal peripheral B-cells. These cells are able to 
proliferate continuously in vitro and express a restricted pattern of eight EBV latent genes 
(EBNAs 1, 2, 3A, 3B, 3C, LP, LMP1 and 2(TP) as well as a defined set of B-cell activation 
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antigens (e.g., CD23, CD30, CD39 and CD70) (Gregory et al., 1987, 1988a,b). The role of 
each of the eight EBV latent genes in specific B-cell transformation has been analysed by gene 
transfection assays in various cell lines. Expression of a particular EBV latent gene in B- 
lymphoma cell lines which do not express EBV (EBV negative Burkitt-type Iymphomas), but 
are at a similar stage of differentiation as EBV positive Burkitt's lymphoma cells has illustrated 
which EBV viral genes induce some of the B-cell phenotypic changes occuring in LCLs. For 
example, EBNAI expression does not result in B-cell growth transformation (Wang et al., 
1987), but appears to be essential for binding to the latent origin of replication (oriP) and 
thereby maintaining the EBV genome in an episomal form (Rawlins et al., 1985, Yates et al., 
1985). Both EBNA 2 and LMPl have been shown to induce cellular changes consistent with 
B-cell activation such as the expression of CD23, CD39 and the reduction in the expression of 
CALLA and CD10 ( Wang et al., 1987; Wang et al., 1990a,b), although EBNA 2 is able to 
upregulate expression of CD23, independently of LMP-1 expression. The clumping fo EBNA 
2 transfected cells in vitro is due to CD23 expression (Wang et al., 1987). EBNA 2 also acts 
as a transcription factor which can activate the expression of LMP1 (Fahraeus et al., 1990; 
Wang et al., 1990b), as well as initiating or enhancing the expression of EBNAs1, 3, 4 and 6 
(Woisetschiaeger et al., 1991). This may explain the inability EBNA 2 deficient mutant viruses 
to initiate the growth transformation of B cells (Hammerschmidt and Sugden 1989). EBNA-2 
expression in Rat-1 cells (a fibroblast cell line), although not able to induce growth 
transformation, can reduce the dependency of these cells for serum growth factors (Dambaugh 
et al., 1986). Expression of LW-1 in continuous fibroblast cell lines has transforming effects 
such as altered morphology, reduced requirement for serum factors and the loss of contact 
inhibition in monolayer culture (reviewed by Leibowitz et al., 1988). LMP-1 can also alter the 
growth of EBV negative Burkitt's lymphoma lines inducing increased intracellular free 
calcium, cell clumping and increased LFA-1, ICAM-1 and LFA-3 expression (Wang et al., 
1988; Wang et al., 1990b). The induction of B-lymphocyte adhesion molecules by LMP-1 
results in cell clumping and may enhance cell growth and survival by increasing the number of 
cells which come into contact with secreted autocrine factors (Liebowitz et al., 1988). LMP-1 
has also been shown to associate with the cytoskeletal protein vimentin as well as increase its 
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expression (Birkenbach et al., 1989). A naturally occurring mutant of LMP- 1 which lacks the 
N-terminus as well as the first four transmembrane domains (wt LMP-1 has six membrane 
spanning domains with both the N and C termini being cytoplasmic) is unable to induce any of 
the above growth transforming effects and does not associate with the cytoskeleton (Wang et 
al., 1988), suggesting this loss of vimentin association blocks LMP-1 induced phenotypic 
changs . 
EBNA 6 (or EBNA 3c) has also been shown to be involved in B-lymphocyte 
transformation, inducing expression of CD21 in the EBV negative B-cell line BJAB (Wang et 
al., 1990a). Transfection experiments in Raji BL cell lines, which do not express EBNA 6 due 
to its partial deletion in the resident EBV virus, has shown that expression of the gene results 
in increased LMP- 1 expression. Increased CD23 expression and expression of the cytoskeletal 
protein vimentin are also induced, consistent with the increased expression of LMP-1 (Allday 
et al., 1993). These results imply that EBNA 6 co-operates with EBNA 2 in enhancing the 
expression of LMP1 but whether this interaction occurs at the transcriptional or post- 
transcriptional level has yet to be established. 
Therefore, it appears that several of the latent genes expressed in LCLs are able to 
induce various increases in specific cellular gene expression associated with B-cell activation. 
Both EBNA 2 and LMP-1 when expressed separately in fibroblast lines, appear to effect the 
cells requirement for serum growth factors thereby increasing the cells ability to survive and 
proliferate in conditions which are growth limiting. Similarly, these viral genes may reduce B- 
cell requirement for growth factor by increased expression of LFA-I, ICAM-1 and CD23 
allowing homotypic B-lymphocyte adhesion and hence either increased autostimulation or 
closer contact with autocrine secreted growth factors. Superinduction of CD23 expression and 
the production of its soluble form (Thorely Lawson and Mann 1985) may be very important in 
maintaining LCL survival since CD23, in combination with IL-la, is a potent survival factor 
for germinal centre B-celis (Liu et al., 1991). LMP-1 induced upregulation of LFA-3, along 
with ICAM-1 and LFA-1 increases the cytotoxic T-cell response to the infected cells due to 
the interaction of LFA-3 with CD2 on T-cells (Springer et al., 1987). Although not 
detrimental to LCLs in vitro, up-regulation of these ligands in vivo would lead to the 
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elimination of the infected B-cell. Hence in both group 1 BL cell lines in vitro and BL tumour 
cells in vivo LMP-1 is not expressed and therefore neither are LFA-1, 3 and ICAM-1, 
providing a mechanism by which the EBV infected B-cell can evade T-cell detection (Gregory 
et al., 1988). Recent work has shown that this restricted expression of EBNA 1 is produced 
by the exclusive use of a newly discovered EBV promotor, F (Schaeffer et al., 1991). The 
expression of the EBNA genes in LCLs appears to be cotrolled by two promotors, the C and 
W promotors and switching between these promotors as well as alternative splicing and poly 
(A) site selection, controls the restricted latent gene expression (reviewed in Rodgers et al., 
1992). Studies on uncultured peripheral blood lymphocytes have indicated that another form 
of EBV latency may exist in vivo in which EBNAl is not expressed, only TP1(LMP2A) gene 
expression is seen, which is consistant with the hypothesis that a minimally active viral 
epísome exisits in resting B cells and hence evades immune recognition due to the absence of 
EBNAs 2, 3 and LMP (Qu and Rowe 1992). The role of TP1 in this form of latency is as yet 
unclear, but it may well represent the normal form of EBV latent infection found in healthy 
individuals. 
Therefore EBV latent gene expression in vivo would normally be predicted to exist in 
a highly conserved form, but in specific clinical circumstances transformed B-cells, exhibiting a 
phenotype similar to that of LCLs, occur within seropositive individuals. Primary EBV 
infection in infants normally occurs without any clinical manefestations. However, infection in 
later life can lead to a condition known as infectious mononucleosis. 0.5-2% of peripheral 
blood B-cells are EBNA positive suggesting that fully EBV growth transformed cells are 
present (Rodgers et al., 1992). LCL like cells are also present in seropositive individuals which 
have undergone organ transplants and hence receive immunosuppressive drugs. These patients 
can develop B-cell lymphomas which are EBV positive, but on removal of the 
immunosuppressive drugs and the re-establishment of T-cell responses the lymphomas regress 
(reviewed by Lenoir and Borakmann 1987). Hence cytotoxic T-cells primed against specific 
EBV antigens are thought to limit the production of growth transformed B-cells expressing all 
eight latent genes in healthy EBV carriers. 
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Therefore, it appears that the differing forms of latent gene expression are produced by 
the utilisation of different latent promotors and that expression of the latent genes is in part 
dictated by the likelihood of cytotoxic T-cell interactions i.e., highly restricted latent gene 
expression in healthy, seropositive individuals, but full latent expression in can be utilised in 
vitro as seen in LCLs. 
The close association of EBV with endemic BL rests on the following well established 
points: 
Patients with endemic BL have unusually high titres of antibodies to 
EBV antigens, show a pattern of reactivity which is specific to the 
disease and undergo changes in antibody levels in association with 
clinical events. 
All tumour cells of about 98% of properly authenticated cases carry 
multiple copies of the EBV genome. 
A WHO prospective seroepidemiology study found 16 cases of endemic 
BL in 42,000 Ugandan children over a 2 year period and were able to 
demonstrate unusually high titres of antibodies to virus capsid antigens 
in those destined to develop tumours many months or years before 
clinical manifestations. The risk of developing BL for those with high 
antibody titres was 80x greater than for matched controls. 
The production of Lymphoblastoid cell lines (LCLs) by infection of 
primary B-cells by EBV. 
EBV is experimentally oncogenic in certain south American sub-human 
primates. 
Animal herpes viruses that produce natural or experimental malignant 
tumours provide striking parallels for EBV and endemic BL (Epstein, 
1985). 
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3.6.3 Sensitivity to apoptosis in EBV latently infected B-lymphocytes 
Unlike EBV lymphoblastoid cell lines, biopsy isolates of EBV positive Burkitt's 
lymphoma cell lines only express one latent gene, EBNA 1. However, if these cells are 
cultured in vitro they will eventually express all eight latent genes, EBNAs 1, 2, 3a, 3b, 3c, LP 
and latent membrane proteins (LMP) 1 and 2 (Gregory et al., 1990). These different forms of 
latency are referred to as group I or group III cell lines respectively (Gregory et al., 1991) and 
were first characterised by observing that cultured EBV positive B cell lines either retain the 
cell surface phenotype of original biopsy cells or show genetic drift and eventually express all 
8 latent genes (Rooney et al., 1986; Rowe et al., 1987). 
These two groups of cell lines were shown to have differing sensitivities to the 
induction of apoptosis in response to various stimuli (Gregory et al., 1991). Group I cells 
readily entered apoptosis in response to serum reduction or the presence of calcium 
ionophore. However, group III cell lines did not enter apoptosis in response to these stimuli. 
Group III cell lines have since been shown to express bcl-2, mediated by the expression of 
LMP1, which produces the insensitivity to apoptotic stimuIi (Henderson et al., 1991). How 
expression of LMP1 induces expression of bcl-2 has so far not been determined. 
The initial sensitivity of group I cell lines to apoptosis may result from the site of 
tumour cell origin within the germinal centres of lymphoid follicles (Mann et al., 1976; 
Gregory et al., 1987). B-cells (centroblasts) within this cellular environment undergo somatic 
hyperrnutation producing immunoglobulin which exhibits either an enhanced binding for 
antigen, or immunoglobulin with unchanged or lower affinity for antigen. Progeny of the 
centroblasts, known as centrocytes, leave the cell cycle, re-express surface Ig and pass through 
the follicular dendritic cell network. Within this environment, if the cells successfùlly bind 
antigen then they are rescued from apoptosis, cells which do not successfblly bind antigen die. 
The surviving centrocytes either become memory B cells or antibody secreting plasma cells 
(see section 3.5). Therefore group I cell lines may act like centrocytes and constantly require 
survival signals in the absence of bcl-2 expression. 
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3.6.4 The Epstein Barr virus gene BHRF1 
Early data bank searches revealed only one protein with homology to bcl-2, the 
Epstein Barr virus (EBV) gene product BHRF1 (Cleary et al., 1986). 
The EBV BamH1 fragment H Rightward open reading Frame 1, BHRF1, encodes a 
putative transmembrane protein, (Pfitzner et al., 1987; Pearson et al., 1987) to which bcl-2 
shows sequence homology (Becker et al., 1991; Cleary et al., 1986). BHRF1 expression in 
EBV cell lines appears to result in the production of a family of mRNAs all with the same 3' 
end but differing in nucleotide chain length (Pfitzner et al., 1987). Exactly what role the 
BHRF1 protein product plays in EBV transformation is not known. BHRF1 is transiently 
expressed in some partially permissive latently infected B-lymphocytes (Kocache and Pearson 
1990), but is abundantly expressed during the early lytic infection cycle (Hummel et al., 
1982a,b; Pearson et al., 1987). The BHRF1 open reading frame consists of 191 codons and 
the predicted translation product has a potential hydrophobic amino-terminal signal sequence, 
a putative external domain of approximately 150 amino acids, a 21 amino acid hydrophobic 
potential transmembrane domain and a carboxy-terminal pentapeptide (Pearson et al., 1987, 
Pfitzner et al., 1987). The localisation of the protein within the cell has cytoplasmic and 
perinuclear distribution (Henderson et al., 1993) with some suggestion of membrane 
association (Kocache and Pearson 1990). 
The 25% primary amino acid sequence homology, which occurs over a 150 amino acid 
region in the carboxy end of the protein, between bel-2 and BHRF1 suggests that bel-2 is 
evolutionarily related to BHRF1 (see figure 3.7) and implies that BHRF1 may exert a similar 
effect on protection from cell death as bel-2 has been shown to do (see section 3.5). This has 
interesting implications in protection from viral infection in vertebrate cells. A paper recently 
published has identified a gene in Baculovinis, p35, which is able to suppress apoptosis on 
infection in insect cells (Clem et al., 1991). Prevention of host cell apoptosis by this gene 
enables the virus to infect and replicate efficiently within the cell. A similar role for BHRF1 
can be envisaged, especially since the gene is expressed early in the lytic cycle. However, 
recent results have shown that BHRF1 is not strictly necessary for efficient viral 
transformation of B-lymphocytes in vitro, (Marchini et al., 1990), but its homology to bcl-2 
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suggests that a survival signal may be necessary in EBV infected B cells in vivo which do not 
express bel-2 (Henderson et al., 1993) 
Section 3.7 Drug resistance in leukaemia/lymphoma 
3.7.1 Introduction 
Over the past few years improvements in the effective high dose delivery of cytotoxic 
drugs along with improved primary patient care has meant that remission rates for many 
cancers have improved dramatically. However, with this success has come the knowledge that 
some cancers become, or are already to some extent, drug resistant. Lister and Rohaitiner 
(1984) reported that not only do higher concentrations of drugs increase rate of remission, but 
that they also increase the rate of relapse free survival. Models for the development of drug 
resistance are mainly determined by the size of tumour burden at presentation. Goldie and 
Coldman (1979) proposed that the expectation of cure was related to both the size of the 
tumour burden at presentation (N) and the spontaneous mutation rate towards resistance (a). 
The chance of attaining a cure is inversely related to both N and a i.e., the higher N and the 
greater a, the lower the probability that a cure will occur. Also of great importance is that a is 
related to one drug. In the combination chemotherapy treatments now commonly in use, three 
or more drugs may be involved and this decreases the overall frequency of resistance, i.e., cells 
must become resistant to around 3 or more drugs instead of just one, and the chances of all 
these independent mutations occurring concomitantly will, in theory, be lower. 
Resistance to cytotoxic drugs can be placed into two categories; primary and 
secondary resistance. Many solid tumours are found to be chemoresistant at diagnosis and 
hence represent a primary resistant tumour. Primary resistance in leukaemia/lymphoma is very 
rare since an initial response to chemotherapy is nearly always seen. Leukaemias which do 
exhibit primary resistance are those for which the majority of the cell population is resistant at 
presentation. Secondary resistance occurs when a cell population appears sensitive at 
diagnosis, but a resistant sub-population emerges as therapy proceeds. On average, mutants 
with a given resistant phenotype occur at a rate of between 1 in and 1 in cell divisions. 
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Tumours will often have around cells at presentation and as a consequence mutation to 
resistance is likely to occur in a short period of time. 
Although several drug resistance mechanisms have been identified, drug resistance is 
still one of the greatest problems facing the clinical oncologist. A single definitive resistance 
mechanism has not so far been shown to account for resistance to a plethora of drugs. Indeed 
it is now thought that drug resistance may be explained by more than one mechanism. 
3.7.2 Classification of drug resistance 
Throughout evolution cells have acquired the ability to deal with foreign bodies or 
chemical toxins. It has been suggested that cancer cells may have enhanced efficiency in using 
some of these detoxification pathways leading to drug resistance. A description of some of 
these mechanisms is outlined in table 3.1 (Hall and Cattan, 1991). 
Although many single drug resistance mechanisms have been identified, i.e., 
dihydrofolate reductase gene amplification in methotrexate resistant cells, one mechanism 
identified so far seems to induce multidrug resistance in response to drugs with differing 
modes of action. Cells which exhibit this form of drug resistance are aptly named multidrug 
resistant cells or MDR cells. 
The MDR phenotype was first characterised in cells displaying reduced permeability, 
or altered membrane glycoprotein content in the presence of drugs such as colchicine (Ling 
and Thompson 1973), or the vinca alkaloids (Beck et al., 1979). Subsequent studies identified 
that these cells were able to internally reduce the level of drug within the cytoplasm by actively 
pumping the drug from the cell (Shen et al., 1986; Fojo et al., 1985). The protein responsible 
for this phenomenon was identified as a membrane glycoprotein, (Juliano and Ling 1976), 
subsequently termed P (for permeability)-glycoprotein. 
Genomic analysis revealed that in humans there are two closely related genes, mdr1 
and mdr2 that encode for highly homologous membrane proteins. Although both genes are 
referred to as multidrug resistance genes this role has only been shown for mdr1. The gene 
codes for a 4.5kb mRNA which produces the 170 kilodalton membrane glycoprotein, known 
as P-glycoprotein, which acts as an ATP dependent drug efflux pump on contact with 
cytotoxic drugs from the naturally derived drug compounds i.e., vinca alkaloids, produced 
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from the periwinkle plant (e.g., vincristine, vinblastin), anthracyclins, produced by 
Streptomyces, (e.g., daunorubicin and doxorubicin) and the epipodophyllotoxins produced 
from plant alcohol extracts, (e.g., etoposide and teniposide). These drugs exhibit differing 
modes of action, but they can all be effectively removed from MDR cells by the action of P- 
glycoprotein (Weinstein et al., 1990). 
Bcl-2 has been shown to mediate "stress resistance" in lymphoblastoid cells by a 
pathway which is independent of heat shock protein expression (Tsujimoto 1989). On 
exposure of these cells to stimuli such as heat, ethanol, methotrexate or low serum, a higher 
rate of survival was seen for the bcl-2 expressing cells. Since stimuli such as methotrexate 
(Barry et al., 1990; Lennon et al., 1990) and low serum (Henderson et al., 1991; Gregory et 
al., 1991; Wyllie et al., 1987) have been shown to induce apoptosis, these effects seem likely 
to result from specific suppression of apoptotic cell death. This is particularly interesting in the 
case of methotrexate, a widely used cytotoxic drug, since it implies that deregulated bcl-2 
expression in some cancer cells may contribute to drug resistance (reviewed by Dive and 
Hickman 1991). It may be possible that bcl-2 or other similar, as yet unidentified genes, could 
contribute to drug resistance by this mechanism. 
3.7.3 Mechanisms of chemotherapeutic drug cytotoxicity 
Drugs which are active against a variety of human cancers have differing modes of 
generating a cytotoxic signal. Since tumours often posses a higher mitotic rate than the normal 
tissues from which they derive, drugs which affect cells in S-phase exhibit greater cytotoxicity 
on the tumour cells than the surrounding tissues. 
One general mechanism of inhibiting S-phase transition is to limit the supply of nucleic 
acids required for DNA replication. Many drugs work on this principle but affect different 
pathways of pyrimidine and purine synthesis. Hydroxyurea, for example, inhibits the enzyme 
ribonucleoside diphosphate reductase which catalyses the reductive conversion of 
ribonucleotides to deoxyribonucleotides, a crucial and probable rate limiting step in the 
synthesis of DNA (Synder 1984). Inhibition of DNA synthesis by this mechanism leads to loss 
dGTP, decrease in dATP and increase in both dTTP and dCTP, although turnover in dTTP is 
also reduced (Skoog and Nordenskjold 1971). Such loss of deoxyribonucleotides also leads to 
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an inhibition of DNA repair which in turn leads to the formation of DNA strand breaks, which 
initially can be repaired on removal of hydroxyurea (Bacchetti and Whitmore 1969) and do not 
cause a loss in cell viability as measured by trypan blue exclusion (Li and Kaminskas 1987). 
The early studies of Bacchetti and Whitmore (1 969) also illustrate that a second wave of DNA 
strand breaks occurs after removal of the drug and that this leads to cell death. Since 
hydroxyurea is now known to induce apoptosis (Lemon et al., 1990), the second wave of 
strand breaks are probably due to the activation of the endonuclease. Bacchett and Whitmore 
also reported a non-S-phase mode of cell killing in which 10-20% of the cells are killed and 
suggested that such deaths result from cells just entering S-phase from G1 and from cells 
which die through "unbalanced growth" i.e., DNA synthesis is reduced but RNA and protein 
synthesis are still occurring. 
Induction of cell death by cytosine arabinoside (araC) has also been associated with 
DNA strand breaks and unbalanced growth as discussed above (Fram and Kufe 1982). In 
order to be effective, araC must be activated within the celi by conversion to the 5'- 
monophosphate nucleotide (araCMP), catalysed by deoxycytidine kinase. AraCMP then reacts 
with other nucleotide kinases to form the diphosphate and triphosphate forms. The 
triphosphate form araCTP is incorporated into the DNA during S-phase and thus causes 
inhibition of DNA synthesis due to a slowing of chain elongation and inhibition of chain 
termination (Momparler 1968, 1972; Zahn et al., 1972). AraCTP may also inhibit DNA 
polymerase by competing with dCTP for binding to this enzyme (Furth and Cohen 1968). 
Other studies have shown that incorporation of araCTP into the DNA is associated with a loss 
of clonogenic survival and suggests that the presence of the arabinose moiety results in alkali- 
labile lesions that produce single strand breaks (Kufe et al., 1980). It also alters the reactivity 
of the 3' terminus due to the conformational and hydrogen bonding differences of the 
arabinose moiety which is responsible for the decrease in chain elongation (Cozzarelli, 1977). 
How the presence of araCTP in the DNA triggers cell death is unclear although recent 
evidence demonstrates that apoptosis is induced as a result treatment with araC and this can be 
associated with an increase in c-jun expression (Gunji et al., 1991). Methotrexate is another 
antimetabolite which is also S-phase specific and induces DNA strand breaks in exposed cells 
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(Li and Kaminskas 1984; Lonn and Lonn 1986). Methotrexate inhibits dihydrofolate 
reductase, an enzyme which catalyses the production of tetrahydrofoiate from dihydrofolate 
(Werkheiser, 1963). Tetrahydrofolate is subsequently converted to 
methylenetetrahydrofolate which is essential for the conversion of deoxyuridine 
monophosphate to deoxythymidine monophosphate by the enzyme thymidylate synthase. 
Therefore methotrexate inhibits both thymidylate and purine nucleotide synthesis (Johns and 
Bertino 1982) and accordingly cell death has been postulated to occur due to a lack of thymine 
and purine (Hryniuk 1972). Once in the cells methotrexate becomes polyglutamylated and this 
form of the drug has been found to be a potent inhibitors of other folate-dependent enzymes 
involved in purine synthesis and folate conversions (Kwok and Tattersall, 1992). Cells treated 
with methotrexate show a progressive accumulation of DNA single strand breaks with 
increased exposure time and fewer cells recover on removal from the drug as treatment time 
increases (Li and Kaminskas 1984; Lonn and Lonn 1986). Failure of the cells to recover is 
assumed to be due to an inability to repair increasing numbers of DNA strand breaks due to a 
restriction in supply of deoxythymidine triphosphate and purine nucleotides. This may be true, 
however, treatment of cells with methotrexate has also been shown to induce apoptosis 
resulting in the cIeavage of the DNA into oligonucleosomal fragments, characteristic of 
apoptosis (Li and Kaminskas 1987; Barry et al., 1990). Precisely which cytotoxic lesion 
induced by methotrexate actually generates the apoptotic signal has yet to be established, but 
the inhibition of DNA synthesis and the resulting DNA damage may be important. 
Not all S-phase drugs act primarily by disrupting nucleotide synthesis, other drugs are 
able to affect enzymes required for DNA replication. An example of the latter are the 
epipodophyllotoxins which act on topoisomerase II. Mammalian topoisomerase II exists as a 
homodimer which forms at least two complexes with DNA that are thought to exist in rapid 
equilibrium (reviewed by Liu 1989). These two complexes are known as the cleavable and 
non-cleavable complexes and represent the broken and non-broken states of double stranded 
DNA produced by the enzyme. Topoisomerase II and topoisomerase I are required during 
DNA replication and transcription to provide swivel points for the DNA, removing the 
torsional stresses which occur as the DNA unwinds from its highly packaged structure to 
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allow access to enzymes such as DNA polymerase. Topoisomerase II (topo. II) is also 
required for the segregation of chromatids prior to mitosis since only topo. II can unlink two 
intertwined DNA circles via its strand passing ability (Yang et al., 1988). Both enzymes 
induce transient protein bridged DNA breaks on one (topo I) or both (topo II) DNA strands. 
The topoisomerase II poisons such as etoposide and teniposide are non-intercalating drugs 
that stabilise the breakage and re-joining reaction i.e., the cleavable complex and hence induce 
DNA strand breaks (Liu 1989). Such complexes are reversed upon removal of the drug which 
raises the interesting question of of why the cell dies (Long et al., 1986; Berger et al., 1991). 
However, recent work has indicated that significant DNA fragmentation often occurs several 
hours after removal of the drug or on prolonged exposure to the drug (Kaufmann 1989, 
Walker et al., 1991). This subsequent DNA fragmentation has been shown to be the result of 
apoptosis-fragmentation of the DNA being produced by the activated endonuclease. It has 
been proposed that the block of replication forks by topo. II inhibition or cleavable complex 
formation triggers apoptosis (Jaxel et al., 1988). Exactly how etoposide induced stabilisation 
of the cleavable complex triggers apoptosis is again unclear. However, results from studies of 
p53 null mice have indicated that the DNA damage produced by etoposide causes an 
accumulation of p53 which apeears to neccessary for cell death because in p53 null mice, p53 
accumulation cannot occur and the cells do not die (Clarke et al., 1993; Lowe et al., 1993) 
(see section 3.4.4). Another possible mechanism for etoposide induced cytotoxicity is by 
specific genetic alterations resulting from increased sister chromatid exchange (SCE) (Berger 
et al., 1991). The increased potential for non homologous recombination due to SCE has been 
postulated to result in genetic loss. The loss of essential genes leads to a loss of a crucial 
protein(s) which are required for continued cell survival. 
The cytotoxic drugs outlined above are most lethal in the S-phase of the cell cycle due 
to their different mechanisms for inducing blocks in DNA replication and nucleotide synthesis. 
Although each of the drugs specifically act in different ways and on different cellular targets 
the damage produced in the cell always appears to signal the induction of apoptosis. The 
molecular form of the drug induced signals for apoptosis have yet to be fully estblished (Dive 
and Hickman 199 1). 
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Section 3.8 In summary ... 
Apoptosis represents an active, controllable form of cell death involved in the 
regulation of cell population growth control (Williams et al., 1992). A cell dying by apoptosis 
goes through characteristic morphological and biochemical changes which can be used to 
distinguish it from necrosis. Therefore, in response to a given stimulus, the type of cell death 
occurring can be determined (Wyllie et al., 1980, Wyllie 1980). Several signalling pathways 
have been identified within apoptotic cells (McConkey et al., 1990a) as have several genes, 
some of which are more normally associated with proliferation, e.g., c- myc and c- fos (Evan 
et al., 1992; Buttyan et al., 1989). 
The bcl-2 gene, which is abnormally expressed by virtue of the t(14;18) translocation 
in follicular lymphoma, was the first gene unequivocally identified with the ability to suppress 
apoptosis (reviewed in McCarthy et al., 1992). Mice transgenic for the bcl-2 gene have shown 
how suppression of cell death within the population of B cells increases both the numbers of 
cells present and the chances that a cell will acquire additional mutagenic changes leading to 
clonal malignant outgrowth (e.g., McDonnell and Korsmeyer 199 1). Several genes have been 
identified with homology to bcl-2, the first of which was the EBV gene BHRF1 (Cleary et al., 
1986). Both genes share 25% primary amino acid sequence homology, but functional 
homology has yet to be determined and is one of the aims of this study. 
Bcl-2 has also been shown to induce stress resistance in response to stimuli such as 
methotrexate in cells expressing an exogenous form of the gene (Tsujimoto 1989). This 
suggests that bcl-2 may produce resistance to chemotherapeutic drugs. 
Finally, deregulation of bcl-2 is a primary step towards the development of lymphoma, 
providing the required genetic background for other mutations, such as mutated myc, to be 
viable (Askew et al., 1991). Therefore, the identification of other genes able to suppress 
apoptosis is important for the further understanding of progressive tumour development. 
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Section 4.1 General Techniques 
4.1.1 Tissue culture and standard aseptic techniques 
Severa1 cell lines were used throughout this project in order to characterise different 
aspects of apoptosis. All tissue culture was carried out in class II cabinets using aseptic 
techniques. All cell lines were cultured using ready-made 1x liquid medium (Gibco) 
supplemented with foetal calf serum (FCS) and 2mM L-glutamine (Flow). Standard and filter 
top or culture flasks (Nunc) were used for routine cell culture and all cell lines 
were incubated at 37°C in a 5% atmosphere. 
4.1.2 Determination of cell viability by vital dye exclusion 
Cell viability was ascertained by the use of a vital dye, Nigrosin (BDH), used at a final 
concentration of 0.1% which is non-toxic to the cells. A 1% Nigrosin solution was routinely 
made up in PBS and filter sterilised before use. of a cell suspension and of vital dye 
were mixed in a small eppendorf and of this was added to a Mod. Fuchs Rosenthal 
haemocytometer to determine cell viability (Hudson and Hay 1980). 
The statistical significance of differences in cell viability was determined using the 
Student t-test (see appendix A). 
This method of determining cell viability measures a very late point in apoptotic celi 
death, i.e., disruption of the cell membrane. Cells which appear viable in a vital dye will not 
necessarily represent a viable cell which is able to form progeny. Therefore, in experiments 
where celi viability needed to be stringently assessed, colony formation in soft agar was also 
used (see section 4.2.3.1). 
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4.1.3 Analysis of apoptosis 
Morphological and biochemical differences exist between cells dying by apoptosis or 
by necrosis (see section 3.1). These can be used to identify which form of cell death is 
occurring in a cell population in response to a specific death stimulus. 
4.1.3.1 Morphology of apoptotic cells 
Cells were assessed for apoptotic morphology by electron microscopy. This method of 
examining morphology clearly shows evidence of DNA condensation within the nucleus and 
morphological changes characteristic of apoptosis. 
1ml of a cell suspension containing approximately cells was pelleted in a 1.5ml 
eppendorf tube (Sarstedt) using a microfuge at low speed (6500rpm at 4°C) for 5 minutes, 
after which the supernatant was carefully removed. The eppendorfs were placed on ice and 
1ml of ice cold 2.5% glutaraldehyde fixative was carefully added without disturbing the pellet. 
The cells remained on ice for 2 hours to allow fixative to perfuse through the cell pellet. The 
pellets were then post-fixed in osmium tetroxide, dehydrated and embedded in epoxy resin. 
Using an ultramicrotome, 70nm sections were cut from the resulting blocks and stained in 
uranyl acetate and Reynolds lead citrate. Sections were examined and photographed using a 
Jeol 1200ex transmission electron microscope. A more detailed summary of the E.M process 
and the relevant recipes are shown in appendix B. 
4.1.3.2 DNA analysis 
DNA analysis by agarose gel electrophoresis was carried out as shown in figure 4.1. 
This method analyses genomic DNA and therefore fragmentation of the DNA is more obvious 
when the wave of apoptosis includes a substantial proportion of the cell population at the time 
of analysis. The solutions used in this protocol are shown in table 4.1. 
In cases where it was not possible to harvest cells and analyse the DNA on the same 
day, cells were sampled, pelleted and washed once in ice cold tris buffered saline. The cells 
were then pelleted in a large eppendorftube, supernatant was removed and the cell pellet was 
rapidly frozen and stored for up to 7 days at -20°C. 
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For some cell lines genomic DNA analysis did not prove sensitive enough to detect 
DNA fragmentation, therefore low molecular weight DNA was isolated. Cleavage of the DNA 
by the endonuclease produces oligonucleosomes representing multiples of 180bp which, on 
lysing the cells, can be separated from the uncleaved high molecular weight DNA. This 
method is based upon the published method of Wyllie et al.,(1982). or cells were 
pelleted in a small eppendorf and resuspended in of cold PBS on ice. Cells were then 
lysed on ice for 5 minutes in of lysis buffer containing 5mM Tris-HCI, 5 m M  EDTA and 
0.5% triton, pH 7.5. The lysate was centrifuged at 18 000rpm (16000g) for 40 minutes at 4°C 
to separate the high molecular weight DNA (pellet) from the low molecular weight DNA 
(supernatant). The resulting supernatant was carefully removed without disturbing the pellet 
and placed in a labelled 1 .5ml eppendorf on ice. The supernatant was then treated as described 
for genomic DNA, (see figure 4.1 and table 4.1) except that 10x concentrations of proteinase 
K and RNase A were added. 
4.1.4 Induction of apoptosis 
Four chemotherapeutic drugs were routinely used throughout this project to induce 
apoptosis; etoposide, an epipodophyllotoxin; methotrexate, cytosine arabinoside (araC) and 
hydroxyurea, ail anti-metabolites. These drugs were chosen because they all cause cell death 
via the disruption of different cellular pathways, as outlined in table 4.2. 
Ail drugs were made up fresh just before addition to the cells. 4.5mg of methotrexate, 
5mg araC and 5mg etoposide were dissolved in of DMSO for etoposide), then 
diluted 1 : 1 O with the appropriate growth medium and filter sterilised using a syringe 
top filter (Costar). Hydroxyurea was dissolved directly in growth medium and filter sterilised 
as described above. Serial dilution to the desired 10x concentration was carried out for all 
drugs and these were kept on ice prior to addition to cell culture. DMSO was used at a final 
concentration of 0.001% or less as a control in at least three repeat experiments and had no 
effect on cell viability. 
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Section 4.2 FDCP- 1 specific methods 
4.2.1 FDCP-1 cell lines 
4.2.1.1 Introduction 
The FDCP-1 cell line, (Factor Dependent Continuous cell line from the Paterson 
laboratory, Manchester (Dexter et al., 1980)), requires the presence of IL-3 for continued 
survival and proliferation. This cell line is representative of a haemopoietic, 
granulocyte/macrophage progenitor cell which is developmentally blocked, i.e., unable to 
differentiate further to produce mature cell lineages. 
FDCP-1 cells were maintained in liquid suspension culture using RPMI 1640 (Gibco) 
supplemented with 10% FCS (Gibco & Advanced Protein Products), 2mM L-glutamine and 
1% mIL-3 (see below). Cells were passaged every 2-3 days by dilution to celIs/ml. 
Growth of the cells to densities of more than was carefully avoided since this results 
in exhaustion of IL-3 and rapid apoptosis. 
Since the FDCP- 1 cell line represents a heterogeneous cell population regarding 
growth and death rates (N. J. McCarthy, unpublished observations) sub-clones of the FDCP-1 
cell line were obtained by soft agar cloning and limiting dilution in an attempt to standardise 
death rates. One of the isolated clones, FDCP-1-B, was used routinely throughout this project 
since its response to IL-3 withdrawal resulted in death by apoptosis over a period of 48 hours 
(O-10% viability), a desirable time course. A second clone, FDCP-1-6 was obtained from a 
culture of FDCP-1 cells which had been deprived of IL-3 for 7 days, then plated in soft agar 
with IL-3 to rescue any surviving cells. 
IL-3 was produced in the form of a supernatant obtained from mIL-3 cells (used by 
kind permission of Prof. Dr. Melchers, Basel Inst. Immunol.). The mIL-3 cells are X63Ag8- 
653 cells which have been transfected with a plasmid containing the murine IL-3 gene and 
therefore secrete large amounts of IL-3 into their growth medium (Karasuyama and Melchers, 
1988). These cells were maintained in RPMI 1640 and 5% FCS supplemented with 2mM L- 
glutamine and were passaged every 3 days or once they had reached confluency. Supernatant 
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from the cells was harvested and screened for FDCP-1 cell growth promotion before use. 
Batches were stored in 500ml bottles at -20°C and were thawed and filter sterilised before 
addition to FDCP- 1 growth medium, or subsequent re-freezing into smaller 1 0ml aliquots. 
4.2.1.2 Removal of cells from IL-3 
Removal of cells from IL-3 was carried out by washing the cells twice in RPMI 1640 
medium containing 10% FCS and 2mM L-glutamine, but without IL-3. Cells were then 
cultured in IL-3-deprived medium for periods varying from 24 hours to 7 days. Medium 
containing low levels of IL-3, sufficient to stimulate cell survival, but not proliferation was 
obtained by adding IL-3 at 0.2% instead of the usual concentration of 1% which is required 
for cell survival and proliferation in normal culture conditions. 
4.2.2 Protocol for chemotherapeutic drug induced apoptosis 
Replicate cultures were set up in a 24 well plate (Nunc) with the desired final 
concentration of drug being added to the appropriate wells; O. methotrexate, 
etoposide, araC and 2mM hydroxyurea (see section 4.1.4). Cells were exposed to the 
drugs for a maximum time course of 96 hours, with viability analysed at 15, 24, 39, 48 and 72 
hours. Morphology was analysed at 24 hours by E.M. and DNA integrity was examined at 
various time points as described in section 4.1.3. 
4.2.3 Electroporation 
Electroporation was used to introduce a plasmid expressing the Epstein Barr virus 
gene BHRF1 or a bcl-2 expressing plasmid into the FDCP-1 cells. BHRF1 was the first of a 
family of bcl-2 homologues to be identified and therefore functional homology between the 
two genes was analysed using the FDCP-1 cell line. The BHRF1 plasmid construct used is 
shown in figure 4.2. The bcl-2 construct used was a kind gift from Yoshihide Tsujimoto and is 
as described in Tsujimoto (1989). 
Electroporation of the BHRF1 construct was carried out as described in figure 4.3 and 
was the method of choice for these cell lines since it is relatively straightforward and because 
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of the clonal nature of the FDCP-1 cell lines, transfectants could be easily selected by cloning 
in soft agar. 
A Bio-Rad Gene-pulser apparatus was used along with a capacitance extender which 
enables higher voltages up to 0.450kV to be used for the electroporation of eukaryotic cells 
and was set to 960 microfarads The FDCP-1 cells were electroporated in phosphate 
buffered saline (PBS) which has a very low resistance due to high ionic strength. This means 
that the time constant is much lower in this media, around 17 msecs as opposed to 170 msecs 
in buffered sucrose. The time constant represents the resistance x capacitance, and is the time 
required for the peak voltage to decay to approximately 37% of the initial voltage. For the 
FDCP-1 cells in PBS this was recommended to be between 17 and 19 milliseconds (Muser et 
al., 1989). 
Sterile cuvettes (Bio-Rad) were used once per electroporation and care was taken not 
to touch the two metal sides of the cuvette, thereby allowing maximum contact between the 
cuvette and the electrodes. Ail appropriate safety procedures were followed during the 
electroporation protocol. 
Approximately 60 million FDCP-1 cells were used per experiment, allowing 20 million 
per cuvette and cells were of high viability and in log phase growth before treatment. Plasmid 
constructs were kept frozen in small aliquots at -40°C and thawed a few minutes before 
addition to the cuvettes. 
After electroporation cells were incubated in growth medium for 24 hours at 37°C and 
5% CO,, to allow the cells to recover. Cell viability was then determined by vital dye 
exclusion (normally around 50%) and live cells were harvested by centrifugation through a 
nycodenz (Nycomed) gradient by the method shown in figure 4.4. This enables removal of the 
dead cells, the presence of which may impair the growth of the remaining live cells, and 
reduces the number of cells which need to be analysed by growth on soft agar. Cells which had 
incorporated the plasmids were selected in the presence of hygromycin (Sigma) by virtue of 
the hygromycin resistance gene within the plasmid construct. 
Cells electroporated with the bcl-2 plasmids were treated exactly the same as described 
for the BHRF1 transfectants in figure 4.3, except for additions of plasmids and antibiotic 
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selection. of (bcl-2 expressing plasmid) was added to cuvette A and of 
(control plasmid) was added to cuvette B. Transfectants were selected for in the 
presence of the antibiotic geneticin (G4 18) (Sigma). 
For properties of antibiotics see table 4.5 in section 4.3. 
4.2.3.1 Soft agar cloning 
The ability of FDCP-1 cells to clone on soft agar in the presence of the selection 
antibiotic hygromycin or geneticin (Sigma) was used to identify which cells had successfiilly 
incorporated either BHRF1 or bcl-2 plasmids. Plating of the cells was carried out as described 
in figure 4.5, which represents the double layer method of soft agar cloning. The selection 
antibiotic was added to the bottom 10ml medium/agar layer at 120% of the required final 
concentration in order to compensate for the 2mls of agar/medium top layer which contained 
the cells. Final concentrations of between 10 and hygromycin or 1-2mg geneticin per 
plate were used. A 100x concentration of antibiotic was made up directly in growth medium 
and filter sterilised before adding the required amount to the cooled (45°C) medium/agar layer. 
Clones which grew in the presence of antibiotic were harvested, grown up in liquid 
culture and selected again by addition of either hygromycin or 2mg/mI geneticin to 
the growth medium. Cells were cultured in the presence of antibiotic for 7 days then in 
antibiotic free medium for 7 days. 
Expression of BHRF1 by the selected clones was assessed by western blotting, to 
detect protein expression, and by survival of the clones in medium without IL-3 or low levels 
of IL-3. The second method was used since the BHRF1 phenotype was predicted to be similar 
to that of FDCP-1 cells expressing exogenous bcl-2 i.e., enhanced survival of cells in the 
absence of IL-3. 
Selected clones, both BHRF1 transfectants and controls as well as bcl-2 transfectants 
and controls, were removed from IL-3 as described in section 4.2.1.2 and were set up in 
replicate cultures in the absence of IL-3. Viability was determined at 24 hour intervals and 
compared to that of an untransfected population of FDCP-1 cells. 
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4.2.3.2 Western blotting. 
Cells were analysed for BHRF1 expression by the method shown in figure 4.6. Buffers 
and solutions used are shown in table 4.3. The BHRF1 antibody solution was kindly provided 
by Dr. Sheila Henderson (Dept. Cancer studies, Birmingham). 
4.2.3.3 Development of a western blot by the ECL method 
Instead of developing the blots using autoradiography, it was decided to use the faster 
method of electrochemiluminescence (ECL). Washed nitrocellulose membranes were placed in 
a 1 : 1 mixture of the two bottled ECL chemicals (Pharmacia) and left at room temperature for 
exactly one minute. This allows the development of the horse radish Peroxidase stain present 
on the second antibody which leads to a fluorescent signal in the area where the antibody has 
attached. The membrane was then quickly removed and carefully rapped in cling film, any air 
bubbles present were removed. The membrane was subsequently placed in an autorad 
cartridge and covered with a sheet of light sensitive film. The cartridge was then closed and 
the film exposed to the membrane for 30 seconds initially, after which the film was removed 
and placed in developer. This was left for 5 minutes and then transferred to fixative for another 
5 minutes. Finally the film was washed in distilled water and hung up to dry. A signal, if 
present, should mark the film within 30 seconds, if strong, to 30 minutes if very weak, 
therefore separate pieces of film were exposed for increasing quantities of time to detect the 
signal. 
4.2.4 Selection protocol for apoptosis deficient mutants 
4.2.4.1 Introduction 
On removal of FDCP-1 cells from IL,-3 and subsequent culture in IL-3 deprived 
conditions for 7 days, a very low number of cells can appear viable by vital dye assessment (N. 
J. McCarthy, B.Sc. thesis 1990). It was possible that these cells represented spontaneous 
mutants which were unable to enter apoptosis on removal of IL-3, or showed enhanced cell 
survival, much like a cell expressing exogenous bcl-2 (Vaux et al., 1988). Therefore, a 
protocol was devised to select these cells for further analysis. At the same time the possibility 
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of mutating FDCP-1 cells and selecting for a bcl-2 like survival phenotype was considered and 
this was incorporated into the selection protocol. The construction of the full protocol will be 
described in results, but the routine elements are described here. 
4.2.4.2 Tritiated thymidine selection 
Cells were exposed to varying levels of tritiated thymidine in the presence 
and absence of IL-3. cells were added into replicate wells in a 24 well plate which 
consisted of; controls with IL-3, controls without IL-3, cells with IL-3 and or cells 
without IL-3 and with Cells were selected under these conditions at 37°C with 5% 
CO, for three days, after which celi viability was determined by vital dye exclusion and more 
stringently by the ability of cells to clone in soft agar. Cells were removed from by two 
washes in growth medium before plating in soft agar at cells per plate, or lower, as 
described previously. Both live and dead cells were plated in soft agar to fully assess viability 
and therefore the number of viable cells per plate was often considerably lower than the 
originai number of cells plated. Plates with highIy viable cells were always included as controls 
to obtain an estimate of maximum cloning efficiency. All plates were gassed, boxed and 
incubated for 14 days after which colonies of greater than 40 cells were scored. 
Sterile (concentration lmCi/ml, 28.8Ci/mA specific activity) (Amersham), was 
made up to a 1Ox stock concentration in growth medium without IL-3. The appropriate 
amount of was then added to each well to give the desired 1x concentration, e.g., 
of was added to 1.5ml medium to give a stock of of this was added 
to of medium with 10% FCS, with or without IL-3 and of cell suspension to give 
a final concentration of 
Section 4.3 Burkitt's lymphoma cell lines, specific materials and methods 
4.3.1 Burkitt's lymphoma cell lines 
Three different Burkitt's lymphoma (BL) cell lines have been used to examine the 
effects of over expression of bcl-2 and BHRF1 on apoptosis. Each cell line has differing 
characteristics which are outlined in table 4.4. Cells were maintained in the presence of RPMI 
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1640 supplemented with 10% FCS (Gibco) and 2mM L-glutamine. Since group 1 cell lines are 
highly sensitive to changes in serum factor concentrations, each batch of FCS must be 
screened in order to maintain a high degree of cell viability and growth. Cells were passaged 
every 2-3 days and were not split below a concentration of 1.3 x The Burkitt's 
lymphoma cell lines were transfected with plasmid constructs expressing either bcl-2 or 
BHRF1 (Henderson et al., 1991, 1993) and were cultured in the presence of selection 
antibiotics in order to maintain gene expression. Cells were grown either in hygromycin at 
(BHRF1 plasmids) or geneticin at 2.5mg/ml (bcl-2 plasmids) and were cultured in 
the antibiotics for 7 days and then grown without antibiotics for 4-6 days before re-selecting. 
All cells were washed free of the drugs 12 to 24 hours before any experiments were carried 
out. For properties of selection antibiotics see table 4.5. 
4.3.2 Induction of apoptosis by chemotherapeutic drugs 
BL cell lines were treated with the following drugs; methotrexate, araC and etoposide 
(Sigma) which were prepared as described in section 4.1.4. 
BL cells, with a starting viability of > 86%, were exposed at cells/ml to 
the desired drug concentration for 14 hours in growth medium at 37°C and 5% Treated 
and untreated controls were washed free of drug by 2 washes in warmed, gassed RPMI, and 
cells were resuspended in at least 3 replicate wells at cells/ml in growth medium. 
Viability was determined after 48 hours by the exclusion of the vital dye Nigrosin. 
Cells were also set up in 1ml replicate cultures with each of the drugs and viability was 
determined at 24, 48 and 72 hours, by vital dye exclusion, in order to obtain a time course of 
drug induced death. 
4.3.3 Exposure to ionising radiation 
Pre-washed, replicate cell suspensions of 3x1 celldmi were irradiated on ice in 1.5ml 
eppendorf tubes and exposed to 8Gy (Chep-BL) or 16Gy (Raji-BL) using a y source. 
After irradiation cells were pelleted and resuspended in 1ml cultures in fresh, warmed growth 
medium and incubated in a 24 well plate (Nunc) at 37°C with 5% Viability was 
determined as previously described and at least 3 replicates were counted per treatment. 
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4.3.4 Fluorescence microscopy 
Acridine orange, an intercalating, fluorescent DNA binding dye, was used to identify 
apoptotic cells with the characteristic condensed nuclear DNA morphology. Differing DNA 
states within viable and apoptotic cells result in differing access for acridine orange into the 
DNA. Hence acridine orange gives out a diffuse yellow/green fluorescence when bound to 
DNA in viable cells and a bright green fluorescence when bound to condensed (and less 
accessible) fragmented DNA in apoptotic cells. RNA in both viable and apoptotic cells emitts 
a red fluorescence. 
Acridine orange was made up to stock in water and filter sterilised. This was 
then diluted to give a stock of of this was routinely added to a cell 
suspension placed on a microscope slide. Both suspensions were mixed briefly on the slide 
with a automatic pipette tip before addition of a coverslip, with care taken to avoid 
trapping any air bubbles. The resulting cell suspension was then viewed immediately under a 
Zeiss fluorescence microscope using the x100 oil immersion objective lens. Cells were 
photographed using 100 ASA colour film. 
For the purposes of determining the numbers of morphologically normal (viable) and 
apoptotic cells, equal volumes of a cell suspension and acridine orange were mixed as 
described above and the numbers of apoptotic vs. live cells were determined by counting all 
cells visible in a field using the x16 objective lens. At least 8 separate fields were counted per 
replicate treatment. 
4.3.5 Giemsa staining of apoptotic cells 
Differences in the morphology of normal and apoptotic cells stained with Giemsa 
(BDH) relies on the differing states of the DNA within these two cell populations. Apoptotic 
nuclei, which appear characteristically condensed, stain a deep purple colour, where as viable 
nuclei stain pink in colour with purple nucleoli often visible. Counter staining is provided by 
Jenners stain (BDH) which gives the cytoplasm a light purple colour. 
cells in of PBS were spun onto labelled glass slides in a cytospin centrifuge 
at 600rpm for 4 minutes. The cells were then fixed in methanol for 10 minutes before staining 
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in diluted Jenners solution for 5 minutes (Jenners diluted 1:3 with Giemsa buffer). Cytospins 
were washed free of excess Jenners stain by rinsing in Giemsa buffer and were then stained 
with diluted Giemsa for 10 minutes (Giemsa diluted 1:10 with Giemsa buffer). Excess Giemsa 
was removed by washing two to three times in Giemsa buffer followed by one wash with 
distilled water. Slides were wiped dry, with care taken to avoid the stained cells, and then left 
for 5-10 minutes to air dry before mounting in DPX. 
Cell morphology was photographed under oil with x100 objective lens using 60 ASA 
artificial light colour film and a glass 82C blue filter which produces a whitish background. 
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Chapter 5 
Results: IL-3 dependent cells 
Section 5.1 Do chemotherapeutic drugs induce apoptosis in FDCP-1 cells? 
Several studies examining the mechanisms chemotherapeutic drug toxicity 
demonstrated that apoptosis was induced as a result of treatment (Wyllie et al., 1980). For 
example, low concentrations of hydroxyurea induce early double strand breaks in cells, 
probably due to the inhibition of DNA synthesis and repair, but these are repaired on removal 
from the drug. However, either a prolonged exposure, or higher concentrations of the drug, 
resulted in subsequent cell death which was associated with the reappearance of double strand 
breaks and fragmentation of the DNA (Li and Kaminskas 1987). Fragmentation of DNA had 
also been shown for etoposide and methotrexate (Kaufmann 1989; Li and Kaminskas, 1984). 
The demonstration of apoptotic morphology on treatment with chemotherapeutic drugs has 
also been reported in several different cell lines (Lennon et al., 1990; Collins et al., 1992; 
Fanidi et al., 1992). However, induction of apoptosis by chemotherapeutic agents in the 
FDCP-1 cell lines was confirmed directly and not assumed. 
Previous work using the FDCP-1 cell line had shown conclusively that apoptosis 
occurred as a result of removal of IL-3 from the cell culture medium (Williams et al., 1990) 
and that the resulting apoptotic morphology was distinctive, i.e., both fragmentation of the 
DNA and condensation of the nuclear chromatin was comparable to that observed in 
thymocytes treated with glucocorticoid (Wyllie et al., 1984). Hence, identification of 
apoptotic morphology in the FDCP-1 cells was predicted to be relatively straight forward. 
The demonstration of apoptosis induced by chemotherapeutic drugs in FDCP- 1 cells is 
an important preliminary step before examining the possibility that inhibition of apoptosis, by 
genes such as bcl-2, can have an effect on drug resistance (see section 3.7.2). 
FDCP-1 sub-clone B cells (FDCP-1-B) were used for these experiments since they 
have a more synchronous death rate than the FDCP-1 cell population (see section 5.3). FDCP- 
1 -B cells were treated with four drugs; methotrexate, hydroxyurea, araC and etoposide, 
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suitable concentrations of which were ascertained by referring to past papers and using 1 O fold 
higher and lower concentrations as well as the suggested value. Drug concentrations which 
produced around 80% loss of viability in 48 hours (see table 5.1) were used in the final 
experiments. Lower concentrations of drug were opted for in order to mimic the low levels of 
drug which can be tolerated in patients, compared to higher levels of drug which can be used 
in vitro. 
Cells were constantly exposed to the pre-determined, optimum drug concentration and 
viability was determined at 15, 24, 39, 48 and 72 hours. The drop in cell viability produced by 
the drugs is depicted in figures 5.1A and 5.1B with cell viability being around 20% or lower 
after 72 hours. The drop in cell viability observed in the control cell population at 15 hours is 
often seen in these cells and appears to be due to the relatively low starting cell density 
cells/ml) compared to the density at which the cells were growing at in culture (6-7 
cell to cell contact being an important factor in maintaining high viabiIity (Dexter et al., 1980). 
Having established a time course of cell death, cells were examined at 24 hours for 
apoptotic morphology by electron microscopy. Fragmentation of the DNA was analysed at 
various different time points. 
As mentioned earlier, apoptotic morphology in these cell lines is quite obvious on IL-3 
withdrawal and proved to be almost as clear on treatment with the chemotherapeutic drugs. 
When compared to untreated cells (see figure 5.2A), in which nuclei have normal diffuse dark 
and light staining chromatin, apoptotic cells, which have characteristically condensed, dark 
staining chromatin, are obvious in cells treated with either O. methotrexate (B); 
etoposide (C); araC (D) and 2mM hydroxyurea (E). 
Fragmentation of the DNA, another classical marker of apoptosis, was detected in cells 
treated with hydroxyurea for 15 hours, see figure 5.3 lane 6 .  For cells treated with 
methotrexate, araC and etoposide, DNA fragmentation was not detected until after 30 hours 
exposure to the drug and more strongly after 48 hours exposure (see figures 5.4A and 5.4B 
lanes 3,4 & 5,  and lanes 4, 5 & 6 respectively). Fragmentation of the DNA caused by 
hydroxyurea is clearly visible at 15 hours, but decreases in intensity at 30 and 48 hours, 
probably because 2mM hydroxyurea induces a more rapid loss of viability in the early stages of 
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Figure 5.1(A), (B) legend 
Displays mean % viabilities +/- standard errors (n=3), determined over a 72 hour period 
% viability, as determined by vital dye exclusion, is expressed as the number of viable cells divided by the total number of cells counted. 
Starting cell density = 2x 1 

Figure 5.2 Electron micrographs showing induction of apoptosis in FDCP-1 -B cells 
treated with chemotherapeutic drugs 
Legend 
Bar sizes represent 
(A) Untreated control cells, note the diffuse appearance of the nuclear chromatin 
Drug treated cells were exposed to (B) O methotrexate, (C) O etoposide. 
(D) O araC and (E) 2mM hydroxyurea for 24 hours before anal) sing 
Note the highly condensed chromatin identifjing the apoptotic cells 


Figure 5.3 Electrophoresis gel showing genomic DNA from FDCP- 1 -B cells exposed 
to chemotherapeutic drugs for 15 hours 
cells were harvested after treatment and analysed as described in materials and 
methods 
Gei lane data 
Lane 1 123bp DNA marker 
Lane 2 Control untreated cells 
Lane 3 
Lane 4 
Lane 5 
Lane 6 
Lane 7 
Cells treated with O araC 
Cells treated with O methotrexate 
O 00 1 % DMSO control 
Cells treated with 2mM hydroxyurea 
Cells treated with O etoposide 
Note the early fragmentation of the DNA in response to 2mM hydroxyurea (lane 6) 
compared to the other drug treated cells (lanes 7.3 & 3) 

Figure 5.4(A) Electrophoresis gel showing genomic DNA from FDCP-1 -B cells exposed to 
chemotherapeutic drugs for 30 hours. 
3x 1 cells were harvested after treatment and analysed as described in materials and methods. 
Gel lane data: 
Lane 1 Control. untreated cells 
Lane 2 0.00 1 % DMSO control 
Lane 3 Cells treated with etoposide 
Lane 4 Cells treated with araC 
Lane 5 Cells treated with 0. 1 methotrexate 
Lane 6 Cells treated with 2mM hydroxyurea 
Lane 7 123bp DNA marker 
Note the DNA fragmentation evident in response to etoposide, araC and methotrexate (lanes 
3-5 respectively). 
Figure 5.4(B) Electrophoresis gel showing genomic DNA from FDCP- 1 -B cells esposed to 
chemotherapeutic drugs for 48 hours. 
3x cells were harvested after treatment and analysed as described in materials and methods. 
Gel lane data: 
Lane 1 123bp DNA marker; 
Lane 2 Control untreated cells; 
Lane 3 
Lane 4 
Lane 5 
Lane 6 
Lane 7 
0.00 1 % DMSO control: 
Cells treated with etoposide: 
Cells treated with O.  1 methotrexate 
Cells treated with araC: 
Cells treated with 2mM hydroxyurea. 
Note the less intense UNA ladder in cells treated with 2mM hydroxyurea ut 48 hours (lane 7). 
compared to cells treated with etoposide methotrexate and araC (lanes 4-6). 
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drug exposure when compared to the other drugs (see figure 5.1A and 5.1B) and may indicate 
that the level of hydroxyurea used was relatively more potent. 
Therefore, in the FDCP-1-B cells both cellular morphology and DNA fragmentation 
were found to be characteristic of apoptosis, conclusively illustrating that the 
chemotherapeutic drugs used in this study induced death by apoptosis. These results are in 
agreement with several papers documenting apoptosis in response to many chemotherapeutic 
drugs in several different cell lines (Lennon et al., 1990; Barry et al., 1990; Miyashita and 
Reed 1992; Collins et al., 1992). 
Having established that chemotherapeutic drugs induce apoptosis in the FDCP- 1 cells, 
the ability of bcl-2 or BHRF1 to prevent apoptosis in these cell lines on treatment with 
chemotherapeutic drugs was investigated. 
Section 5.2 Electroporation of BHRF1 and bcl-2 into FDCP-1 cells 
Both bcl-2 and its viral homologue BHRF1 were electroporated into FDCP-1 cells to 
analyse the effect of constant expression of these genes on induction of apoptosis. Since bcl-2 
had been clearly shown to inhibit cell death in the FDCP-1 cell line on IL-3 withdrawal (Vaux 
et al., 1988), analysis of BHRF1 was carried out first. 
The EBV gene BHRF1 was one of the first genes to be identified as a homologue of 
bcl-2, exhibiting 25% primary amino acid sequence homology (Clearly et al., 1986) (see 
section 3.6.4). In the light of this, albeit limited, homology with bcl-2, it was interesting to see 
if BHRF1 showed some degree of functional homology to bcl-2 in the FDCP-1 cell lines. 
Therefore, a plasmid construct containing the BHRF1 open reading frame (designed and 
produced by Dr. David Huen, Dept Cancer studies, Birmingham) was electroporated into the 
cells (see section 4.2.3 for details of electroporation protocol and plasmid construct). 
After electroporation, cells were plated on soft agar in the presence of the selection 
antibiotic hygromycin at concentrations of per plate. No cell growth was observed 
at ranges from but selective clonal cell growth was seen on concentrations 
between 20 and (see table 5.2). Colonies representing clones which should have 
constructs expressing BHRF1 (A clones), clones which should have the control plasmid 
construct (B clones), and "no plasmid" control clones (C clones) which grew in the presence 
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of hygromycin were harvested from the plates and grown up in liquid culture. These clones 
were then re-plated in the presence of hygromycin at the concentration from which they were 
originally isolated. For example, clone was isolated from a plate containing 
hygromycin and was re-cloned on several plates of the same hygromycin concentration. After 
two subsequent rounds of re-cloning or maintenance in the presence of 3 hygromycin 
in liquid culture, A and B clones, isolated from either or hygromycin 
plates, (since none or relatively few control cells (C) were able to clone in these concentrations 
of hygromycin), were analysed for BHRF1 expression by two methods: 
(i) The ability of the cells to survive in the absence of IL-3, i.e., 
identification of a 'bcl-2 like' phenotype. 
Western blot analysis to determine if the BHRF1 protein was expressed. (ii) 
5.2.1 Analysis by removal from IL-3 
If BHRF1 had the ability to function as a molecular suppressor of apoptosis, much like 
bcl-2 in these cells (Vaux et al., 1988), then it is was probable that the cells expressing 
BHRF1 would show enhanced survival, but no proliferation in the absence of IL-3. Therefore, 
six of the clones isolated at selective hygromycin concentrations were removed from E - 3  and 
viability was determined by vital dye exclusion, after a 48 hour period. All the A clones tested, 
which in theory may have contained the BHRF1 expressing plasmid, had the same rate of cell 
death as the B clones, i.e., cells having the control plasmid, and both cell populations (A and 
B) were less viable than a control population of normal FDCP-1 cells, as shown in table 5.3. 
This suggested that either BHRF1 did not produce the same effect on cell death as bcl-2, 
despite its homology, or the suppressive effect was not as efficient as bcl-2 and was not 
evident in the complete absence of IL-3, or finally, although cells were selected and grown in 
the presence of hygromycin, the cells did not express BHRF1. Expression of the BHRF1 
protein within the cells would be clarified by western blotting, so evidence for a less efficient 
suppressive effect produced by BHRF1 was investigated by analysing cell viability in low 
levels of IL,-3. Previous experiments with FDCP-1 cells illustrated that levels of IL-3 around 
0.4% to 0.2% gave enhanced cell survival at 24 hours, but produced a loss in viability at 48 
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hours, as shown in figure 5.5. Therefore, all six clones were once again analysed, this time in 
levels of IL-3 at 0.2%. The results show that no significant inhibition of cell death was shown 
in the A clones compared to the B clones or the control population of untransfected FDCP-1 
cells (see table 5.4). 
In the light of the above results, it appears that either BHRF1 does not function like 
bcl-2 in these cell lines, or BHRF1 is not being efficiently expressed in these cells. Therefore 
the clones were analysed by western blotting to determine expression levels of the BHRF1 
protein. 
5.2.2 Western blotting analysis to detect BHRF1 expression 
Western blotting was carried out as described in materials and methods, section 4.2.3. 
The results obtained illustrated that none of the A clones isolated, i.e., those electroporated 
with the BHRF1 expressing construct, expressed BHRF1 protein at detectable levels, 
therefore explaining why no inhibition of cell death was seen in these clones on removal of IL- 
3. 
Further analysis of these clones would have involved Southern blotting to check that 
transfection of the plasmid by electroporation had resulted in the integration of the BHRF1 
gene into the cell's genome, although selection of the cells in hygromycin should have 
indicated this. However, since time was of the essence and a slightly different BHRF1 
expressing plasmid had been transfected into EBV positive Burkitt's lymphoma cell lines by 
Dr. S heila Henderson (Dept. Cancer studies, Birmingham), analysis of the functional 
homology of BHRF1 to bcl-2 and whether or not both genes were able to suppress 
chemotherapeutic drug induced apoptosis was transferred to these cell lines (see chapter 6). 
Possible reasons why BHRF1 was not expressed in the FDCP-1 cell lines are discussed 
in chapter 7. 
5.2.3 Electroporation of bcl-2 expressing plasmids 
Bcl-2 expressing constructs and controls were electroporated into FDCP- 1 cells and 
these cells were cloned and selected in the presence of the antibiotic geneticin (G418). 
Electroporation, cell selection in antibiotic and subsequent analysis of selected clones was 
Page 65 
Figure 5.5 legend 
Displays mean % viabilities +/- standard errors (n=3) 
% viability, as determined by vital dye exclusion, is expressed as the number of viable cells divided by the total number of cells counted. 
Starting cell density = 3x 1 
1% IL-3 is the concentration which is required to induce both proliferation and survival of FDCP-1 cells and is used at this level in standard culture conditions. 
Concentrations of IL-3 used at 0.4% and 0.2% produce limited survival of the cells for a short period of time, delaying the onset of apoptosis when compared to 
cells in 0% IL-3. 
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carried out as described for BHRF1 transfected cells. Although expression of bcl-2 was 
known to produce enhanced survival of FDCP-1 cells on IL-3 withdrawal (Vaux et al., 1988) 
this was not observed in the clones which had been selected for plasmid possession in the 
presence of G418 (see table 5.5). Therefore, it appeared that bcl-2 was not expressed using 
the Tsujimoto construct in these cells. 
Expression of bcl-2 in the FDCP-1 cell lines by Vaux et al., (1988) was produced 
using a retroviral construct and may have produced much better integration of bcl-2 into the 
host cell genome and hence stable bcl-2 expression. The Tsujimoto construct, used in the 
present study, is based on an EBV plasmid construct which in cells infected with EBV allows 
the plasmid to be maintained and transcribed in an episomal form, without integration into host 
cell DNA. Therefore, expression of the gene of interest can occur directly from the plasmid 
and so does not have the added complication of stable integration of the transfected gene in a 
suitable area of the genome as occurs with normal plasmid constructs. Hence, expression of 
the gene is more likely to occur using an EBV construct within an EBV infected cell line 
(Tsujimoto 1989). These points will be discussed further in chapter 7. 
Section 5.3 Development of a protocol for isolating apoptotic mutants of 
FDCP-1 cells 
Withdrawal of IL-3 from FDCP-1 cells results in a very low cell viability (-5% on 
average) by 72 hours as determined by vital dye exclusion. However, a very small, but 
identifiable set of cells do not become dye permeable, even when E-3 has been absent for 7 
days. These cells may simply be cells which have died, but not lost membrane integrity. 
However, the cells do not appear to have progressed through apoptosis since they maintain a 
viable cell appearance, there being no marked change in the cytoplasm and no ruffling of the 
cell membrane. This suggested the possibility that these cells were viable and unable to die on 
IL-3 withdrawal, either because they were factor-independent, or because they were blocked 
from entering apoptosis. Since FDCP-1 cells are easily cloned in soft agar at low cell 
concentrations, i.e., <1000 cells per plate, it was plausible that these cells, if actually alive, 
could be reclaimed from culture after 7 days without IL-3 by cloning on soft agar medium 
containing IL-3. Any surviving clones could then be harvested from the plates and the 
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phenotype of these cells could be identified. The clones isolated from these plates were 
predicted to be of two phenotypes: 
(i) Cells which are IL-3 independent, i.e., are able to secrete their own IL-3 
or short circuit the need for IL-3 stimulation and hence survive and 
proliferate in the absence of the cytokine (Cook et al., 1985; Cleveland 
et al., 1989). These were expected to appear more frequently since 
FDCP-1 cells are thought to develop IL-3 independent growth during 
normal prolonged tissue culture (Askew et al. , 1991). 
(ii) Cells which have a mutation in the apoptotic pathway and cannot enter 
apoptosis on IL-3 withdrawal and hence are unable to either grow or die 
in the absence of IL-3, but maintain a survival state, much like 
FDCP- 1 s expressing transfected bcl-2. 
Three populations of FDCP-1 cells were used throughout the development of the 
protocol, the FDCP- 1 s themselves and two subclones, FDCP- 1-B and FDCP- FDCP- 1 
cells show asynchronous levels of death on IL-3 withdrawal (N.J. McCarthy, B.Sc. thesis 
1990) and over a prolonged period of time in culture can develop factor independent cells 
(Elaine Spooncer, personal communication; Askew et al. , 199 1). FDCP- 1 -B cells (isolated by 
limiting dilution cloning of normal FDCP-1 cells) were used because they have a more rapid 
rate of cell death on IL-3 removal when compared to FDCP-1s (O-15% after 48 hours 
compared to O-30% for FDCP-1) and were thought to be less likely to develop factor 
independent cells. was isolated from an FDCP-1 cell culture which had been 
deprived of IL-3 for 7 days and subsequently cloned on soft agar containing IL-3. Although it 
seemed plausible that this clone may have a longer survival period in the absence of IL-3 than 
normal FDCP-1 cells, showed no enhanced survival when analysed over a period of 
72 hours (see table 5.9). 
The number of cells able to survive in the absence of IL-3 for 7 days was determined 
for each of the FDCP-1 cell populations by soft agar cloning. Although the FDCP-1 cells 
clone efficiently in agar, if increasingly greater numbers of live cells are plated, then this 
eventually causes a loss in colony formation efficiency due to a lack of IL-3 (see figure 5.6). 
Page 67 
Figure 5.6 legend 
Displays mean YO cloning efficiency +/- standard errors (n=3) 
% cloning efficiency is expressed as the number of colonies with > 40 cells present on the plate divided by the number original number of cells present per plate 
(5x 1 per plate). 
N.R. Note the decreasing cloning efficiency seen as the concentration of live cells per plate increases. 
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Therefore, cells were never plated above cell per plate. After incubation without IL-3 
for 7 days numbers of dead and live cells were ascertained by vital dye exclusion and then cells 
were either plated directly on to agar plates i.e., both live and dead cells together, or the cells 
were purified, using a nycodenz gradient in order to separate dead cells from any live cells. 
The second method was used in case a large number of dead cells present on the plate 
inhibited efficient colony formation. In order to check that a low level of live cells could be 
efficiently isolated from a large number of dead cells, 1000 live cells were added to dead 
cells prior to separation of viable cells by centrifugation through a nycodenz gradient and 
plating in soft agar. Separation of the added live cells from the dead cells and recovery of the 
added live cells from the agar plates was found to be efficient, as demonstrated in table 5.6. 
Therefore, any live cells present after 7 days without IL-3 should be isolated from the large 
numbers of dead cells by gradient purification. However, some cells could show a reduction in 
cell size after 7 days without IL-3 (as is seen in bcl-2 transfected cells on prolonged IL-3 
withdrawal), producing a change in buoyant density, causing some live cells to be lost during 
gradient separation. Therefore, dead and live cells were also plated out without prior 
purification. A drop in cloning efficiency may arise due to the presence of the dead cells, so to 
investigate this 1000 live cells were added to plates containing increasing numbers of dead 
cells. The results, shown in figure 5.7, illustrate that the presence of dead cells does interfere 
slightly with live cell cloning efficiency, the average cloning in the presence of dead cells being 
2-3%, as compared to 7 +/- 1.9% efficiency normally. However, a consistent reduction in 
plating efficiency was seen whether live cells were plated with 500 dead cells as a background 
or dead cells and therefore a useful number of viable clones can still be isolated using 
this method, even when a large number of dead cells are present. 
The numbers of cells able to survive 7 days without IL-3 and subsequently clone are 
shown in table 5.7 and do not appear to be very high, i.e., there doesn't appear to be a large 
number of spontaneous survival mutants from which it will be difficult to identify the less 
frequent apoptotic mutants. In order to determine which clones were apoptotic mutants as 
opposed to IL-3 independent cells, the differences between the cell cycle states of the two 
populations in the absence of IL-3 was exploited. 
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Figure 5.7 legend 
Displays mean % cloning efficiency +/- standard errors (n=3) 
% cloning efficiency is expressed as the number of colonies with > 40 cells present per plate, divided by the number of live cells originally plated i.e., 1000 
Control plate (1000 live cells with no background of dead cells) cloning efficiency = 7 +/- 1.9% 
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The fundamental difference between the two isolated cell types is that one will 
proliferate and hence be in cell cycle in the absence of IL-3 (IL,-3 independent cells) and one 
will not (apoptotic mutants, predicted to maintain a state). Since it was the latter cell 
population that were of interest in this study, the former population of cells were eliminated by 
selection in an S-phase specific drug. This was carried out by using a standard tritiated 
thymidine suicide protocol based on the selection of mutant yeast (Thompson et al., 
1970) (see section 4.2.4.2). 
In order to obtain a high level of cell kill by normal FDCP-1 cells, growing in 
IL-3, were incubated for 72 hours with differing levels of A 72 hour incubation period 
with should ensure that all cells progress through the celi cycle to and reach S-phase 
where death due to the presence of should occur. Viability, after treatment was 
determined initially by vital dye exclusion and more stringently by colony formation in soft 
agar. Results are shown in figure 5.8 and illustrate that at produced a cell kill 
of 80%, only leaving 20% of surviving cells to be re-selected, therefore, was used in 
the final protocol. 
5.3.1 Implementation and testing of the full protocol 
After all the preliminary experiments described above, the full selection protocol was 
constructed and used as shown below: 
The required number of cells (between and were removed from culture and 
washed free of IL-3 by two washes in RPMI supplemented with 10% FCS and 2mM L- 
glutamine. 
After the second wash and pelleting, cells were resuspended in 5ml of growth medium 
without IL-3 and viability and cell number were determined. 
After readjustment to cells per mi, 5ml of the cell suspension was added to 15 mls of 
warmed, pregassed growth medium without IL-3 in a tissue culture flask. The cells 
were then incubated for 4 days at 37°C with 5% 
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Figure 5.8 (A) legend 
FDCP-1 cells were treated with in the presence of IL-3 for 72 hours, before removing from the and cloning in soft agar containing IL-3. 
% colony formation is expressed as the number of colonies per plate, divided by the number of colonies counted per plate from a control, untreated FDCP-1 cell 
population 
All plates were plated with a starting cell density of 5x 1 per plate. 
Figure 5.8(B) legend 
The % viability of the FDCP- 1 cell population after 72 hours treatment with in the presence of IL-3 was determined by vital dye exclusion prior to 
plating on soft agar (as described in figure 5.8(A)). 
This graph represents the viabilities of the cells which were subsequently plated giving the results shown in figure 5.8(A). % viability is expressed as number of 
viable cells divided by the total number of cells counted. 
N.B.  induced ~80% cell kill of cells proliferafing in the presence ofII>-3. This concentration was chosen-for use in the final protocol to 
eliminate IL-3 independent cells able to proliferate in the absence qf IL-3. 
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After 4 days cell viability was determined by vital dye exclusion (on average <1% viability) 
and cells were purified on nycodenz gradient according to the normal protocol (see materials 
and methods). 
After purification, cells harvested from the medium/nycodenz interface were resuspended 
in of growth medium without IL-3 and cell numbers, both live and some dead, were 
determined (normally between cells). Cells were then added to 1ml cultures 
containing again with no IL-3, and were incubated under these conditions for 
a further 3 days, bringing the total number of days without IL-3 to 7. 
Cell number and viability were determined, initially by vital dye exclusion and then by 
plating in soft agar containing IL-3. Cells which reached this stage normally came to less than 
so only one plate was generally needed. The plates, including live cell control plates to 
monitor cloning efficiency, were gassed and boxed. Numbers of colonies with greater than 40 
cells were scored after 14 days. 
Table 5.8 shows the number of FDCP- 1 -B cells and FDCP- cells which grew after 
selection in the above protocol. The results are representative of 5 replicate experiments with 
the total number of cells having been screened equalling for each cell type. The levels 
of cells surviving the selection protocol may be too low to obtain spontaneous mutants which 
exhibit a block in the apoptotic pathway, i.e., these rates represent between one and ten 
colonies formed per seventy million cells. Although some of these colonies were harvested 
from the plates, they very rarely grew well once placed in liquid culture, suggesting that the 
clones were non-viable. 
To increase the number of survival mutants, the possibility of mutating the FDCP-1 
cells using insertional mutagenesis was considered and subsequently carried out in 
collaboration with Dr. Farzin Farzaneh (Rayne Inst., London). This could increase the 
numbers of mutants by 10 to 20 fold. Although FDCP-1-B cells have now been successfully 
mutated using this method, they were not available in time for analysis in the protocol. 
Further developments and refinements of this protocol will be discussed in chapter 7 
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5.3.2 Analysis of clones obtained from plates after 7 days without IL-3 
Clones which were isolated after 7 days without IL-3 were analysed to see if they were 
either factor independent or candidate apoptosis mutants. The clones were removed from IL-3 
and left for 72 hours before determining viability and were compared to a normal population 
of and FDCP-1-B cells. Clones which were IL-3 independent will grow by 
definition in the absence of IL-3 and therefore an increase in cell number would be expected 
over the 72 hour period. If a clone was specifically blocked from entering apoptosis, then a 
higher viability compared to normal FDCP-1 cells, but no increase in cell number, would be 
expected during the period of IL-3 withdrawal. No enhanced survival of the isolated clones 
was seen compared to normal FDCP-1-B and cells, see table 5.9. FDCP-1 and FDCP-mix 
cells which express bcl-2 generally lose viability slowly over a period of 2-3 weeks, with 
viability being around 50-70% after 8 days (Vaux et al., 1988; Fairbairn et al., 1993), a result 
which was never observed in these clones on IL-3 withdrawal. This suggests that the cells 
which are able to survive without IL-3 for 7 days, as judged initially by vital dye exclusion, do 
not necessarily represent cells which have either become factor independent or cannot enter 
apoptosis, but may represent one of the heterogeneous cell phenotypes found within the 
FDCP- 1 cell population. Sub-clones of FDCP- 1 cells which show enhanced survival have been 
obtained previously by limiting dilution cloning without removing the IL-3 (N.J. McCarthy, 
B.Sc. thesis 1990). These FDCP-1 sub-clones exhibited enhanced survival over 72 hours when 
compared to parental FDCP-1 cells, but this effect was lost over a period of 3-4 weeks in 
normal culture conditions (see chapter 7 for further discussion). 
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Chapter 6 
Results: Burkitt's lymphoma cells 
Section 6.1 Introduction 
Analysis of the effects of bcl-2 and BHRF1 on drug induced apoptosis were 
investigated using several EBV genome positive BL cell lines which had been transfected with 
plasmid expressing either BHRF1 or bcl-2 (Henderson et al., 1991, 1993; Tsujimoto, 1989). 
EBV positive Burkitt's lymphoma is primarily a childhood lymphoma endemic in areas 
defined by the African malaria belt. The lymphoma is highly aggressive, but very sensitive to 
treatment with chemotherapeutic drugs (Calvalli 1991), possibly due to its origin in the 
germinal centre and/or the presence of a deregulated c-myc gene produced as a result of the 
t(8; 14) translocation. Several cell lines were established from biopsies, primarily from African 
children, and have proved very useful as in vitro models of EBV-BL (Epstein 1985). 
Three BL-cell lines have been used as models for drug induced apoptosis in this study, 
two of which, Cheptages (Rooney et al., 1986) and Akata (Takada and Ono 1989), are 
representative of group I cell lines, which are sensitive to apoptosis, and Raji-BL cells (Rymo 
et al., 198 1 )  which exhibit some of the group III cell line characteristics, but retain group I like 
sensitivity to apoptosis. Group I cell lines express only one EBV latent gene, EBNA 1, where 
as the group III cell lines express all eight EBV latent genes, EBNAs 1, 2, 3a, 3b, 3c, LP and 
LMP 1 and 2 (Gregoy et aí., 1990). Group III cell lines are thought to be resistant to 
apoptotic stimuli due to the up-regulation in expression of host cell bcl-2 (Henderson et al., 
1991). However, Raji-BL cell lines do not express bcl-2, possibly due to point mutations 
within the LMP 1 gene (Hatfull et aí., 1988), which has been proposed to facilitate the up- 
regulation of host cell bcl-2 in EBV-BL cell lines (Henderson et al., 1991; S. Henderson, 
personal communication) and therefore remain sensitive to apoptosis. 
BL cell lines latently infected with EBV have circular forms of the EBV genome 
present i.e., episomes. EBNA 1 is the only gene from the EBV genome which needs to be 
expressed during latency in order to maintain the episomal state by binding to and activating 
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the latency origin of replication. This can result in the expression of genes from the episome 
without prior integration within the host cell DNA (Rodgers et al., 1992). The construct used 
for the BHRF1 expressing plasmid in these cells was based on the pHebo vector which can be 
episomally maintained in the presence of EBNA 1 (Henderson et al., 1993). Therefore, 
because the plasmid does not need to integrate within a suitably active expressed region of the 
host cell genome in order to express the gene of interest, the chance of attaining cells 
expressing the gene of interest is much increased. The bcl-2 construct used in these cells 
(Henderson et al., 1991) is also an EBV based vector (Tsujimoto 1989) and hence the same 
arguments apply regarding episomal gene expression. 
Cells transfected with either BHRF1 or bcl-2 show no significant increase in cell cycle 
time when compared to control transfectants, as shown in table 6.1. 
Although preliminary work illustrated that chemotherapeutic drugs induced apoptosis 
in the FDCP- 1 cells (see section 5. 1), this had not been established for the EBV-BL cell lines 
used in the present study. Therefore, the cell lines were exposed to three chemotherapeutic 
drugs; methotrexate, etoposide and araC. 
Two different protocols for exposing the cells to the drugs were used; cells were either 
exposed to the drug for a limited period of 14 hours after which the cells were washed and 
incubated in normal growth medium for a further 48 hours before determining viability, or 
cells were constantly incubated in the presence of the drug at slightly lower concentrations 
than those used for the 14 hour exposure period. 
Section 6.2 Induction of apoptosis by chemotherapeutic drugs and y 
radiation 
To investigate whether the BL cell lines underwent apoptosis on treatment with 
cytotoxic drugs, morphological analysis was carried out by electron microscopy for all three 
celi lines, by acridine orange fluorescence in Akata-BL and Raji-BL cells and also by Giemsa 
staining in the Raji-BL cells alone. 
Morphological changes characteristic of cell death by apoptosis were seen in treated 
cells and are shown unequivocally in the electron micrographs. 
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Results: Burkitt's lymphoma cells 
Untreated control Raji-BL cells (A) and drug treated cells are shown in figure 6.1 with 
the condensed chromatin, a characteristic marker of apoptotic cells, being clearly visible in 
cells treated with methotrexate (B), etoposide (C) and araC (D). The 
induction of apoptosis in response to ionising radiation which has been documented for several 
cell lines (Sellins and Cohen, 1987; Yamada and Ohyama 1988; Collins et al., 1992), was 
confirmed for these Burkitt's cell lines. Raji-BL cells were exposed to 16Gy of y radiation and 
morphology was examined 24 hours after treatment. Figure 6.1(E) illustrates the apoptotic 
morphology evident at this time point. 
Similar apoptotic morphology was observed in drug-treated Akata-BL cells (figure 
6.2B) in response to etoposide and in Chep-BL cell lines in response to 
methotrexate (D), etoposide (E) and araC (F). Cells treated with araC often 
showed additional degradative changes indicating cell damage which could either be 
independent of the process of apoptosis, or could represent early onset of secondary necrosis 
(to be discussed further in chapter 7). 
Fluorescence microscopy can also be very useful when identifying apoptotic 
morphology, as well as providing an alternative method for counting live vs. apoptotic cells. 
Both Raji-BL and Akata-BL cells were examined for apoptotic morphology by staining with 
the fluorescent dye acridine orange. The different appearance of apoptotic and 
morphologically normal cells is clearly shown in figure 6.3. Control untreated Raji-BL cells 
(A) show the bright diffuse orange staining of morphologically normal cells with intact DNA 
when compared to Raji-BL cell lines treated with the chemotherapeutic drugs (B, C, D) or y 
radiation (I) in which the condensed, fragmented green fluorescing DNA is evident as a 
marker for apoptotic morphology. Akata-BL cell lines also demonstrate the differing 
morphology in response to either methotrexate (F) or etoposide (H). 
For fùrther illustration of apoptosis in response to chemotherapeutic drugs in these cell 
lines a third method of cell staining was used. Raji-BL cells were stained with Giemsa (see 
figure 6.4) which stains normal nuclei a faint pink with purple nucleoli and apoptotic nuclei 
dark purple, which appear as condensed and fragmented masses within the apoptotic cells. 
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Figure 6.1 Electron micrographs showing induction of apoptosis in Raji-BL cells treated with 
chemotherapeutic drugs and y radiation 
Legend 
Bar sizes represent 2pm 
(A) Untreated control cells, note the regular appearance of the cytoplasm and normal nuclear 
chromatin state Drug treated cells were exposed to (B) methotrexate, (C) etoposide 
and (D) araC, for 14 hours and subsequently grown at 37°C free of drug for 24 hours 
before morphological analysis Apoptotic morphology is clearly shown in all drug treated cells by 
the condensation and margination of the chromatin around the nuclear membrane (E) Cells treated 
with 16Gy of y radiation again showing the margination of chromatin at the nuclear membrane, 
indicative of apoptosis, 24 hours post irradiation 


Figure 6.2 Electron micrographs showing induction of apoptosis in Akata and Chep-BL cells treated 
with cytotoxic drugs and y radiation. 
Legend 
Bar sizes represent 
(A) Untreated Akata-BL control cells, note the regular appearance of the cytoplasm and normal 
nuclear chromatin state. Drug treated Akata-BL cells were exposed to (B) etoposide, for 
14 hours and subsequently harvested for morphological analysis. Note the highly condensed and 
fragmented nuclear chromatin. 
Untreated Chep-BL control cells are shown in (C), again, note the regular appearance of the cells 
compared to cells treated with (D) methotrexate, (E) etoposide and araC. 
Cells were harvested directly after 14 hours exposure to drugs, without the subsequent growth in 
drug free medium since Chep-BL can often show a considerable drop in viability at this point and 
any later analysis may result in apoptotic morphology being overlooked. Despite this. cells treated 
with araC showed additional degradative changes, normally associated with necrosis. This suggests 
that death induced by this drug in this cell line is rapid. which may have resulted in the onset Of 
secondary necrosis by the time the cells were analysed. 



Figure 6.3 Apoptotic morphology in drug treated Raji-BL and Akata-BL cells stained with the 
fluorescent dye acridine orange. 
Legend 
Acridine orange is an intercalating DNA dye which produces yeliow/green fluorescence in double 
stranded DNA and red fluorescence in single stranded DNA or RNA. Therefore viable cells have 
bright diffuse staining DNA and apoptotic cells have featureless condensed DNA which give off a 
brighter green fluorescence. 
Untreated control Raji-BL cells are shown in (A) demonstrating the bright yellow colour associated 
with viable cells with intact DNA In contrast, cells treated with (B) 1 methotrexate, (C) 1 
etoposide and (D) araC appear both condensed as a whole and nuclear chromatic stains 
green and is fragmented within the cell Similar morphologies are s h o w  for Akata-BL cells with 
control cells shown in (E) and cells treated with etoposide shown in (F) 
Cells were treated with drugs for 14 hours and the subsequently grown in drug free conditions for 24 
hours before harvesting for morphological analysis 
Magnification = x100 oil immersion objective lens 



Figure 6.3 legend (cont.) These photographs were enlarged to illustrate clearly the morphology of 
single apoptotic cells. Control Raji-BL cells were enlarged (G)  to compare against Akata-BL cells 
treated with methotrexate (H) and Raji-BL cells treated with 16Gy y-radiation (I). 
Magnification = originally x100 oil immersion objective lens 

Figure 6.4 Raji-BL cells stained with Geimsa to illustrate apoptotic cells after treatment with 
chemotherapeutic drugs , 
Legend 
(A) Untreated control cells, note the pink appearance of the nucleus with purple nucleoli present. 
Cells treated with (B) methotrexate. (C) etoposide and (D) araC for 14 hours 
with 24 subsequent drug free growth before harvesting. Control cells are also shown (E) in 
comparison to cells analysed 24 hours after treatment with 16Gy of y-radiation (F). Note the dark 
pink/purple condensed chromatin evident in the apoptotic cells (indicated by stars). 
Magnification = x100 oil immersion objective lens. 



Results: Burkitt's lymphoma cells 
Apoptotic nuclei (marked by *) are evident in Raji-BL cell lines which have been treated with 
chemotherapeutic drugs (figure 6.4 B, C and D) and with y radiation (F). 
Therefore, all three BL cell lines undergo apoptosis in response to chemotherapeutic 
drugs and in Chep-BL and Raji-BL cell lines, after treatment with y radiation, as determined 
by morphological analysis. 
A further characteristic of many apoptotic cells is the activation of a calcium dependent 
endonuclease resulting in fragmentation of the DNA into multiples of 180bp (Wyllie 1980; 
Cohen and Duke 1984). Figure 6.5 shows an electrophoresis gel of low molecular weight 
DNA from Raji-BL cells after treatment with etoposide, methotrexate or araC, (lanes 3-5) 
with fragmentation being clearly visible. Electrophoresis of genomic DNA at 12 hours post y 
radiation also demonstrates DNA fragmentation in Raji-BL cells (see figure 6.6 lane 3). 
However, in Chep-BL and Akata-BL cell lines, fragmentation was not detectable regardless of 
whether genomic or low molecular weight DNA was analysed. This is most likely due to a 
high level of cells entering apoptosis asynchronously or cells undergoing DNA cleavage which 
does not produce the characteristic low molecular weight oligonucleosomal fragments, but 
produces larger, higher molecular weight fragments which are not obvious on agarose gels 
(Cohen et al., 1992; Brown et al., 1992; Tomei et al., 1993) (see chapter 7 for further 
discussion). 
A further classical point of apoptosis is the suppression of cell death by inhibitors of 
RNA and protein synthesis (Cohen and Duke 1984; Wyllie et al., 1984; McConkey et al., 
1989a). Although this has since been shown to be dependent on cell type (Vedickis and 
Bradshaw 1983; Martin et al., 1990) it was interesting to determine if new protein or RNA 
synthesis was required in drug induced apoptosis in these cell lines. Raji-BL cells were 
incubated with the drugs for 14 hours with or without cycloheximide. Cells were then 
washed free of both cycloheximide and drugs and were incubated for a further 48 hours before 
determining cell viability. Figure 6.7 clearly illustrates significant inhibition of cell death by 
cycloheximide in the presence of either methotrexate (p<0.01) or 1 etoposide 
(P<0.001). A significant inhibition of death was not evident in response to araC. This 
implies that both methotrexate and etoposide require active protein synthesis to induce death, 
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Figure 6.5 Electrophoresis gel showing low molecular weight DNA from drug treated and untreated 
Raji-BL control transfectant cells. 
cells were exposed to cytotoxic drugs for 14 hours and then washed free of the drug and 
cultured in normal growth medium for a further 12 hours before analysis (see materials and 
methods). 
Gel lane data: 
Lane I 123bp DNA marker; 
Lane 2 Untreated control; 
Lane 3 
Lane 4 
Lane 5 
Cells treated with etoposide; 
Cells treated with 1 methotrexate; 
Cells treated with 1 araC. 
Note the DNA fragmentation evident in cells treated with the chemotherapeutic drugs (lanes 3-5). 
Figure 6.6 Electrophoresis gel showing genomic DNA from Raji-BL cells exposed to 16Gy of y 
radiation. 
cells were harvested 12 hours after treatment and analysed as described in materials and 
methods. 
Molecular sizes in kilobase (kb) pairs are indicated 
Gel lane data 
Lane 1 Control transfectants, untreated. 
Lane 2 
Lane 3 
Lane 4 
Lane 5 
Lane 6 
Control transfectants mock-treated on ice, 
Control transfectants exposed to 16Gy y radiation, 
BHRF 1 transfectants untreated, 
BHRF 1 transfectants mock-treated on ice, 
BHRF 1 transfectants exposed to 16Gy y radiation 
Note the suppression of fragmentation in the BHRF1 transfectants when compared to the 
transfected controls in response to y radiation (lanes 6 and 3 respectively). 



Results: Burkitt's lymphoma cells 
however, this does not appear to be evident in araC induced death. Inhibition of protein 
synthesis by cycloheximide may have induced a cell cycle delay which would have caused a 
drop in toxicity of the S-phase drugs resulting in the suppressive effect. However, etoposide is 
not exclusively S-phase specific and araC, which is an S-phase specific drug, showed no 
inhibition of death in the presence of cycloheximide, so the suppression of cell death by 
cycloheximide appears not to be due to a delay in cell cycle. 
Overall, several aspects of drug induced cell death in the BL-cell lines are characteristic 
of apoptosis, especially in the Raji-BL cells where fragmentation of the DNA is evident and 
apoptotic morphology is quite clear in response to all stimuli investigated in this study. 
However, araC does appear to produce morphology in Chep-BL cells which is not typical of 
apoptosis and is not affected by the presence of cycloheximide, suggesting new protein 
synthesis is not required for apoptosis induced by this drug. Therefore, in these cell lines araC 
may operate to induce apoptosis via different pathways when compared to etoposide and 
methotrexate. 
Section 6.3 Expression of transfected bcl-2 affords protection against 
chemotherapeutic drugs and y radiation 
Having established that treatment of the BL cell lines with several cytotoxic agents 
resulted in apoptosis, Chep-BL-bcl-2 transfectants were analysed for protection from cell 
death in response to these stimuli. Figure 6.8A illustrates the viability of Chep-BL-bcl-2 
transfectants and controls after exposure to 8Gy of y radiation. High levels of suppression of 
apoptosis are seen for Chep-BL-bcl-2 transfectants when compared to controls at 24 and 48 
hours post treatment (p<0.00 1). 
Bcl-2 is also able to suppress apoptosis in response to cytotoxic drugs as shown in 
figure 6.8B. Significant inhibition of cell death (p<0.001) is seen for Chep-BL-bcl-2 
expressing transfectants compared to controls treated with either 1 etoposide or 
methotrexate. Chep-BL-bcl-2 expressors show a smaller inhibition of cell death in response to 
treatment with araC and the observations are statistically significant at the 10%, but not at the 
5% level. 
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Results: Burkitt‘s lymphoma cells 
Fluorescence microscopy of cells stained with acridine orange allows identification of 
cells with apoptotic morphology before cell lysis (see figure 6.3), potentially representing a 
more accurate method for establishing numbers of apoptotic vs. viable cells. When apoptosis 
was monitored by this technique, bcl-2 expression was found to inhibit apoptosis induced by 
either methotrexate or etoposide, but the inhibition of apoptosis induced by araC was once 
again found to be relatively small and not highly statistically significant, see figure 6.9A. 
Chep-BL-bcl-2 transfectants and controls were also incubated in the presence of 
chemotherapeutic drugs for up to 72 hours to determine the rate of cell death. Results of the 
time course are shown in figure 6.10 and again, although significant inhibition of cell death is 
seen for bcl-2 expressing transfectants when compared to controls in response to 
methotrexate (A) (p<0.02) and etoposide (B) (p<0.001) at 72 hours, there is no 
inhibition of death in cells treated with araC (C) by 72 hours. This latter result may 
identify a pathway of drug induced cell death for which bcl-2 is not a potent inhibitor or the 
result may reflect the necrotic morphology sometimes observed in these cells in response to 
araC. These points will be discussed further in chapter 7. 
In order to verify that the inhibition of apoptosis induced by cytotoxic drugs was a 
reproducible effect produced by the expression of bcl-2 and not a characteristic caused by an 
unknown mutation in any one clone, two further Chep-BL-bcZ-2 expressing clones were also 
treated with etoposide. Suppression of apoptosis was again demonstrated and is shown in 
table 6.2. 
These results extend the range of apoptosis-inducing stimuli for which bcl-2 provides a 
protective effect in Chep-BL cells, protection against apoptosis induced by serum withdrawal 
or calcium ionophore having been previously documented for these cell lines (Henderson et 
al., 1991). The direct demonstration of inhibition of apoptosis induction also confirms that, as 
found in other cell types, bcl-2 expression increases cell culture viability after treatment with 
cytotoxic drugs by inhibiting apoptosis rather than stimulating proliferation. 
Section 6.4 The EBV gene BHRF1 can also suppress apoptosis 
The EBV gene BHRF1 was the first gene shown to have any significant homology to 
bcl-2 (Cleary et al., 1986), suggesting the possibility that it too might possess the unusual and 
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Figure 6.10 legend 
Significant suppression of apoptosis is seen for bcl-2 transfectants. .relative to 
controls in response to 1 methotrexate (A), 1 etoposide (B). Cells treated with 
araC (C) do not show significant suppression of cell death. Both bcl-2 transfectants 
and controls 
Means and S.E. are representative of 3 replicate counts. % viability as determined by vital dye 
exclusion, is expressed as number of viable cells divided by the total number of cells counted. 
remain highly viable in the absence of drugs. 


Results: Burkitt's lymphoma cells 
potentially highly significant property of suppressing apoptosis (Williams, 199 i ) .  Raji-BL cells 
transfected with BHRF1 or relevant plasmid controls were exposed to 16Gy of y radiation and 
their viabilities were determined at 24 and 48 hours post treatment. Inhibition of apoptosis is 
seen for BHRF 1 -expressing transfectants showing significant inhibition (p<0.02) of cell death 
when compared to controls (see figure 6.1 1A). This suppression of cell death can also be seen 
by monitoring DNA fragmentation. Figure 6.6 shows a qualitative delay in fragmentation in 
BHRF1 transfectants compared to controls analysed at 12 hours post irradiation (lanes 6 & 3 
respectively). 
On treatment with cytotoxic drugs, BHRF1 expressing Raji-BL cells show significant 
suppression (p<0.001) of apoptosis in response to ali three drugs tested, as illustrated in figure 
6.1 1B. Again, greatest suppression is seen in response to etoposide, followed by methotrexate, 
then araC. These results were also verified by directly counting apoptotic cells stained with 
acridine orange (see figure 6.9B). 
A time course of drug induced cell death was also established in these cells, see figure 
6.12. Suppression of cell death is again evident in BHRF1 transfectants when compared to 
controls in response to methotrexate (p<0.00 1), etoposide (p<0.00 1) and araC (p<0.05) at 72 
hours. 
To ensure that the effect was not confined to Raji-BL cells, nor indeed the result of an 
undefined mutation within the Raji-BL transfectants, BHRF 1 -transfected Akata clones were 
also studied using etoposide and methotrexate (neither araC or y-radiation could be used with 
Akata clones since the parent Akata cells are insensitive to high levels of araC 
and y-radiation (30Gy) see table 6.3). Figure 6.13 shows significant suppression of apoptosis 
in response to methotrexate (p<0.01) and etoposide (p<0.05), and further 
indicates that BHRF1 is able to prevent apoptosis in different genetic backgrounds. 
Section 6.5 In summary... 
The BL cell lines used in this study have been shown to enter apoptosis in response to 
several chemotherapeutic drugs and for two of the lines, Chep-BL and Raji-BL, in response to 
y-radiation. Expression of exogenous bcl-2 is able to significantly suppress cell death produced 
by the above stimuli. This suppression is noticeably smaller for araC, possibly indicating that 
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Figure 6.12 legend 
Significant suppression of apoptosis is seen for BHRF 1 transfectants relative to 
controls in response to methotrexate (A), etoposide (B) and 
araC (C). Both BHRF1 transfectants and controls+ remain highly viable in the 
absence of drugs. 
Means and S.E. are representative of 3 replicate counts. 
% viability, as determined by vital dye exclusion, is expressed as the number of viable cells 
divided by the total number of cells counted. 




Results: Burkitt's lymphoma cells 
araC acts in part through a bcl-2 independent pathway. BHRF1 expression in two BL cell 
lines, Raji and Akata also affords protection against drug induced cell death and therefore is 
functionally homologous to bcl-2 in these cell lines. Since BHRF1 is a viral gene, this result 
has interesting implications for both efficient viral production i.e., delaying the onset of cell 
death in order to maximise virus production and the association of viruses such as EBV with 
human cancers. Both bcl-2 and BHRF1 induce a novel form of drug resistance in these cell 
lines by their ability to inhibit, or delay the onset of cell death. Therefore, inhibition of 
apoptosis by specific genes could represent an alternative mechanism with which to explain 
multidrug resistance in some cancer cell lines. 
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Chapter 7 
Discussion 
Section 7.1 Introduction 
Perhaps one of the most important features of apoptosis is that this form of cell death 
is active and can be regulated by both internal and external factors (reviewed in Williams et al., 
1992). Many cells rely on growth factors to provide a survival stimulus, withdrawal of which 
results in cell death (Williams et al., 1990; Nunez et al., 1990; Rodriguez-Tarduchy et al., 
1990). This suggests that cell populations which overgrow should eventually encounter an 
environment where growth factors are limiting for some of the cells, which results in 
apoptosis, thereby maintaining the original population size. However, certain genes, such as 
bcl-2, can block apoptosis, resulting in a survival signal which keeps the additional numbers of 
cells alive. This appears to be an early step in tumour progression, as demonstrated in bcl-2 
transgenic mice which have an expanded B-cell population, the increased numbers of which 
heighten the chances of other oncogenic mutations occurring, resulting in clonal malignant 
outgrowth (McDonnell et al., 1989: McDonnell and Korsmeyer 1991). Therefore, genes 
which actively suppress apoptosis can provide an environment which is suitable for the 
acquisition of further malignant mutations (Askew et al., 1991). 
The first gene to be identified with homology to bcl-2 was the Epstein Barr virus gene 
BHRF1, the two genes sharing 25% primary amino acid sequence homology. This suggested 
that BHRFl may possess the ability to suppress apoptosis much like bcl-2, and for this reason, 
the effect of both bcl-2 and BHRF1 on chemotherapeutic drug induced cell death was 
investigated. The anti-cancer drugs and y-irradiation were chosen as a death stimulus primarily 
because of a paper published by Tsujimoto (1989) which suggested that bcl-2 was able to 
suppress chemotherapeutic drug induced and radiation induced cell death. This suppressive 
effect could represent a novel form of multidrug resistance, if shown to occur in response to a 
variety of chemotherapeutic agents. 
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In this study, induction of apoptotic cell death by anti-cancer treatments has been 
demonstrated in an IL-3 dependent cell line as well as three EBV positive Burkitt's lymphoma 
cell lines. The morphological examination of the cells was carried out using both light and 
electron microscopy and evidence for the characteristic endonuclease activation resulting in 
fragmentation of the DNA was shown by agarose gel electrophoresis. Expression of either 
bcl-2 or BHRFl in the EBV-BL lines produced suppression of apoptosis on treatment with 
several chemotherapeutic agents and y-radiation, as determined by vital dye exclusion. These 
results have broadened the stimuli for which BHRFl acts as an apoptotic suppressor, 
resistance to serum withdrawal and treatment with calcium ionophore having been previously 
shown (Henderson et al., 1993). The results further illustrate that the suppression of apoptosis 
produced by either bcl-2 or BHRF1 can produce a novel form of drug resistance. The ability 
of BHRF1 to suppress apoptosis also has implications for EBV infection and virus production 
in human cells. 
Although bcl-2 was the first gene identified with the ability to suppress apoptosis, it 
was not thought to be the only gene able to produce this effect for several reasons, including 
the fact that bcl-2 is unable to prevent cell death in response to all apoptotic signals so far 
investigated. Indeed, three new cellular genes which have homology to bcl-2 have recently 
been identified (reviewed in Williams and Smith 1993). The identification of genes with 
homology to bcl-2, or of other genes which are able to suppress apoptosis, is important since 
these genes may represent early genetic mutations essential for the successful progression of a 
cell along the malignant pathway. In this study a protocol has been designed to identify E - 3  
dependent cells which are blocked from entering apoptosis so that new genes which act within 
the apoptotic pathway can be identified. 
Section 7.2 Transfection of FDCP-1 cells with bcl-2 or BHRF1 
The EBV gene BHRFl was one of the first genes to be identified with homology to 
bcl-2, and now forms part of an extending bcl-2 family (Williams and Smith 1993), which 
includes bcl-x and bax (Boise et al., 1993; Oltvai et al., 1993). BHRFl is expressed primarily 
in the lytic cycle of EBV infection with some expression in the latent cycle after cells have 
been recultured after serum starvation (Kocache and Pearson 1990). BHRF1's homology to 
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bcl-2 was thought to reflect the fact that it was expressed in the lytic cycle and may protect 
against cell death during viral infection, a hypothesis which was supported by the discovery of 
a baculovirus gene product, p3 5,  which suppressed insect cell apoptosis during infection 
(Clem et al., 1991). This suggested that some viral genomes may have evolved genes which 
suppress cell death during infection and that induction of cell death by the infected host cell 
may represent a primitive cell defence mechanism. Several other viral genes have now been 
identified which suppress cell death during infection (Nielan et al., 1993; White et al., 1992), 
indicating a widespread viral mechanism of celi death suppression potentially aimed at 
prolonging viral replication. 
Since a role for BHRFl in the EBV lytic cycle had been suggested, it was very 
important to determine whether or not BHRFl was functionally homologous to bcl-2. A 
BHRFl expressing construct was produced by Dr. David Huen (Dept of Cancer Studies, 
Birmingham) which could be expressed in several cell lines including the factor dependent 
FDCP-1 cell lines. A bcl-2 construct (a gift from Y. Tsujimoto) was used to compare the 
effects of FDCP-1 cells transfected with bcl-2 with the effect of BHRFl transfected cells, 
enabling a direct comparison of the functional homology. The FDCP-1 cell lines were initially 
used as hosts for the bcl-2 and BHRF1 constructs for several reasons, the primary one being 
that bcl-2 had already been shown to suppress apoptosis on withdrawal of IL-3 in these cell 
lines (Vaux et al., 1988). Therefore, if BHRFl was functionally homologous to bcl-2, the 
phenotypic effect should be the same on withdrawal of IL-3 and easily identifiable. 
Although one of the objectives of this study was to examine the potential functional 
homology between BHRF1 and bcl-2, the primary objective was to determine whether or not 
suppression of apoptosis by bcl-2 or BHRFl, was able to induce drug resistance in response 
to anticancer treatments. As mentioned above, the main impetus for this study came from a 
paper by Tsujimoto (1989) which described stress resistance induced by bcl-2 in response to a 
variety of treatments including methotrexate, suggesting that bcl-2 suppressed 
chemotherapeutic drug induced cell death. Drugs such as methotrexate, araC, etoposide and 
hydroxyurea have been shown in this study to induce apoptosis in the FDCP-1 cell lines (see 
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section 5.  1), so any delay in the onset of cell death caused by bcl-2 or BHRFl in this cell line 
was likely to be due to the suppression of apoptosis. 
The initial investigation to examine the possibility of functional homology between bcl- 
2 and BHRFl expressed in the FDCP-1 cells, was by induction of apoptosis on removal of IL- 
3 (Williams et al., 1990). The phenotypic effect of exogenous bcl-2 expression in FDCP-1 
cells on removal from the cytokine is a survival in of the cell cycle (Vaux et al., 1988; 
Fairbairn et al., 1993) and for cells expressing BHRFl this was also the predicted phenotype. 
Cells transfected with either BHRFl or bcl-2 expressing constructs were removed 
from IL-3 for 2-3 days and then viability was compared to control transfectants and 
untransfected FDCP- 1 cells. Approximately 60 million cells were electroporated in the 
presence of either the bcl-2 plasmid construct or the BHRF1 construct and no cells were 
produced which expressed the genes at a level sufficient to suppress apoptosis in the absence 
of IL-3 (see section 5.2). There are several reasons why this may have occurred. 
As mentioned above, bcl-2 has been expressed in these cell lines before (Vaux et al., 
1988), however, the transfection of the bcl-2 construct was not by electroporation into the 
FDCP-1 cells, but involved using a retroviral construct. The use of viral transfection in general 
ensures that the gene of interest is effectively integrated within the genome of the host cell and 
this results in the stable expression of a copy or copies of the gene. There is also a high 
efficiency of gene transfer into the target cell mainly due to the exploitation of the retrovirus 
life cycle. Retroviral RNA encoding the gene of interest is turned into DNA by the viral gene 
reverse transcriptase. The resulting viral DNA circularises and integrates into the host cell 
genome, aided by a viral DNA site-specific recombinase (Varmus 1988). Interestingly, much 
of the work in FDCP-1 cells which has involved expression of other genes such as myc 
(Cleveland et al., 1990) and raf(Rapp et al., 1990) has also been produced by using retroviral 
constructs. It is probable that to attain efficient expression of a gene within FDCP-1 cells 
retroviral expressors are most efficient. 
Transfection of plasmid constructs by electroporation can result in a low yield of cells 
expressing the transfected gene (~ 0.1% Frohman and Martin 1989), but this is often off-set by 
the simplicity of electroporation in comparison to retroviral infection. Retroviral infection of 
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cells involves the use of a defective viral construct, containing the gene of interest, which is 
unable to efficiently replicate itself due to the absence of virus capsid antigens. The virus can 
only be expressed in a virus packaging cell line and viral infection of the cells of interest is 
attained by coculture with the lethally irradiated packaging cell line which expresses the virus 
(Leslie Fairbairn, personal communication). Cells are selected in antibiotic after virus infection 
since cells which have incorporated the plasmid will be resistant to the antibiotic by virtue of a 
resistance gene present in the construct. The transfected cell line must be checked to make 
sure that the virus construct has not mutated and is being expressed from the cells. This 
possibility, along with the influence of the viral genes in the construct, increases the risk that 
the gene could be efficiently expressed in other organisms. Since I had not previously worked 
with retroviral constructs together with the fact that electroporation is a safer method, 
retroviral transfection was considered, but decided against. 
A second point to be made concerning the bcl-2 construct used in the FDCP-1 cells is 
that the construct is based on an EBV plasmid. Cells infected with EBV can express the virus 
in an episomal form. EBV genes can be expressed from the episome as long as the infected cell 
expresses EBNA 1. Expression of this gene is necessary to maintain the episomal state and to 
act as an enhancer for the latency origin of replication. EBV infected cells, which express 
EBNA 1, electroporated with constructs based on EBV plasmids are therefore able to 
maintain the plasmid in the episomal form and express genes from it without requiring 
successful integration into the host cell DNA. Non-EBV plasmid constructs which are 
electroporated into cells lose this advantage in that once in the cell they must integrate within a 
actively expressed area of the host cell genome. This introduces another reduction in the 
chances of attaining an expressible integrated version of the gene. Since the FDCP-1 cells do 
not express EBNA 1, the episomal form the plasmid cannot be maintained and so to gain 
expression of the bcl-2 gene successful integration and expression of the gene must occur 
within the host cell genome. Therefore, this reduces the probability of obtaining clones which 
efficiently express the gene. 
The BHRF1 construct used in the FDCP-1 cells, engineered by Dr. David Huen, was 
not based on an EBV construct, and therefore relied on normal host cell integration after 
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electroporation. Although not successfully expressed in the FDCP- 1 cell lines, a similar 
construct was expressed in EBV positive BL cell lines ( S .  Henderson Ph.D. thesis 1992) and 
expressed a truncated version of the BHRF1 protein which suppressed apoptosis on culturing 
the cells in low serum concentrations. The reason for expression of the truncated protein was 
not clear, however a second recombinant plasmid based on the pHebo plasmid, which can be 
episomally maintained in EBV infected cells, was engineered with the human growth hormone 
gene, present in the first construct, replaced by an intron from the ß-globin gene. This 
construct, when successfully expressed in the same EBV-BL cells resulted in the full length 
expression of the BHRFl protein (Henderson et al., 1993). It is unclear whether or not the 
truncated expression of BHRFl produced inefficient expression of BHRFl in the FDCP-1 
cells. Since BHRF1 and bcl-2 were successfully expressed in the EBV-BL cell lines, analysis 
of the functional homology between the two genes and the ability of the genes to suppress 
chemotherapeutic drug induced apoptosis was transferred to these cell lines. As a final point to 
this section, Dr Graham Cowling (personal communication) has also reported that the FDCP 
cell lines as a whole are difficult to transfect successfully. 
Section 7.3 Protocol for the selection of apoptotic mutants 
Removal of FDCP-1 cells from IL-3 for 7 days can often result in some cells which 
appear viable as determined by vital dye exclusion (N. J. McCarthy, B.Sc. Thesis 1990). When 
such cultures are re-cloned on soft agar containing IL-3, surviving clones can be obtained as 
shown in section 5.3. However, these clones were not representative of the cell types which 
were predicted to exist i.e., either IL-3 independent cells - cells which secrete their own IL-3 
or have another mechanism producing auto stimulation (Cook et al., 1985; Askew et al., 
1991), or apoptotic mutants - cells which are unable to enter apoptosis and remain in a 
state for a prolonged period of time, much like a bcl-2 expressing phenotype in FDCP-1 cells. 
Although several survivor clones, once isolated from the plates, were grown up in liquid 
culture, none of these showed any enhanced survival in the absence of IL-3 (see 
clone and survivor FDCP-1-B-clones, section 5.3.2, table 5.9). As mentioned briefly in results, 
FDCP- 1 sub-clones showing some enhanced survival on IL-3 withdrawal were previously 
isolated simply by cloning the cells using limiting dilution in the presence of IL-3 (N. J. 
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McCarthy, B. Sc. thesis). Interestingly, these sub-clones lost their enhanced survival capacity 
after 3-4 weeks in normal culture conditions, suggesting that the growth of cells in conditions 
which are not optimal, such as the growth of a single cell devoid of other cell to cell contacts, 
causes epigenetic effects leading to a temporary change in cell phenotype. This could also 
explain the small enhancement of survival seen in the FDCP-1-B survivor clones on the first 
analysis, which was not repeated on re-analysis several weeks later (see table 5.9). The clones 
isolated in the present study which survive IL-3 deprivation also appear to represent cells 
within the FDCP-1 population which can adapt temporarily to lack of growth factor and may 
reflect the fact that FDCP-1 cells already have a high rate of self-renewal. Although these cells 
are not fully transformed i.e., do not produce tumours when injected into mice, they may be 
sufficiently transformed to enable adaptation in growth limiting environments. One such 
adaptation maybe the survival, but not proliferation, of cells produced by other growth factors 
present in the FCS, which is not removed in IL-3 deprived cultures. Such a phenotype could 
be lost on re-culturing in IL-3. This hypothesis could be tested by culturing cells in the absence 
of IL-3 and FCS, or low level FCS to see if any clones survive after 7 days. This is an 
important consideration for the full screening protocol, since the results presented in this study 
show a small proportion of cells survive the protocol without any block in the apoptotic 
pathway, while appearing to have the desired phenotype. However, if these cells do exist due 
to the above reasons, then they can also be screened out after using the selection protocol. 
After a period of culture in the presence of IL-3, the removal of IL-3 from these cells should 
result in cell death within 72 hours, as has been seen for the survival clones analysed so far, 
and any real apoptotic mutants should lose viability at a much slower rate. 
Although the characterisation of IL-3 independent cells was not important in the 
development of the screening protocol, the isolation and determination of the numbers of cells 
with this phenotype was required, especially since such cells had been previously described to 
occur in this cell line by several groups (Cleveland et al., 1989; Askew et al., 1991). The IL-3 
dependent cells were predicted to be the most frequent within the FDCP-1 population, large 
numbers of which would have made the identification of apoptotic mutants difficult, since they 
were expected to occur at a lower frequency. High numbers of IL-3 independent cells would 
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also have caused problems when mutagenising the cells because the numbers of IL-3 
independent cells would have increased significantly. However, the frequency of clones able to 
survive for 7 days in the absence of IL-3 was very low, around 5 per million in FDCP-1 and 
FDCP-1-B cells and 15 per million for Analysis of some these clones, as described 
above, did not reveal any IL-3 independent cells. Therefore, these results indicate that the 
levels of spontaneous IL,-3 independent mutants were of a sufficiently low frequency i.e., 
below 15 per million, to allow the identification of apoptotic mutants. 
The absence of cells with the IL-3 independent phenotype from the experiments carried 
out in this study is probably due to the fact that the cells were not placed repeatedly in IL-3 
deprived conditions, spontaneous mutants having been produced by continually re-challenging 
the cells to IL-3 deprived conditions (Cleveland et al., 1989). This suggests that IL-3 
independent cells will only be isolated from the protocol once cells have been repeatedly 
removed from IL-3. However, the repeated selection of cells in should minimise this. 
A small number of clones, 2 from 70 million FDCP-1-B cells and 10 from 70 million 
FDCP-1-6 cells were present on soft agar plates after subjecting the cells to the full selection 
protocol, including selection (suggesting that the isolated clones were not in cell cycle 
when in the absence of IL-3 and therefore not IL-3 independent). However, selection 
only kills 80% of cycling FDCP-1 cells in the presence of IL-3, therefore 20% of cells are 
likely to survive this selection protocol suggesting that selection is useful, but not absolute. 
The few clones which were harvested from the plates did not grow for a prolonged period in 
normal liquid culture conditions, suggesting that the cells which survived this protocol were 
not stable mutants and proved to be non-viable when cultured further, Overall, these results 
demonstrate that the level of apoptotic mutants occurring spontaneously in FDCP-1 cells is 
likely to be too low to efficiently isolate and characterise new genes involved within the 
apoptotic pathway, but isolation of such mutants produced by mutagenesis should be possible 
using this protocol. 
An alternative method for isolating apoptotic mutants of FDCP-1 cells was to actively 
mutate them, increasing the numbers of mutants present. Cells could be treated with N-methyl- 
N-nitro-N-nitrosoguanine (MNNG) and the cells subsequently run through the selection 
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protocol as described in section 5.3.2. However, although useful mutants would undoubtedly 
be produced by this method, it would be very difficult to identify which gene(s) have been 
mutated. For example, if an FDCP-1 apoptotic mutant was produced by MNNG mutation, the 
gene involved would have to be identified, either by screening for a variety of possible genes, 
such as bcl-2, or if the gene was unknown, by comparing DNA libraries from normal cells and 
mutant cells deprived of IL-3. In addition, many mutations, such as point mutations will not be 
detected using this method. However, if the cells were mutagenised by the process of 
insertional mutagenesis, then the gene(s) affected would be marked (Farzaneh and Gaken 
1991; Stocking et al., 1988, 1993). Insertional mutagenesis works on the principle of placing 
the cell lines of interest in contact with a virus, produced by a virus packaging cell line. The 
virus is normally a defective virus, no longer able to fully replicate due to the inability to 
produce virus capsid antigens (as described for retroviral infection of bcl-2 into FDCP-1 cell 
lines, section 7.2). Defective expression of the viral envelope is also useful because its 
presence results in a low number of integrations per cell by preventing re-infection of the cell 
with additional copies of the virus. Once a virus enters the cell, it copies its RNA to DNA by 
the use of reverse transcriptase and integrates in the host cell DNA (Varmus 1988) and this 
happens for several virus genomes per cell. The mutagenic effect occurs when the virus infects 
a cell and integrates within a gene of interest, either activating it or disrupting it, to produce 
the desired mutant phenotype. With this system, however, the mutated gene is easy to identify 
because the gene will be marked by the presence of viral enhancer elements found in the long 
terminal repeat sequences of the viral DNA, which can be identified by southern blotting. 
Therefore the genetic area in which the mutation has occurred can be identified, proving 
especially useful if the mutated gene(s) is unknown. If the mutation required to produce the 
desired phenotype is a recessive somatic mutation i.e., the mutant phenotype is a loss of 
function mutant, then two mutation events must occur in order to mutate or knockout both 
copies of the gene, unless the gene exhibits functional haploidy. This mutant phenotype 
therefore occurs less often because of the two mutation events required. Gain of function 
mutants are more frequently the result of insertional mutagenesis because only one copy of the 
gene needs to be deregulated to produce the phenotypic effect (Farzaneh and Gaken 1991). 
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Based on the reasons discussed above, insertional mutagenesis was the method used to 
produce mutant FDCP-1s and was carried out in collaboration with Dr. Farzin Farzaneh 
(Rayne Inst. London). At first, the mutation of the FDCP-1s was problematic since they were 
difficult to infect to a high level with the ecotropic virus for which they have receptors. This 
problem of low level infection was solved and mutant clones of the FDCP-1-B cells have been 
produced. However, the initial delay in infection meant that the cells were not mutated in time 
for me to analyse the mutant clones using the devised protocol. 
One would predict that some apoptotic mutants would be present after mutagenesis 
and that not all of the mutants would have deregulated bcl-2 genes- the most obvious 
possibility to produce the desired phenotype. In the light of the recent papers on the bcl-2 
family (Boise et al., 1993; Oltvai et al., 1993; Kozopas et al., 1993) it seems likely that a 
mutant phenotype could be produced by mutating bcl-x or possibly MCL-1, a bcl-2 
homologue found in myeloid cells for which functional homology with bcl-2 has yet to be 
established. The discovery of these bcl-2 homologues also indicates that other molecular 
suppressors of apoptosis are likely to exist, some probably without homology to bcl-2. The 
identification of these genes may be very important in highlighting those which are involved in 
the early mutagenic events of oncogenesis. 
Section 7.4 Bcl-2 and BHRF1 are functionally homologous and able to 
suppress apoptosis induced by anticancer drugs and irradiation 
Since both BHRFl and bcl-2 had also been transfected into EBV positive Burkitt's 
lymphoma B-cells, using EBV based constructs, the examination of functional homology 
between bcl-2 and BHRFl was carried out using these celi lines. 
When first recorded by Dennis Burkitt (1958) the endemic nature African Burkitt's 
lymphoma the cancer was a puzzle. However, Epstein suggested that a virus may well be 
associated with the disease and once a BL cell line was established in vitro, electron 
microscopy revealed the presence of numerous virus particles within the cells. The virus was 
identified as a gammaherpesvirus and named Epstein-Barr virus after Epstein himself and his 
colleague Yvonne Barr (Epstein 1985). Although not the only factor involved in BL, EBV is 
able to transform B-cells in vitro producing lymphoblastoid cell lines (LCLs) which 
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characteristically express eight EBV latent genes; EBNAs 1, 2, 3a, 3b, 3c, LP, LMP 1 and 2, 
suggesting that certain viral genes may contribute to the cancer. Indeed, LMP 1 has been 
shown to be tumorigenic in nude mice (Wang et al., 1985). In addition to EBVs ability to 
express its own genes within the host, it can also upregulate certain host cell genes producing 
a highly transformed phenotype e.g., LCLs express high levels of the B-cell activation antigens 
CD23, CD30, CD39 and CD70 (Thorley-Lawson and Mann, 1985) as well as the cellular 
adhesion molecules LFA-1, ICAM-1 and LFA-3 (Gregory et al., 1988). Interactions between 
LFA-1 and ICAM-1 are thought to result in the characteristic cell clumping seen during the 
tissue culture of LCLs. Fresh biopsy cells, however, when first cultured in vitro, only express 
one EBV latent gene, EBNA 1, and two tumour markers (CD10 and CD77). The cells also 
lack detectable expression of a wide range of B cell activation antigens e.g., (CD21, 23, 30, 
39, 70, BB1 and G28.10) and adhesion molecules ICAM-1 and LFA-3, but show some 
expression of LFA-I. These cells are known as group I BL cell lines (Gregory et al., 1990). If 
such cells are subsequently passaged in vitro, then drifting of the phenotype is seen producing 
cell lines much like LCLs. These cell lines are known as Group III cell lines and express all 
eight latent genes as well as activation antigens and cell adhesion molecules as described for 
LCLs. Some cells show an apparent intermediate phenotype, expressing both CD10 and CD77 
as well as some of the B-cell activation adhesion/antigen molecules, but further passages result 
in attainment of the group III phenotype (Gregory et al., 1990). As well as differing in the 
expression of both EBV latent genes and B-cell activation antigens/adhesion molecules, group 
I and III cell lines differ in their sensitivity to apoptotic stimuli, the former being highly 
sensitive and the latter very insensitive (Gregory et al., 1991). These differences were 
primarily thought to be due to the expression LMP 1 in group III cells, which is able to 
upregulate host cell bcl-2 expression and suppress apoptosis (Henderson et al., 199 1). 
However, it would appear that LMP 1 may not be able to cause the upregulation in bcl-2 
expression since this effect is not seen in other cell lines in which expression of LMP1 has been 
analysed (B. Sugden, personal communication). 
Since group III cell lines already express bcl-2, these in general were not used to 
express either bcl-2 or BHRF1. However, one group III cell line, Raji-BL, does not express 
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bcl-2. The reason for this is unclear, but the Raji EBV genome has mutations found in both the 
EBNA 3c gene and the LMP 1 gene, possibly affecting EBV's ability to unpregulate host cell 
bcl-2 efficiently (S. Henderson, personal communication). Therefore, Raji-BL remains 
sensitive to apoptosis and was used to express the BHRF1 construct. The other two cell lines 
used were Akata- and Chep-BL both of which are stable group I cell lines and are sensitive to 
apoptotic stimuli. Interestingly, Akata-BL does express low levels of bcl-2 and although this 
makes the cell slightly more resistant to certain apoptotic stimuli, it does not prevent the cells 
from dying when placed in low serum concentrations (Henderson et al., 1993). 
The BL cell lines used in this study had been shown to enter apoptosis in low level 
serum and in response to calcium ionophore (Gregory et al., 1991; Henderson et al., 1991, 
1993), but, had not been incubated with chemotherapeutic drugs. Apoptosis was clearly 
demonstrated to occur in response to methotrexate, etoposide and araC as well as y-radiation 
(see section 6.2). Suppression of cell death in response to methotrexate and etoposide was 
clearly shown in Chep-BL cells expressing bcl-2 and Raji and Akata-BL cells expressing 
BHRF1 . Suppression of apoptosis in response to y-radiation was also evident in Chep-BL cells 
expressing bcl-2 and Raji-BL cells expressing BHRF 1 when compared to controls. Akata-BL 
cells proved to be resistant to treatment with y-radiation (up to 30Gy) and therefore could not 
be used to examine the resistance produced by the expression of BHRF1, Methotrexate is also 
relatively well tolerated, being at a higher concentration, in Akata-BL cells, whereas it 
is only used at in Raji-BL cells to induce a comparable -60% loss in viability, 48 hours 
post drug treatment. Akata-BL cells also show an inherent resistance to high concentrations of 
araC, no real loss of viability being evident after treatment with Therefore, in 
response to certain anticancer treatments, Akata-BL show greater resistance when compared 
to Chep and Raji-BL. Why Akata are resistant to these stimuli is not clear, but suppression of 
apoptosis in EBV cells may be mediated by as yet unidentified mechanisms which are 
independent of bcl-2 expression (Milner et al., 1992). A direct comparison of group I Mutu- 
BL lines with group III Mutu-BL lines demonstrated that the levels of bcl-2 expressed in 
group III cells did not account fully for the resistance seen to apoptotic stimuli such as serum 
withdrawal, anti Ig antibodies or ionomycin. A comparable level of resistance in group I cells 
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transfected with bcl-2 plasmids is only seen when bcl-2 is over expressed five fold above the 
levels of expression found in group III cells. Therefore, group III cells exhibit a degree of 
apoptotic suppression which is bcl-2 independent and may be attributable to EBV's ability to 
upregulate other host cell genes which are as yet unidentified. Prolonged passage of group I 
cells (around p240-250 compared to p40-50) can also produce resistance to anti Ig antibodies 
without a concomitant upregulation of bcl-2. Exposure of group I Mutu-BL to IFN a can also 
suppress apoptosis in response to calcium ionophore, anti-Ig antibodies and serum depravation 
without any upregulation in bcl-2 expression being apparent. Whether or not the bcl-2 
independent suppression mechanism could be due to upregulation of a bcl-2 homologue such 
as remains to be seen. 
Chep-BL cells on the other hand have a greater sensitivity to the presence of 
chemotherapeutic drugs and y-radiation. For example, substantial cell death was evident after 
treatment with 8Gy of y-radiation compared to 16Gy needed to induce a comparable amount 
of cell death in Raji-BL cells. The effect of bcl-2 expression on araC induced cell death in 
Chep-BL cells was interesting in that the cells showed around a 60% loss in viability post drug 
treatment, and although suppression of cell death was evident at 48 hours post treatment, the 
difference was not statistically significant at the 5% level. The reason for this is unclear, but it 
does not seem to be the result of higher levels of toxicity produced by araC, since the overall 
loss in membrane integrity at 48 hours is less for araC than for either methotrexate or 
etoposide. The morphological appearance of the cells after 14 hours incubation with araC is 
not classically apoptotic, however, it may be that the cells had already progressed through 
apoptosis by 14 hours and had started to undergo secondary necrosis. In the light of the above 
results it would seem unlikely that araC induces necrosis in the Chep-BL cell lines, so this does 
not explain why bcl-2 is unable to significantly inhibit araC induced cell death in this cell line. 
A protection from araC induced cell death by Bcl-2 has been shown in S.49, WEHI 7.2 and 
697 pre-B-leukaemia cell lines (Miyashita and Reed 1992, 1993). However, some cell lines 
transfected with bcl-2 can show no resistance to a specific drug, whereas another cell line 
transfected with bcl-2 is resistant to the drug. For example, in this present study and in the 
work of Miyashita and Reed (1992), resistance to methotrexate in a variety of bcl-2 
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transfected cell lines has been shown. However, resistance to methotrexate is not seen in small 
cell lung cancer cell lines expressing exogenous bcl-2, but resistance to other drugs such as 
adriamycin is (Ohmori et al., 1993). Such conflicting results could possibly reflect differing 
cellular responses to chemotherapeutic drugs which occur due to the transformed nature of the 
cell lines themselves. 
Evidence of DNA fragmentation in response to treatment with both cytotoxic drugs 
and y-radiation proved to be elusive, but was demonstrated in the Raji-BL cells (see chapter 6, 
figures 6.5 and 6.6).  Fragmentation of the DNA in Akata and Chep-BL was not detected 
either by analysis of genomic DNA or by separation of low molecular weight DNA by 
centrifugation using as many as 1 O7 cells. Endonuclease activation producing 
oligonucleosomal DNA fragments in Chep-BL cells during incubation in low serum 
concentrations has been shown by agarose gel electrophoresis (Henderson et al., 1991), but 
only after sampling cells and harvesting the low molecular weight DNA by Centrifugation. 
Whether the absence of a detectable DNA ladder is due to asynchronous apoptosis or 
relatively little fragmentation to low molecular weight DNA is not clear. For some cell lines 
which morphologically go through apoptosis, DNA fragmentation is not always evident 
(Cohen et al., 1992), possibly due to limited cleavage of the DNA into high molecular weight 
fragments (Brown et al., 1992; Tomei et al., 1993). This implies that not all cells which die by 
apoptosis necessarily have to fragment their DNA to the extent documented in thymocytes on 
treatment with glucocorticoid. Destruction of the DNA so that it becomes unreadable by RNA 
polymerase is hypothetically the most important outcome of endonuclease activation and may 
explain why not all cells fully fragment their DNA, but do cut the DNA into higher molecular 
fragments, which are not visible on agarose gels. The other possibility is that the BL cell lines 
enter apoptosis very asynchronously and therefore to detect any fragmentation a large number 
of cells need to be sampled and low molecular weight DNA separated from high molecular 
weight DNA by centrifugation. This was the method by which fragmentation produced by 
cytotoxic drugs in Raji-BL cells was detected, but did not solve the problems of detecting 
fragmentation in either Akata or Chep-BL cells. 
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The results presented in chapter 6 clearly demonstrate that the BL cell lines Raji, Chep 
and Akata undergo death by apoptosis in response to chemotherapeutic drugs and y-radiation, 
which can be suppressed by the expression of transfected bcl-2 or BHRF1. These results also 
demonstrate that bcl-2 and BHRF1, as well as being able to inhibit apoptosis induced by 
serum withdrawal and calcium ionophore (Henderson et al., 1993), can also suppress 
apoptosis induced by anti-cancer treatments, thus extending the boundaries of their functional 
homology. 
Although suppression of apoptosis is evident 48 hours post drug or y-radiation 
treatment, whether or not the BHRF1 or bcl-2 can keep the surviving cells alive indefinitely is 
not clear. An attempt to address this point was made by analysing colony formation in soft 
agar after treatment of the cells with low levels of y-radiation (1Gy). Although control Raji-BL 
transfectants would plate in soft agar with an efficiency of -5%, this was very rarely 
repeatable and was partly dependent on the cells having been cultured in the absence of the 
selection antibiotic hygromycin for at least 72 hours. Neither Akata or Chep-BL cells would 
form colonies on soft agar. Hence the actual survival state of these cells after anti-cancer 
treatment is still undetermined. Similar results have been documented for the Mutu-BL cell 
lines (Fisher et al., 1993). Colony formation in 697 cells (pre-B-cell leukaemia line) 
transfected with bcl-2 was assessed after treatment with dexamethasone, methotrexate and 
vincristine (Miyashita and Reed, 1993). bcl-2 transfected cells treated with dexamethasone 
retained the ability to clone (53%) when compared to untreated controls, however, colony 
formation was significantly reduced for 697-Bcl-2 cells treated with methotrexate (6%) 
and completely abolished for 697-Bcl-2 cells treated with vincristine. Differences in the 
toxicity of the drugs was not thought to be responsible for this result. All bcl-2 transfected 
cells were resistant to the above drugs as determined by vital dye exclusion, indicating that this 
measure of cell viability does not reflect colony forming ability. Although the results of 
Miyashita and Reed are limited in their relevance to all anti-cancer drugs acting on many 
different cell lines, they suggest that bcl-2 cannot block apoptosis in response to all 
chemotherapeutic drugs to the degree of maintaining colony forming ability. Therefore 
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suppression of apoptosis may prove to be only one factor involved in multidrug resistance (see 
below). 
Section 7.5 BHRF1 and bcl-2 suppress chemotherapeutic drug induced 
apoptosis-implications for multidrug resistance 
The question of whether or not bcl-2 or BHRF1 induce increased cell survival or 
simply delay cell death is important when addressing the ability of such genes to produce drug 
resistance. Several recent papers have documented suppression of chemotherapeutic drug 
induced cell death produced by the deregulated expression of bcl-2 (Fanidi et al., 1993; 
Miyashita and Reed 1992, 1993; Collins et al., 1992; Walton et al., 1993; Fisher et al., 1993), 
many of whom have suggested that this represents an alternative form of multidrug resistance. 
The basis for this argument was that the documented mechanisms of drug resistance (as 
outlined in section 3.7) could not realistically be induced simultaneously by simply 
upregulating the expression of one gene, i.e., bcl-2. For example, in the present study, three 
drugs were used, methotrexate, araC and etoposide, all of which have different documented 
classical resistance mechanisms, i.e., either target enzyme increases (dihydrofolate reductase in 
methotrexate resistance, increases in amount of topoisomerase II and in its activity in 
etoposide resistance (Zwelling et al., 1989) or decrease in drug activation (araC is converted 
into araCDP and araCTP in order to be incorporated into the DNA, absence of an enzyme 
araC-kinase inhibits this producing resistance (Drahovsky and Keis, 1970). It would be highly 
surprising, although not impossible, for the inappropriate expression of bcl-2, or indeed 
BHRF1, to result in all these effects. There is, however, a more realistic possibility, i.e., that 
bcl-2 has an effect on the multidrug resistance gene mdr1. This human gene codes for a 
170kDa protein product which is an energy dependent transport protein. In some human 
cancers, such as liver and kidney, this protein, known as p170, is highly over expressed 
resulting in the active removal of drugs such as the vinca alkaloids, epipodophyllotoxins and 
anthracyclins from the cytoplasm. Because of this rapid removal, drugs never reach toxic 
levels within the cell and so the cells are effectively drug resistant. p170 is only active on 
naturally occurring cytotoxic drugs such as those listed above, but since many of these drugs 
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are used in chemotherapy regimes against many human cancers, this form of multidrug 
resistance can produce very real problems for clinical treatment. 
Although many cell lines have been produced in vitro with MDR1 over expression by 
continuous growth in the presence of MDR1 associated drugs, over expression of MDR1 in 
clinical specimens has only recently been characterised (Goldstein et al., 1988). Cancers which 
show high levels of MDR1 expression are commonly those of kidney, adrenal gland, colon and 
liver, presumably because non-cancerous cells from the corresponding normal tissues have 
been shown to express the MDR1 protein. In general, these cancers are resistant to 
chemotherapy (Fojo et al., 1987). The physiological role of MDR 1 is not clear, but it may act 
as a detoxification system, hence its high level expression in the liver and kidney (Weinstein et 
al., 1990). 
Not all drug resistant tumours however, whether exhibiting primary (intrinsic) or 
secondary (acquired) drug resistance, can be explained by the MDR1 mechanism. MDR1 
expressing cells have mainly been studied in vitro, with drug resistant cell lines being produced 
by exposing cells to progressively higher concentrations of an MDR1 drug. This can result in 
cell lines which exhibit resistance which is 100 times greater than any documented in vivo. 
Therefore, although in vitro studies have identified the mechanism behind MDR1 resistance, in 
vivo studies have proved somewhat inconclusive as to which cancers are drug resistant due to 
MDR1 over expression. As mentioned above MDR1 expression in cancers of the liver, kidney, 
adrenal glands and the colon is well documented, but its relevance to leukaemia/lymphoma 
drug resistance is less clear. 
p170 expression is found in leukaemias such as acute myeloid leukaemia (AML), 
chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML) in blast crisis, 
but its expression does not always correlate with the type of drug resistance which is 
observed. 
In CML for example, cells can acquire resistance to hydroxyurea when the disease 
enters the stage of blast crisis. In cells at this stage the MDR 1 gene is expressed, but only at 
levels which are comparable to cells which remain drug sensitive (Weide et al., 1990). It may 
be that the drug resistance found in blast crisis is due in part to the constant activation of abl 
Page 96 
Discussion 
produced by the t(9;22) translocation, resulting in the bcrlabf fusion protein found in almost 
all cases of CML (de-Klein et al., 1982). Expression of a temperature sensitive mutant of v- 
abl in myeloid cells has shown that expression of the gene produces very high levels of drug 
resistance to busulfan (C. Dive, personal communication) and hydroxyurea (R. Chapman, 
personal communication). This implies that a constant activity of abl  is able to suppress 
apoptosis, a factor which was unknown when the MDR analysis was carried out by Weide and 
colleagues in 1990. Although MDR1 expression may produce resistance to certain drugs in 
CML cells it does not seem to be responsible for the drug resistance which is observed during 
blast crisis. The resistance produced by v-abl to chemotherapeutic drugs now suggests that the 
bcrlabl fusion gene could be involved in drug resistance in CML. 
MDR1 expression in patients with CLL shows no defined pattern which correlates 
with either stages of the disease or acquisition of drug resistance due to previous treatment 
with MDR1 associated drugs, indeed some patients have high levels of MDR1 expression at 
diagnosis (Shustik e? al., 1991). The facts which lead Shustik and colleagues to draw the 
above conclusions were that no gain of MDR1 expression was seen during chemotherapy for 
patients who were MDR1 negative at the start of treatment, but MDR1 expression was lost by 
some patients who had MDR1 positive CLL cells at the start of treatment. Expression of 
MDR1 was lost either during treatment with chlorambucil, a drug not affected by the presence 
of MDR1, or spontaneously in the absence of treatment. 
The work described above indicates that multidrug resistance may not be explained 
solely by the over expression of MDR1, indeed it is now thought that drug cross resistance is 
most likely to be multi-factorial. This implies that there are other unknown mechanisms 
involved in drug resistance which could be explained in part by the ability of genes to suppress 
apoptosis in response to chemotherapy. 
This present study has shown that the expression of either bcI-2 or BHRFl in EBV-BL 
cell lines will cause drug resistance to methotrexate, etoposide and araC, but whether this is 
independent of known resistance mechanisms described above, cannot be fully addressed. 
However, since etoposide is the only drug affected by MDR1 expression used in this study and 
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resistance to methotrexate, araC and y radiation is also seen, it is probable that bcl-2 and 
BHRF1 cause a novel form of multidrug resistance. 
A paper which addresses the role of bcl-2 in drug resistance directly has recently been 
published in which bcl-2 produces drug resistance in response to, amongst others, 5- 
fluorodeoxyuridine (Fisher et al., 1993). This drug inhibits the thymidylate synthase (TS) 
enzyme, which is important in the methylation of dUMP to TMP, causing a reduction in TTP 
pools. Inhibition of TS also produces DNA strand breaks due to the mis-incorporation of 
dUTP into the DNA and the incorporation of FdUTP into the DNA. Since the levels of TS are 
easy to identify and the pharmacological mechanisms of FdUrd toxicity are established, the 
effect of bcl-2 expression on these parameters can be analysed. bcl-2 was expressed in EBV 
Mutu-BL group I cell lines using the Tsujimoto plasmid construct (Milner et al., 1992; 
Tsujimoto, 1989). Resistance to FdUrd was shown in the bcl-2 transfectants with the 
pharmacological pathways remaining unaltered in the bcl-2 transfectants when compared to 
controls (Fisher et al., 1993). This demonstrated that bcl-2, by suppressing apoptosis in 
response to chemotherapeutic drugs, produces a form of multidrug resistance which is 
independent of some of the classical mechanisms of drug resistance. Although these results 
further support the hypothesis that bcl-2 does induce a novel form of drug resistance, 
multidrug resistance mechanisms such as MDR1 have yet to be fully investigated in relation to 
bcl-2 expression. 
Whether bcl-2 induced resistance enables cells to survive and continue to proliferate on 
removal of the drug, or whether it simply delays the onset of death has yet to be fully 
established. As mentioned in section 7.4, bcl-2 is able to completely prevent apoptosis in a 
significant proportion of 697 pre-B leukaemia cells of which 53% are able to clone in semi- 
solid medium after treatment with dexamethasone. However, bcl-2 is unable to fully prevent 
apoptosis in these cells after treatment with vincristine since no colony formation is seen 
(Miyashita and Reed 1993). Therefore, bcl-2 may not be able to completely protect cells from 
apoptosis in response to all chemotherapeutic drugs, but much more research has yet to be 
carried out on this subject. 
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Section 7.6 BHRF1 is a molecular suppressor of apoptosis-implications for 
EBV virology 
A role for genes which are able to suppress apoptosis during virai host cell infection in 
order to increase viral production through delaying host cell death has become apparent over 
the past few years. Clem and colleagues (1991) identified a baculovirus gene product, p35, 
which is able to suppress apoptosis in infected insect cells. A second apoptosis suppressing 
gene, iap, has also been found in this virus (Crook et al., 1993). 
Transformation of primary rodent cells by adenovirus is facilitated by both Ela  and 
E lb  protein products (Branton et al., 1985). Although Ela  is capable of producing cellular 
immortalisation, Co-expression of El  b is required for high efficiency transformation. The E l  b 
gene encodes two distinct proteins of 19kDa and 55kDa, either of which is able to enhance the 
transforming ability of Ela. Transformation of cells by Ela  alone is inefficient due to the cell's 
inability to by-pass a phase of cell death which occurs after focus formation. This cell death 
bears the hallmarks of apoptosis and can be prevented by the expression of the 19kDa Elb 
protein (White et al 1991, White et al 1992, Hashimoto et al., 1991). Two separate reports 
have shown that the cell death induced both by TNFa (White et al., 1992) and also by anti-Fas 
antibodies (Hashimoto et al., 1991) can be prevented by expression of the E1b 19kDa protein 
product. Both anti-Fas antibodies and TNFa have been shown to produce apoptosis in a 
number of cell lines (Duvall and Wyllie 1986; Laster et al 1988; Trauth et al 1989; Kyprianou 
et al., 1991; Itoh et al., 1991; Yonehara et al., 1990), implying that the adenovirus Elb  19kDa 
protein product acts as a suppressor of apoptosis. Two other oncogenes, v-abl and 
HER2/ERBB2, have also been shown to suppress TNFa cytotoxicity and so may suppress 
apoptosis (Suen et al., 1990, Hudzaik et al., 1988). Both genes have tyrosine kinase activity 
which, in the case of c-abl, has been shown to be synergistic with c-myc in producing factor- 
independent cells (see Cleveland et al., 1988 and section 7.7). 
In the case of p35 and E1b 19kDa proteins, the viral proteins appear to prevent 
apoptosis in order to obtain prolonged replication of the virus without killing the host cell. 
However, in the case of E1b it appears that the gene is also able to prevent apoptosis induced 
by external stimuli such as TNFa. 
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Although the above argument can be used to define a role for BHRF1 in EBV 
infection, especially since BHRFl is expressed almost exclusively in the lytic cycle, work by 
Marchini and colleagues (1991) has shown that BHRFl is not essential for effective infection 
and virus production in vitro. However, they could not rule out the possibility that BHRFl 
may be expressed in group I cell lines (BL tumour cells) in vivo which express EBNA 1, but 
none of the other latent genes and therefore presumably do not have the ability to upregulate 
the expression of host cell bcl-2. EBV latent infection resulting in the group I phenotype is 
thought to promote an escape from host T cell immune surveillance since the cells express 
only one antigen instead of all eight (Gregory et al., 1988). If a gene is required to prolong 
EBV infected host cell survival in vivo and bcl-2 cannot be upregulated, BHRF1 may be able 
to fulfil this function (Marchini et al., 1991; Henderson et al., 1993). Additionally, the BHRFl 
promoter is not far from the promoter which drives EBNA 1 expression suggesting that both 
could be upregulated by a common element. The effect of BHRF1 on EBV replication in bcl-2 
null cells needs to be investigated to establish a clear role for BHRFl in EBV infection. 
The existence of viral genes which are able to suppress both cell death during viral 
infection and apoptosis in response to stimuli such as TNFa has implications in the 
identification of the molecular pathways by which some viral genes are able to transform cells. 
Section 7.7 Relevance of c-myc 
Three recent papers have illustrated that c-myc appears to be involved in the nuclear 
decision of a cell to enter apoptosis (Askew et al., 1991; Evan et al., 1992; Shi et al., 1992). 
Deregulated expression of c-myc induces apoptosis in conditions where growth factors are 
limiting and the cells would normally enter a Go state by down regulating c-myc expression 
(Askew et al., 1991; Evan et al., 1992). Induction of apoptosis by c-myc under certain 
conditions appears to contradict its role as a Co-transforming gene. The decision of a cell 
expressing c-myc to proliferate or die may depend heavily on the signals the cell is receiving 
both from its environment and its genome (see Williams et al., 1992). The ability of c-myc to 
induce apoptosis in these cells could act as a safety mechanism against deregulation of c-myc 
expression leading to malignancy (Askew et al., 1991). A cell which constantly expressed c- 
myc would gain the ability to continuously proliferate in normal cellular conditions but would 
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require secondary changes to grow independently of appropriate survival signals from the 
surrounding environment. Continuous expression of c-myc in the absence of other changes will 
trigger apoptosis if proliferation is no longer stimulated by the surrounding environment. 
Evidence for this hypothesis has been demonstrated in the transgenic mouse model in 
which B-cells from these mice have been shown to die in vitro more rapidly than B-cells from 
normal littermates when removed from a cell feeder layer (Langdon et al., 1988). In 
2/myc mice however, bcl-2 provides a survival signal which blocks the apoptotic pathway and 
presumably provides c-myc with a genomic environment amenable to continuous cell 
proliferation. Deregulation of c-myc, therefore, would only lead to tumourigenesis if other 
genetic changes prevent the induction of apoptosis. The presence of a deregulated c-myc gene 
in BL cells may be one of the reasons why EBV has two survival mechanisms, upregulation of 
host cell bcl-2 and expression of BHRFl, by which it can suppress the death of the cell, 
especially when growth factors are limiting. 
Other transformation studies in cell lines using different combinations of myc and other 
oncogenes also support the hypothesis of mutually compatible oncogenic mutations. 
Preneoplastic bursal stem cell populations transformed with the myelocytomatosis virus, which 
contains v-myc, show a greater sensitivity to apoptosis induced by y-radiation when compared 
to the normal embryonic B cell population (Neiman et al., 1991). If the preneoplastic cells are 
then infected with a virus containing the v-rel oncogene, a neoplastic lymphoid population 
results which is insensitive to apoptosis induced by either y-radiation or dexamethasone. This 
result is paralleled in neoplastic populations derived from v-myc and v-rel transformed bursal 
lymphocytes. Therefore, transformation by v-rel and progression from preneoplastic to 
neoplastic stages in v-myc induced lymphoma is accompanied by the suppression of apoptosis. 
The proto-oncogenes abl and c-raf have also been shown to synergise with c-myc in 
transformation studies. In genetically normal myeloid cells c-Raf is phosphorylated in the 
presence of mitogenic stimuli and is therefore thought to be involved in the signal transduction 
pathway of such effectors (Rapp et al., 1988). Over expression of c-raf has been shown to 
produce IL-3 independent cells after several challenges in IL-3 deprived conditions and this 
effect is greatly enhanced in the presence of virally expressed myc. The IL-3 independent 
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clones obtained did not exhibit autocrine production of IL-3, suggesting that an alteration in 
the growth factor signalling pathway may have occurred, by-passing the need for IL-3 
receptor stimulation. Interestingly, abl and other tyrosine kinase oncogenes have also been 
shown to result in factor independent cell growth in the myeloid cell line FDCP-1 (Cook et al., 
1985; Cleveland et al., 1988). Expression of exogenous c-myc in this cell line results in partial 
or full abrogation of growth factor dependence (Rapp et al., 1985, Dean et al., 1987). Factor 
independent clones could also be subsequently derived from the partially factor independent 
clones, suggesting that secondary genetic changes other than c-myc activation were required 
for factor independence. It is not surprising that abrogation of IL-3 dependence by abl and 
other tyrosine kinase oncogenes is associated with the constitutive expression of c-myc since 
in the FDCP-1 cell line c-myc expression is normally regulated by the presence of IL-3. 
Recently, expression of a temperature sensitive v-abl gene has been shown to produce 
suppression of apoptosis at the permissive temperature (32°C) on IL-3 withdrawal in a 
myeloid cell line, but the cells do not proliferate in the absence of the cytokine (Evans et al., 
1993), again suggesting that additional mutations are required to produce factor independent 
cells. The involvement of abl in IL-3 independence has been investigated further by examining 
raf-1 expression in FDDP-2 cells, a subclone of the FDCP-1 cell line which express a 
temperature sensitive v-abl gene construct (Cleveland et al., 1989). At the non-permissive 
temperature (39°C) v-abl has low activity and the cells are IL-3 dependent. Addition of IL-3 
results in c-raf- 1 phosphorylation and therefore activation. At the permissive temperature 
(32°C) v-Ab1 is active and as a result the cells are IL-3 independent and show constant 
activation of c-ruf-1, a state which is not altered by the addition of IL-3 (Rapp et al., 1990). 
Both c-abl and c-raf therefore seem to lie on the same signal transduction pathway resulting in 
similar synergistic effects with c-myc in producing factor independence. If such oncogenes are 
able to mimic the relevant intracellular signals normally provided by IL-3 then this would 
provide the conditions alluded to earlier enabling c-myc to produce constant proliferation 
without the possibility of a proliferative block leading to apoptosis. 
A high level of c-myc expression has also been correlated with a more rapid response 
to DNA damage in the presence of teniposide and etoposide, two cytotoxic drugs which 
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inhibit topoisomerase activity (Bertrand et al., 1991). Such cytotoxic drugs can result in two 
types of DNA damage; (i) primary damage, which is reversible and represents a stage where 
double stranded breaks occur within the DNA on exposure to the drug and are subsequently 
repaired after drug removal; (ii) secondary DNA damage which is irreversible and results from 
an attempt to repair the primary DNA damage and resume normal cell growth. Secondary 
damage is characterised by fragmentation of the DNA into oligonucleosome sized fragments, 
representing the onset of apoptosis. Cell lines, such as the promyelocytic HL60 line, which 
have a high c-myc expression level, responded in a comparable manner to other human tumour 
cell lines to primary DNA damage induced by the drugs. However, the HL60 cells and other 
high level c-myc expressing tumour cells had a more rapid onset of secondary DNA damage 
which often resulted in more rapid cell death. Etoposide has been shown to induce DNA 
fragmentation and apoptosis in other cell lines (Kaufmann 1989; Fanidi et al., 1992; Miyashita 
and Reed 1992) suggesting that a high level of c-myc expression may promote cell death by 
apoptosis in response to chemotherapeutic drugs. 
Burkitt's lymphoma cell lines express deregulated c-myc by virtue of the t(8;14) 
translocation associated with both EBV positive and negative BL (Dalla-Favera et al., 1982). 
Burkitt's lymphoma is very sensitive to treatment with either chemotherapeutic drugs or 
radiation, and the possibility exists that this is due to deregulated c-myc. The sensitivity of 
these cells could also be a reflection of the site of tumour origin, i.e., centrocytes, present in 
the germinal centre. These cells have undergone a process of somatic hypermutation and now 
the require a positive signal to prevent apoptosis. Cells in this situation may be ready to 
apoptose, with all the required proteins being present, therefore withdrawal of growth factor 
or presence of a stressful environment will result in rapid cell death. These hypotheses have 
not been fully investigated in Burkitt's cells as yet, but the fact that biopsy cells drift towards 
the group III phenotype and up regulate bcl-2 suggests that a continual survival signal is 
advantageous for these cells in vitro. 
In addition, inhibition of c-Myc synthesis within T-cell hybridomas by antisense 
oligonucleotides results in the suppression of activation-induced cell death (Shi et al., 1992). 
Under certain conditions both immature T-cells (Smith et al., 1989) and some T-cell 
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hybridomas (Ucker et al., 1989; Odaka et al., 1990) undergo apoptosis in response to CD3/T- 
cell receptor activation. This stimulus in both mature and immature T cells is associated with a 
cascade of gene expression including the early induction of c-myc (Altman et al., 1990), 
therefore illustrating that in this cell system c-myc expression is an essential component for 
activation-induced cell death to occur. 
Therefore, under specific conditions and in specific cells, the level of c-myc expression 
can be important in deciding whether a cell lives or dies, but it is unlikely to be an essential 
gene for all documented occurrences of apoptosis. 
Section 7.8 Significance of p53 expression during apoptosis 
Expression of wild type p53 in a myeloid cell line M1, which normally does not express 
the protein, results in apoptosis (Yonish-Rouach et al., 1991). The reasons behind this cellular 
response were, and still are to a degree, unknown. Wild type p53 is known to act as a tumour 
suppressor gene, producing a block in when expressed in transformed cell lines which lack 
wt p53 expression, whereas cells expressing active wt p53 are more refractory to this effect 
(Michalovitz et al., 1990; Chen et al., 1990). The mechanism by which wt p53 produces this 
cell cycle arrest is unknown. It would appear that M1 cells are not able to block in when 
expressing exogenous wt p53, but they do show preferential induction of apoptosis in 
rather than in S phase (Yonish-Rouach et al., 1993). Why this occurs is not clear, but it may 
be due to the internal genetic environment of the M1 ceils (Yonish-Rouach et al., 1993) where 
there is a conflict between proliferation signals and growth arrest. Initially it was suggested 
that this may be because the cells produce high levels of c-Myc, which can lead to apoptosis in 
the absence of the cytokine, without the cells blocking in (Evan et al., 1992, Askew et al., 
1991). However, wt p53 expression produces repression of c-myc mRNA, therefore this gene 
is not highly expressed when M1 cells enter apoptosis and does not explain the induction of 
apoptosis by wt p53 in this cell line. 
An upregulation in the expression of p53 has been documented after treatment of cells 
with agents which cause DNA damage, allowing cells to block in presumably to facilitate 
effective DNA repair prior to re-entering the cell cycle (Kastan et al., 1991). It has been 
suggested in the light of Yonish-Rouach's work that p53 signals DNA damage effecting a cell 
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cycle block and if the DNA damage incurred by the cell is too great then the cell undergoes 
apoptosis (Lane 1992). The role of p53 as a sensor of DNA damage was neatly illustrated by 
examining apoptosis in thymocytes from p53-null mice (Clarke et al., 1993; Lowe et al., 
1993). p53 nullizygous thymocytes treated with glucocorticoid or anti-CD3 antibodies still 
undergo death by apoptosis as normal, but when treated with agents which damage DNA such 
as etoposide or radiation, the thymocytes are resistant. Therefore, in the absence of p53 the 
cell is not signalled to leave the cell cycle and repair the DNA damage, nor to die. This 
effectively means that a cell can progress through the cell cycle with significant levels of 
damage, the replication or repair of which is likely to lead to mutation. 
p53 expression may also be important in the induction of apoptosis in response to 
growth factor withdrawal (Yonish-Rouach et al., 1991; Lotem and Sachs 1993). Exposure of 
M1 cells to IL-6 leads to an inhibition of apoptosis induced by wt p53 expression . IL-6 does 
not produce this effect by inhibiting p53 expression, and appears to act downstream of p53. 
IL-6 induces differentiation in these cells under these conditions and the cells become cytokine 
dependent. This cytokine dependence is irreversible and independent of wt p53 expression by 
this stage. Therefore expression of wt p53 in these cells under the above conditions re-asserted 
growth inhibitory 'circuits' within the cells implying that normal growth control had been at 
least partially restored within these cells. 
The possible involvement of p53 in apoptosis induced by cytokine withdrawal suggests 
that p53 expression or repression may have important implications for the ability of tumour 
cells to evade death. Most human tumours show mutation of the p53 gene affecting p53 
expression (Levine et al., 1991), but it appears that this is not a primary requirement for 
cancers to develop. However, p53 may be more involved in cells acquiring a more aggressive 
phenotype possibly leading to metastic growth. The point at which p53 mutation occurs in 
tumour development may be dependent on the preceding oncogenic activation events. Murine 
prostate cells, for example, which express exogenous ras produce hyperplasia within the 
prostate only after mutation of the p53 gene. If the same cells are transfected with c-myc as 
well as ras then malignant cells are produced in the presence of wild type p53 (Lu et al 1992). 
The latter cells are also unaffected by the expression of exogenous wild type p53 illustrating 
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that ras and myc are together able to promote tumour growth without the need to block p53 
expression. This again illustrates ways in which successful tumour cells gain mutations which 
enable the highest chance of continuous cell growth and survival, independent of the external 
and internal cellular environment. This has also been reflected in lymphomas arising in Ep- 
myclbcl-2 transgenic mice which surprisingly did not show high levels of p53 mutation (T. J. 
McDonnell, personal communication). The explanation for this is likely to be bcl-2's ability to 
suppress p53 induced apoptosis in response to DNA damage, even though wt p53 is induced 
normally. This has suggested that p53 mutations maintain a similar genetic survival advantage 
to deregulated bcl-2, i.e., as mentioned in the previous section, bcl-2 provides the survival 
signal which complements deregulated c-myc allowing constant proliferation. In the absence of 
expression of a complementary oncogene like bcl-2, cells which express deregulated c-myc 
must mutate another gene which gives a survival advantage. In some cases such a step could 
involve mutating p53 which may block cell death on growth factor withdrawal (Lotem and 
Sachs 1993) 
Expression of wt p53 in Burkitt's lymphoma cell lines has been shown to induce 
apoptosis (Yonish-Roauch, personal communication). The cells used in the present study all 
show different p53 expression patterns, Chep-BL express wt p53, Raji-BL express mutant p53 
and Akata-BL express no p53 (Lawrence Young, personal communication; Duthu et al., 
1992). Wt p53 expression in Chep-BL may help to produce the extreme sensitivity of these 
cells to changes in serum concentration when compared to Raji and Akata-BL. Raji-BL 
express mutated p53, due to mis-sense mutations in both alleles. Mutant p53 in this cell line 
may provide some protection against cell death since Raji-BL lack bcl-2 expression, which is 
normally seen in group III cell lines. However, mutations in p53 do not result in resistance to 
apoptosis in Raji-BL cells. Akata-BL are relatively resistant to some apoptotic stimuli when 
compared to Chep-BL. In addition, Akata-BL unusually express low levels of bcl-2 
(Henderson et al., 1993), but, very high levels of bcl-2 expression are required to induce the 
same degree of resistance in group I cell lines as is found in group III cells (Mïlner et al., 
1992). Therefore, the low level expression of bcl-2 in Akata is unlikely to increase the 
resistance of this cell line significantly. The non-expression of p53 may explain why Akata-BL 
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show resistance to induction of apoptosis in response to certain stimuli such as y-radiation. 
However, when considering the results obtained in p53 null thymocytes, Akata-BL cells 
should also be insensitive to other stimuli which damage the DNA, such as the presence of 
etoposide. Akata-BL cells remain sensitive to etoposide in the absence of p53 and this is 
difficult to reconcile with the hypothesis put forward to explain the role of p53 in the induction 
of apoptosis after DNA damage. 
Future research into the interaction of p53 effector pathways with specific oncogene 
products such as Bcl-2 and C-Myc should provide further insight into the molecular 
mechanisms by which apoptosis is induced or suppressed. Of particular interest will be the role 
of p53 in the blocking of cells in after induction of DNA damage by chemotherapy, and the 
pathways by which some cells may escape such a pause in the cell cycle and as a result 
progress further towards metastic growth or possibly drug resistance. 
Section 7.9 The growing bcl-2 family 
The existence of other cellular genes with functional homology to bcl-2 has long been 
assumed. Initial studies illustrated that bcl-2 was able to prolong cell survival in B cells from 
bcl-2 transgenic mice and also in mature memory B cells (McDonnell et al., 1989; McDonnell 
and Korsmeyer 1991; Nunez et al., 1991). The ability of bcl-2 to suppress apoptosis in 
cytokine dependent cells is also well documented (Vaux et al., 1988; Williams et al,, 1990; 
Rodriguez-Tarduchy et al., 1990), but apoptosis is not prevented by bcl-2 when expressed in 
cells dependent on IL-6 (Nunez et al., 1990) and is not expressed in all human cell lineages 
(Hockenbery et al., 1990). It would be unlikely that one single gene would control cell 
population growth by being able to prevent apoptosis. Such an important part of the 
development of multicellular organisms would surely be controlled by many genes acting in 
different tissues and in response to different external stimuli. 
Painstaking investigations carried out in invertebrates have shown how a hierarchy of 
genes are able to control cellular development. The existence of death regulating genes was 
shown clearly by studying cell lineage development in the nematode C. elegans (Ellis and 
Horvitz 1986). Two genes, ced 3 and ced 4 were found to be necessary for cell death to occur 
and acted in a cell autonomous manner (Yuan and Horvitz 1990). These genes were found to 
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be regulated by ced 9, gain of function mutants of which exhibited no cell death during lineage 
development (Hengartner et al., 1992). This suggested that ced 9 was comparable to bcl-2 in 
function as an active suppressor of cell death and this was confirmed by the ability of bcl-2 to 
substitute for ced 9 to prevent cell death in C. elegans (Vaux et al., 1992). Again the 
functional homology between ced 9 and bcl-2 suggested that this type of gene had an 
important role in multi-cellular organisms and that, for more complex animals, several genes 
would be expected to fulfil this role. 
The discovery of BHRF1 and its low level homology to bcl-2, along with other viral 
genes which suppress cell death during infection, has suggested that these genes are related 
through evolution. Indeed, another viral gene LMW5-HL from African swine fever virus also 
shows limited sequence homology to bcl-2 (Neilan et al., 1993). 
One of the first mammalian genes to be identified with homology to bcl-2 was MCL-1 
(myeloid cell leukaemia-1). MCL-1 was identified primarily as an early response gene involved 
in the differentiation of M1 cells and has homology to bcl-2 by virtue of similar carboxyl 
terminus sequences (Kozopas et al., 1993). The 139 amino acid carboxyl terminal of MCL-1 
shares 35% primary amino acid sequence homology with the corresponding region of bcl-2. 
Two amino acid stretches within these portions exhibited striking similarities. Both MCL- 1 
and BHRFl share greater homology with bcl-2 than with each other, possibly suggesting a 
diverging pattern of evolution. Functional homology to bcl-2 has so far not been established 
for MCL-1, however this might be expected in the light of work by Fairbairn and colleagues 
(1 993) who have demonstrated that bcl-2 expression can facilitate differentiation in the 
absence of IL-3 in early myeloid progenitor cells, without the need for proliferation in some 
cases. 
Very recently, two genes have been identified which exhibit around 40% homology to 
bcl-2 (Oltvai et al., 1993; Boise et al., 1993). bax (Bcl-2 associated x gene ) was isolated 
from IL-3 dependent cells by immunoprecipitation of bcl-2, the two proteins again sharing 
homology in the c-terminus region. bax has several alternative mRNA forms a, ß, and y , of 
which a appears to be the dominant form. Expression of a bax a containing plasmid in an IL-3 
dependent cell line did not result in suppression of cell death, indeed high levels of Bax a 
Page 108 
Discussion 
increased the rate of cell death on cytokine removal, but had no effect on cell viability in the 
presence of IL-3. If bcl-2 and bax a are Co-expressed in the same cell then homo- and hetero- 
dimers of these molecules are found. Bax preferentially exists in the form of homodimers, but 
high expression of Bcl-2 identified Bax/Bcl-2 heterodimers and Bcl-2 monomers. The 
presence of Bax a can considerably limit the suppressive effect of Bcl-2, and therefore Oltvai 
and colleagues have suggested that Bax may act to regulate Bcl-2 through the ratio of Bcl-2 
monomers to heterodimers and Bax/Bax homodimers. 
bcl-x was identified by low stringency hybridisation with cDNA from the chicken 
Bursa of Fabricius, one of the early sites of haemopoietic development within this animal 
(Boise et al., 1993). The chicken bcl-x gene, which is expressed from a different genetic locus 
from chicken bcl-2, was used to identify a bcl-x-like gene in humans. Alternate mRNA splicing 
produces two forms of Bcl-x in human cells, and bcl-x, contains an open 
reading frame of 233 amino acids with similar domains to bcl-2. bcl-x, encodes a 170 amino 
acid protein, its truncated length being due to the absence of 63 amino acids which correspond 
to the region of highest homology to bcl-2. These two different transcripts result from 
differential usage of two 5' splice sites within the first coding exon. 
Expression of either or Bcl-x, in IL-3 dependent cells revealed that acts 
as a functional suppressor of apoptosis on IL-3 withdrawal, much like bcl-2, but that bcl-x, 
did not suppress cell death. Co-expression experiments using expressed with either 
or Bcl-x, has revealed that expression of with Bcl-2 does not produce a 
synergistic survival effect on removal of IL-3. Expression of with Bcl-2 demonstrated 
that Bcl-x, was able to block the effect of Bcl-2, resulting in cell death on IL-3 withdrawal. 
The ability of Bcl-x, to function in this manner is perhaps not surprising when the two main 
regions of amino acid homology between bcl-2 and are absent from bcl-x,. This also 
suggests that the functional activity of bcl-2 is dependent on these two regions. The different 
roles of and Bcl-x, are reflected in the tissues in which their mRNA is expressed. 
Immature, double positive thymocytes express high levels of bcl-x, mRNA, a reflection of a 
thymocytes readiness to enter apoptosis unless rescued. This may also explain why bcl-2 
transgenic mice expressing bcl-2 in thymocytes, still undergo successful negative selection 
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(Sentman et al., 1991; Strasser et al., 1991). Conversely, high levels of mRNA are 
expressed in mature neural structures and may contribute to the longevity of these post mitotic 
cells. 
The emerging bcl-2 gene family now consists of BHRF1, LMW5-HL, MCL-1, bax, 
bcl-x and also ced 9 (from C. elegans) which exhibits functional homology (Vaux et al., 1992) 
as well as some low level amino acid sequence similarities (M. Hengartner, personal 
communication). The existence of these genes illustrates that the regulation of death is 
understandably under various levels of control, possibly comparable to the regulation of Myc 
by Max and Mad (Blackwood and Eisenman 1991; Littlewood et al., 1992; Ayer et al., 1993). 
The highly homologous regions within the bcl-2 gene family are almost all focused on two 
regions, 4 and 5 ,  and this has identified these areas as highly important to the function of Bcl- 
2. This may aid the search in identifying how the bcl-2 protein functions within the cell and 
how this is associated with its membrane form. The emerging bcl-2 family has also shown that 
some of the genes, such as bax and bcl-x, have a relatively high degree of homology, but that 
other genes, such as BHRFl have low level homology, but all are involved in the regulation of 
cell death. Whether the genes which suppress cell death are related through evolution has yet 
to be fully investigated, but the ability of bcl-2 to substitute for ced 9 in C. elegans, coupled 
with the varying degrees of homology between all the genes, suggests that this is likely. 
Section 7.10 In conclusion ... 
When first observed, apoptosis represented a new and morphologically distinct 
classification of cell death. As research into the phenomenon increased, apoptosis was shown 
to be an active, controllable form of cell death, akin to cell suicide, the cell having to 
transcribe, or have transcribed, specific genes in order to die. Comparable models from 
invertebrates, such as C. elegans, implied that cell death could be used to limit the number of 
cells which make up a given cell population. With the discovery of the gene bcl-2, which was 
able to suppress this active cell death in mammalian cells, control of cell population size at the 
cell death level was recognised in higher order animals, including mammals. bcl-2 transgenic 
mice demonstrated that bcl-2 could inhibit cell death in vivo increasing the cell population 
number and thereby heightening the chances of mutations occurring, resulting in clonal tumour 
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outgrowth. bcl-2 now appears to be one of the early sites of advantageous mutations which 
complement the deregulation of genes such as c-myc, giving the autonomous growth 
advantage which tumour cells exhibit. A similar role may also be attributed to c-abl since this 
gene is also able to prevent cell death on cytokine withdrawal (Evans et aí., 1993) and is 
actively expressed, by virtue of the bcrlabl fusion protein, in myeloid leukaemia cells. 
After the initial published identification and long term study of apoptosis in 
thymocytes, diversification of analysis into other cell lines revealed that not all cells conform 
exactly to one morphological or biochemical pattern of apoptosis. For example, CEM cells 
treated with novobiocin undergo DNA cleavage due to the activation of a independent 
endonuclease (Alnemri and Litwack 1990). 
Cellular genes with classically defined roles in the cell cycle, such as p53, c-myc and c- 
fos, have also been shown to be involved in some pathways of apoptosis. p53, for example, 
appears primarily to signal the growth arrest of cells in the presence of DNA damage which, if 
irreparable, leads to apoptosis. In general, p53 may be a gene which is primarily required to 
trigger the expression of genes involved in specific pathways of apoptosis, i.e., after DNA 
damage or possibly during cytokine withdrawal. Therefore, research at present time has 
associated p53 with specific apoptotic stimuli suggesting the existence of multiple apoptotic 
pathways. This is supported by the observation that bcl-2 dependent and independent forms of 
cell death occur (Cuende et al., 1993; Milner et al., 1992) suggesting that there are apoptotic 
pathways which bcl-2 is able to inhibit and other pathways on which it does not act. In 
addition, the identification of several endonucleases, some of which are dependent and 
others pH dependent, also suggests that different cytoplasmic pathways can activate the 
endonuclease without the need for a definitive signal (D. J. McConkey, personal 
communication). Conversely, the two different mechanisms of endonuclease activation may be 
present to accommodate activation signals produced by a number of different cytoplasmic 
pathways. 
The expression of either bcl-2 or BHRFl in the three BL cell lines used in this study 
has shown that genes which suppress apoptosis can produce a novel form of drug resistance. 
The varying genetic backgrounds of the three BL cell lines produced very useful and 
Page 111 
Discussion 
sometimes thought provoking results. Chep-BL cell lines are unquestionably sensitive to 
apoptotic stimuli, a factor which may be aided by the presence of wt p53, or possibly other 
genes such as bcl-x, which have not yet been investigated. The expression of transfected bcl-2 
in Chep-BL lines produced suppression of apoptosis in response to methotrexate, etoposide 
and y-radiation, but had a smaller, not statistically significant effect on cell death in response to 
araC. This result is consistent with the morphological appearance of the cells which are not 
classically apoptotic after 14 hours exposure to araC. It has not been possible to address 
whether earlier time points i.e., <14 hours drug exposure, would have revealed apoptotic 
morphology. However, since the cells do not show a rapid reduction in membrane integrity 
after treatment with araC, especially when compared to methotrexate and etoposide, this 
implies that cell death is not by rapid lysis as would be expected in necrosis. araC itself may 
induce death by a number of pathways, which appear to be independent of protein synthesis, 
and therefore may produce morphology which is not distinctively apoptotic. The inability of 
bcl-2 to suppress araC induced cell death in Chep-BL cells could also be attributable to the 
cell line itself Other cells, such as T-cell lymphomas and lung cancer cell lines, which have 
been transfected with bcl-2, produce contradictory results when addressing for which drugs 
Bcl-2 can produce resistance (Myashita and Reed 1992; Ohmori et al., 1993). 
Perhaps the most fundamental point behind the discovery of apoptosis is that it 
represents an active, controllable, physiological form of cell death which can be produced by a 
number of cellular pathways, resulting in the commitment to death and the marking of the celi 
for phagocytosis either by a passing macrophage or a surrounding viable cell. Whether or not 
cells fully cleave their DNA into oligonucleosomal fragments in multiples of ~1 80bp, or show 
a reduction in cytoplasmic volume may not be of crucial significance to the cell, but the ability 
to die when required is fundamentally important for cell population growth control. Cancer 
research as a whole in the last 10 years has shown that tumour cells bearing mutations which 
facilitate the survival of the cells irrespective of their surrounding environment have been 
positively selected for. It would now appear that these mutations provide the required 
backgrounds to allow genes, which produce constant proliferation, to be tolerated in growth 
limiting environments. 
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Viruses also appear to have gained survival advantages in expressing genes such as 
BHRFl, p35 and LMW5-HL which prevent apoptosis of the host cell during infection (Levine 
et al., 1993). The work presented in this thesis and the work of others has shown that such 
viral genes are also able to suppress apoptosis in response to chemotherapeutic drugs and 
TNFa. Whether the expression of such genes is important to cancer development and drug 
resistance in vivo has yet to be closely investigated. 
BHRF1 is not essential for the production of LCLs in vitro by EBV, but the expression 
of the gene could be required for the survival of EBV cells in vivo, especially since bcl-2 is not 
thought to be expressed by EBV-BL biopsy cells. An additional possibility exists in that EBV- 
BL cells in vivo may express a different bcl-2 homologue which provides an adequate survival 
background to tolerate the presence of deregulated c-myc, present in BL cells. 
These possibilities need to be examined in order to determine whether the viral 
apoptosis suppressing genes can contribute towards cancer formation and acquired drug 
resistance and if so, how this can be clinically circumvented. 
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